Exhibit 10.2

Execution Copy

OPTION AND LICENSE AGREEMENT

This Option and License Agreement (this “Agreement”) is made effective as of
December 21, 2006 (the “Effective Date”) by and between ImmunoGen, Inc., a
Massachusetts corporation with a principal place of business at 128 Sidney
Street, Cambridge, Massachusetts 02139 (“ImmunoGen”), and sanofi-aventis U.S.
LLC, a limited liability company organized and existing under the laws of
Delaware with offices at 1041 Rt. 202-206, Bridgewater, NJ 08807
(“sanofi-aventis”).  Each of sanofi-aventis and ImmunoGen is sometimes referred
to individually herein as a “Party” and collectively as the “Parties.”

WHEREAS, sanofi-aventis is the owner of or otherwise Controls certain Patent
Rights and Technology relating to certain proprietary Antibodies; and

WHEREAS, ImmunoGen is the owner of or otherwise Controls certain proprietary
Patent Rights and Technology relating to or otherwise useful in the conjugation
of certain maytansine compounds to Antibodies; and

WHEREAS, ImmunoGen has entered into agreements based on the so-called
“Revolving-Door” structure with a number of Third Parties whereby such Third
Parties are obligated to grant back to ImmunoGen the right to such Third
Parties’ improvements to Technology and Patent Rights, and pursuant to which
ImmunoGen has the right to grant access to such Third Party Improvements to
sanofi-aventis; and

WHEREAS, sanofi-aventis desires to have access to such Technology, Patent Rights
and Improvements for research, discovery and development of Ab-MAY Products (as
defined below); and

WHEREAS, in connection therewith, sanofi-aventis desires to receive, and
ImmunoGen desires to grant, Options to obtain one or more licenses to Licensed
Technology having the terms set forth in one or more License Agreements to be
executed by the Parties.

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and
for other good and valuable consideration, the receipt and adequacy of which are
hereby acknowledged, the Parties hereby agree as follows:

1.             DEFINITIONS

Whenever used in this Agreement with an initial capital letter, the terms
defined in this Section 1 shall have the meanings specified below.

1.1           “AB-MAY PRODUCT” MEANS ANY PRODUCT CONTAINING A CONJUGATE OF A
SANOFI-AVENTIS ANTIBODY WITH A MAY COMPOUND IN WHICH THE SANOFI-AVENTIS ANTIBODY
IS DIRECTED AGAINST A TARGET THAT IS NOT AN EXCLUDED TARGET.

1.2           “AFFILIATE” MEANS, WITH RESPECT TO ANY PARTY, ANY PERSON THAT,
DIRECTLY OR THROUGH ONE OR MORE AFFILIATES, CONTROLS, OR IS CONTROLLED BY, OR IS
UNDER COMMON CONTROL WITH, SUCH PARTY.  FOR PURPOSES OF THIS DEFINITION,
“CONTROL” MEANS (A) OWNERSHIP OF MORE THAN FIFTY PERCENT (50%)

Portions of this Exhibit were omitted and have been filed separately with the
Secretary of the Commission pursuant to the Company’s application requesting
confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934.

1

--------------------------------------------------------------------------------

of the shares of stock entitled to vote for the election of directors in the
case of a corporation, or more than fifty percent (50%) of the equity interests
in the case of any other type of legal entity, (b) status as a general partner
in any partnership, or (c) any other arrangement whereby a Person controls or
has the right to control the board of directors of a corporation or equivalent
governing body of an entity other than a corporation.

1.3           “ANTIBODY” MEANS A POLYCLONAL OR MONOCLONAL ANTIBODY, WHETHER
MULTIPLE OR SINGLE CHAIN, RECOMBINANT OR NATURALLY OCCURRING, WHOLE OR FRAGMENT,
AND ANY VARIANTS, DERIVATIVES OR CONSTRUCTS THEREOF, INCLUDING BUT NOT LIMITED
TO, ANTIGEN BINDING PORTIONS INCLUDING FAB, FAB’, F(AB’)2, FV, DAB AND CDR
FRAGMENTS, SINGLE CHAIN ANTIBODIES (SCFV), CHIMERIC ANTIBODIES, DIABODIES AND
POLYPEPTIDES (INCLUDING ANY HUMANIZED VERSIONS THEREOF) THAT CONTAIN AT LEAST A
PORTION OF AN IMMUNOGLOBULIN THAT IS SUFFICIENT TO CONFER SPECIFIC ANTIGEN
BINDING TO THE POLYPEPTIDE.

1.4           “ANTIBODY-MAY COMPOUND CONJUGATE” MEANS ANY COMPOUND CONTAINING A
CONJUGATE OF AN ANTIBODY WITH A MAY COMPOUND.

1.5           “APPLICABLE LAWS” MEANS FEDERAL, STATE, LOCAL, NATIONAL AND
SUPRA-NATIONAL LAWS, STATUTES, RULES AND REGULATIONS, INCLUDING ANY RULES,
REGULATIONS, GUIDANCE, GUIDELINES OR REQUIREMENTS OF REGULATORY AUTHORITIES,
NATIONAL SECURITIES EXCHANGES OR SECURITIES LISTING ORGANIZATIONS, THAT MAY BE
IN EFFECT FROM TIME TO TIME DURING THE TERM AND APPLICABLE TO A PARTICULAR
ACTIVITY HEREUNDER.

1.6           “BUSINESS DAY” MEANS A DAY ON WHICH BANKING INSTITUTIONS IN NEW
YORK, NEW YORK ARE OPEN FOR BUSINESS.

1.7           “CONFIDENTIAL INFORMATION” MEANS (A) WITH RESPECT TO IMMUNOGEN,
ALL TANGIBLE EMBODIMENTS OF LICENSED TECHNOLOGY AND LICENSED PATENT RIGHTS; (B)
WITH RESPECT TO SANOFI-AVENTIS, THE IDENTIFICATION BY SANOFI-AVENTIS OF A
PROPOSED TARGET AND THE EXERCISE BY SANOFI-AVENTIS OF ANY OPTION WITH RESPECT TO
AN OPTIONED TARGET; AND (C) WITH RESPECT TO EACH PARTY, ALL INFORMATION AND
TECHNOLOGY DISCLOSED OR PROVIDED BY OR ON BEHALF OF SUCH PARTY (THE “DISCLOSING
PARTY”) TO THE OTHER PARTY (THE “RECEIVING PARTY”) OR TO ANY OF THE RECEIVING
PARTY’S EMPLOYEES, CONSULTANTS, AFFILIATES OR SUBLICENSEES, PROVIDED, THAT, NONE
OF THE FOREGOING SHALL BE CONFIDENTIAL INFORMATION IF: (I) AS OF THE DATE OF
DISCLOSURE, IT IS KNOWN TO THE RECEIVING PARTY OR ITS AFFILIATES AS DEMONSTRATED
BY CREDIBLE CONTEMPORANEOUS WRITTEN DOCUMENTATION, OTHER THAN BY VIRTUE OF A
PRIOR CONFIDENTIAL DISCLOSURE TO SUCH RECEIVING PARTY; (II) AS OF THE DATE OF
DISCLOSURE IT IS IN THE PUBLIC DOMAIN, OR IT SUBSEQUENTLY ENTERS THE PUBLIC
DOMAIN THROUGH NO FAULT OF THE RECEIVING PARTY; (III) IT IS OBTAINED BY THE
RECEIVING PARTY FROM A THIRD PARTY HAVING A LAWFUL RIGHT TO MAKE SUCH DISCLOSURE
FREE FROM ANY OBLIGATION OF CONFIDENTIALITY TO THE DISCLOSING PARTY; OR (IV) IT
IS INDEPENDENTLY DEVELOPED BY OR FOR THE RECEIVING PARTY WITHOUT REFERENCE TO OR
USE OF ANY CONFIDENTIAL INFORMATION OF THE DISCLOSING PARTY AS DEMONSTRATED BY
CREDIBLE CONTEMPORANEOUS WRITTEN DOCUMENTATION.  FOR PURPOSES OF CLARITY, THE
TERMS OF THIS AGREEMENT SHALL CONSTITUTE CONFIDENTIAL INFORMATION OF EACH PARTY.

1.8           “CONTROL” OR “CONTROLLED” MEANS (A) WITH RESPECT TO TECHNOLOGY OR
PATENT RIGHTS, THE POSSESSION BY A PARTY OF THE RIGHT TO GRANT A LICENSE OR
SUBLICENSE TO SUCH TECHNOLOGY OR PATENT RIGHTS AS PROVIDED HEREIN WITHOUT THE
PAYMENT OF ADDITIONAL CONSIDERATION TO, AND WITHOUT VIOLATING THE TERMS OF ANY
AGREEMENT OR ARRANGEMENT WITH, ANY THIRD PARTY AND (B) WITH

2

--------------------------------------------------------------------------------

RESPECT TO ANY ANTIBODY, THE POSSESSION BY A PARTY OF THE RIGHT TO SUPPLY SUCH
ANTIBODY TO THE OTHER PARTY AS PROVIDED HEREIN WITHOUT THE PAYMENT OF ADDITIONAL
CONSIDERATION TO, AND WITHOUT VIOLATING THE TERMS OF ANY AGREEMENT OR
ARRANGEMENT WITH, ANY THIRD PARTY.

1.9           “DESIGNATED SENIOR OFFICER” MEANS, WITH RESPECT TO A PARTY, THE
SENIOR OFFICER OF SUCH PARTY OR AN AFFILIATE DESIGNATED BY SUCH PARTY TO HAVE
FINAL DECISION MAKING AUTHORITY OVER DISPUTED MATTERS.

1.10         “FIELD” MEANS ALL HUMAN THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC
USES.

1.11         “IMMUNOGEN ANTIBODY” MEANS ANY ANTIBODY CONTROLLED, OWNED OR MADE
AVAILABLE BY IMMUNOGEN.

1.12         “IMPROVEMENT” MEANS ANY ENHANCEMENT, IMPROVEMENT OR MODIFICATION TO
THE LICENSED TECHNOLOGY OR THE LICENSED PATENT RIGHTS.

1.13         “LICENSE AGREEMENT” MEANS A WRITTEN LICENSE AGREEMENT EXECUTED BY
THE PARTIES UPON EXERCISE OF ANY OPTION PURSUANT TO SECTION 2.2.2 IN
SUBSTANTIALLY THE FORM SET FORTH IN APPENDIX A ATTACHED HERETO.

1.14         “LICENSED PATENT RIGHTS” MEANS ANY OF THE PATENTS AND PATENT
APPLICATIONS DESCRIBED IN SCHEDULE 1 ATTACHED HERETO, AND ANY DIVISIONALS,
CONTINUATIONS, CONTINUATIONS-IN-PART (TO THE EXTENT THAT ANY
CONTINUATIONS-IN-PART ARE ENTITLED TO THE PRIORITY DATE OF AN INITIAL PATENT OR
PATENT APPLICATION WHICH IS THE SUBJECT OF THIS AGREEMENT), REISSUES,
REEXAMINATIONS, CONFIRMATIONS, REVALIDATIONS, REGISTRATIONS, PATENTS OF
ADDITION, RENEWALS, EXTENSIONS OR SUBSTITUTES THEREOF, OR ANY PATENTS ISSUING
THEREFROM OR ANY SUPPLEMENTARY PROTECTION CERTIFICATES RELATED THERETO,
INCLUDING ANY IMPROVEMENT RELATED THERETO THAT IS CONCEIVED OR REDUCED TO
PRACTICE BY IMMUNOGEN OR ITS THIRD PARTY COLLABORATORS, THAT ARE CONTROLLED BY
IMMUNOGEN AND THAT INCLUDE ONE OR MORE CLAIMS THAT COVER LICENSED TECHNOLOGY.

1.15         “LICENSED TARGET” MEANS AN OPTIONED TARGET FOLLOWING EXERCISE OF AN
OPTION AS SET FORTH IN SECTION 2.2.2 AND WHICH IS THE SUBJECT OF A LICENSE
AGREEMENT BETWEEN THE PARTIES.

1.16         “LICENSED TECHNOLOGY” MEANS ANY TECHNOLOGY CONTROLLED BY IMMUNOGEN
AS OF THE EFFECTIVE DATEORTHAT IS CONTROLLED BY IMMUNOGEN AT ANY TIME DURING THE
TERM INCLUDING, WITHOUT LIMITATION, ANY IMPROVEMENT RELATED THERETO THAT IS
CONCEIVED OR REDUCED TO PRACTICE BY IMMUNOGEN OR ITS THIRD PARTY COLLABORATORS
AND THAT IS, IN ANY CASE, NECESSARY OR USEFUL FOR SANOFI-AVENTIS TO PRACTICE THE
RESEARCH LICENSES SET FORTH IN SECTION 2.3.

1.17         “MANUFACTURING COST” MEANS, WITH RESPECT TO ANY PRECLINICAL
MATERIALS MANUFACTURED BY IMMUNOGEN, IMMUNOGEN’S FULLY-BURDENED COSTS (INCLUDING
THE COSTS ASSOCIATED WITH PRODUCT TESTING AND RELEASE ACTIVITIES) OF PRODUCING
AND PACKAGING SUCH PRECLINICAL MATERIALS, INCLUDING THE SUM OF THE FOLLOWING
COMPONENTS: (A) DIRECT COSTS, INCLUDING (1) MATERIALS DIRECTLY USED IN PRODUCING
AND PACKAGING SUCH PRECLINICAL MATERIALS AND (2) WITH RESPECT TO ANY PRECLINICAL
MATERIALS OBTAINED BY IMMUNOGEN FROM A THIRD PARTY AND SUPPLIED TO
SANOFI-AVENTIS WITHOUT MODIFICATION, THE AMOUNT PAID BY IMMUNOGEN TO SUCH THIRD
PARTY FOR THE SAME; (B) MANUFACTURING OVERHEAD COSTS ATTRIBUTABLE TO THE COST OF
GOODS UNDER THE FOREGOING CLAUSE(A)(1), INCLUDING MANUFACTURING AND QUALITY
LABOR AND MANUFACTURING AND QUALITY

3

--------------------------------------------------------------------------------

SUPERVISORY SERVICES, OPERATING AND ADMINISTRATIVE COSTS OF THE MANUFACTURING
AND QUALITY DEPARTMENTS AND OCCUPANCY COSTS WHICH ARE ALLOCABLE TO COMPANY
DEPARTMENTS BASED ON SPACE OCCUPIED OR HEADCOUNT OR ANOTHER REASONABLE
ACTIVITY-BASED METHOD; FOR THE PURPOSE OF CLARITY, ANY COST ALLOCATION SHALL BE
(I) IN ANY CASE, APPLIED IN ACCORDANCE WITH GAAP, AND (II) APPLIED CONSISTENTLY
BY IMMUNOGEN IN RELATION TO ALL OTHER THIRD PARTIES FOR WHICH IMMUNOGEN
MANUFACTURES COMPARABLE MATERIALS; (C) ANY OTHER REASONABLE AND CUSTOMARY
OUT-OF-POCKET COSTS BORNE BY IMMUNOGEN FOR THE TESTING, TRANSPORT, CUSTOMS
CLEARANCE, DUTY, INSURANCE AND/OR STORAGE OF SUCH PRECLINICAL MATERIALS; AND (D)
IMMUNOGEN’S GENERAL AND ADMINISTRATIVE COSTS, INCLUDING PURCHASING, HUMAN
RESOURCES, PAYROLL, INFORMATION SYSTEM AND ACCOUNTING, WHICH ARE DIRECTLY
ATTRIBUTABLE OR REASONABLY ALLOCABLE TO COMPANY DEPARTMENTS BASED ON SPACE
OCCUPIED OR HEADCOUNT.

1.18         “MAY COMPOUND” MEANS ANY AND ALL MAYTANSINOID COMPOUNDS (INCLUDING,
WITHOUT LIMITATION, MAYTANSINOL, ANSAMITOCINS, DM1 AND DM4), WHETHER PRODUCED BY
A BOTANICAL SOURCE, NATURAL FERMENTATION, CHEMICAL SYNTHESIS OR OTHERWISE, AND
SHALL INCLUDE, WITHOUT LIMITATION, ALL VARIANTS, FRAGMENTS OR DERIVATIVES OF ANY
OF THE FOREGOING, IN EACH CASE CONTROLLED BY IMMUNOGEN.

1.19         “OPTION AGREEMENT” MEANS THE OPTION AGREEMENT BETWEEN THE PARTIES
DATED AS OF AUGUST 31, 2006.

1.20         “OPTION GRANT DATE” MEANS, WITH RESPECT TO A PROPOSED TARGET THAT
IS NOT AN EXCLUDED TARGET, THE DATE OF THE OPTION RESPONSE PROVIDED BY
IMMUNOGEN.

1.21         “OPTIONED TARGET” MEANS ANY PROPOSED TARGET THAT IS NOT AN EXCLUDED
TARGET AND BECOMES THE SUBJECT OF AN OPTION GRANTED BY IMMUNOGEN PURSUANT TO
SECTION 2.2.1.

1.22         “PATENT RIGHTS” MEANS THE RIGHTS AND INTERESTS IN AND TO ISSUED
PATENTS AND PENDING PATENT APPLICATIONS (INCLUDING INVENTOR’S CERTIFICATES AND
UTILITY MODELS) IN ANY COUNTRY OR JURISDICTION WITHIN THE TERRITORY, INCLUDING
ALL PROVISIONALS, SUBSTITUTIONS, CONTINUATIONS, CONTINUATIONS-IN-PART,
DIVISIONALS, SUPPLEMENTARY PROTECTION CERTIFICATES, RENEWALS, ALL LETTERS PATENT
GRANTED THEREON, AND ALL REISSUES, REEXAMINATIONS, EXTENSIONS, CONFIRMATIONS,
REVALIDATIONS, REGISTRATIONS, PATENTS OF ADDITION THEREOF, PCTS AND FOREIGN
COUNTERPARTS.

1.23         “PRECLINICAL MATERIALS” MEANS ANY MATERIALS (INCLUDING WITHOUT
LIMITATION ANY SUPPLIES OF MAY COMPOUND OR AB-MAY PRODUCT) MANUFACTURED BY
IMMUNOGEN FOR SANOFI-AVENTIS PURSUANT TO THIS AGREEMENT AND IN ACCORDANCE WITH
APPLICABLE LAWS AND ALL APPLICABLE SPECIFICATIONS FOR USE IN PRECLINICAL
TESTING.

1.24         “SANOFI-AVENTIS ANTIBODY” MEANS ANY ANTIBODY AND OTHER BINDING
PROTEINS CONTROLLED BY, OWNED BY OR MADE AVAILABLE TO SANOFI-AVENTIS.

1.25           “SANOFI-AVENTIS IMPROVEMENT” MEANS ANY IMPROVEMENT THAT IS
CONCEIVED OR FIRST REDUCED TO PRACTICE BY SANOFI-AVENTIS IN CONNECTION WITH THE
EXERCISE BY SANOFI-AVENTIS OF THE LICENSES SET FORTH IN SECTION 2.3.

4

--------------------------------------------------------------------------------

1.26         “TARGET” MEANS ANY PARTICULAR ANTIGEN (WHETHER A PROTEIN,
CARBOHYDRATE, ETC.) THAT IS BOUND BY A PARTICULAR ANTIBODY USED TO CREATE AN
AB-MAY PRODUCT, AND ALL EPITOPES OF SUCH PARTICULAR ANTIGEN.

1.27         “TECHNOLOGY” MEANS, COLLECTIVELY, ALL INVENTIONS, DISCOVERIES,
IMPROVEMENTS, TRADE SECRETS AND PROPRIETARY METHODS, WHETHER OR NOT PATENTABLE,
INCLUDING WITHOUT LIMITATION, MACROMOLECULAR SEQUENCES, DATA, FORMULATIONS,
PROCESSES, TECHNIQUES, KNOW-HOW AND RESULTS (INCLUDING ANY NEGATIVE RESULTS).

1.28         “TERRITORY” MEANS ALL COUNTRIES OF THE WORLD.

1.29         “THIRD PARTY” MEANS ANY PERSON OR ENTITY OTHER THAN IMMUNOGEN,
SANOFI-AVENTIS AND THEIR RESPECTIVE AFFILIATES.

ADDITIONAL DEFINITIONS.  IN ADDITION, EACH OF THE FOLLOWING DEFINITIONS SHALL
HAVE THE RESPECTIVE MEANINGS SET FORTH IN THE SECTION OF THIS AGREEMENT
INDICATED BELOW:

Definition

 

Section

 

 

 

Agreement

 

Recitals

Covered Results

 

4.3

Disputed Matter

 

8.14.1

Excluded Target

 

2.2.1

Expired Option

 

2.2.3

Expired Option Tail Period

 

2.2.3

ImmunoGen

 

Recitals

ImmunoGen Indemnitees

 

8.17.1

Indemnifying Party

 

8.18

License Response

 

2.2.5

License Request

 

2.2.5

Option

 

2.2.1

Option Period

 

2.2.2

Option Request

 

2.2.1

Option Response

 

2.2.1

Party/Parties

 

Recitals

Proposed Target

 

2.2.1

Research Term

 

2.3.5

Research Term Exercise Fee

 

3.2

sanofi-aventis

 

Recitals

sanofi-aventis Indemnitees

 

8.17.2

Terminated Option

 

2.2.4

Term

 

7.1

Third Party Right

 

2.2.1

 

2.             GRANT OF RIGHTS

2.1           OPTION TO INITIATE RESEARCH TERM.  IMMUNOGEN HEREBY GRANTS
SANOFI-AVENTIS AN OPTION (THE “RESEARCH TERM OPTION”), AT SANOFI-AVENTIS’ SOLE
DISCRETION, TO INITIATE THE RESEARCH

5

--------------------------------------------------------------------------------

TERM BY PROVIDING WRITTEN NOTICE OF ELECTION TO IMMUNOGEN AND PAYING THE
RESEARCH TERM EXERCISE FEE ON, OR PRIOR TO, AUGUST 31, 2008 (THE DATE OF SUCH
ELECTION, THE “RESEARCH TERM EXERCISE DATE”).

2.2           EXCLUSIVE TARGET OPTIONS.

2.2.1        OPTION REQUEST AND GRANT.  SANOFI-AVENTIS MAY FROM TIME TO TIME
DURING THE RESEARCH TERM PROVIDE WRITTEN NOTICE TO IMMUNOGEN REQUESTING THE
GRANT BY IMMUNOGEN OF AN EXCLUSIVE OPTION (EACH SUCH OPTION, AN “OPTION”) (THE
“OPTION REQUEST”) TO OBTAIN AN EXCLUSIVE LICENSE IN THE TERRITORY UNDER THE
LICENSED TECHNOLOGY AND LICENSED PATENT RIGHTS, WITH RESPECT TO ANY TARGET
SPECIFIED IN THE OPTION REQUEST (EACH, A “PROPOSED TARGET”), FOR THE SOLE
PURPOSE OF RESEARCHING, MAKING AND HAVING MADE, AB-MAY PRODUCTS DIRECTED TO SUCH
PROPOSED TARGET, FOR ANY AND ALL USES WITHIN THE FIELD.  IMMUNOGEN SHALL PROVIDE
A WRITTEN RESPONSE (THE “OPTION RESPONSE”) TO SANOFI-AVENTIS WITHIN [***]
([***]) BUSINESS DAYS OF ANY OPTION REQUEST SPECIFYING WHETHER OR NOT THE
PROPOSED TARGET IS AVAILABLE TO BE THE SUBJECT OF AN OPTION AND, IF UNAVAILABLE,
THE REASONS FOR SUCH UNAVAILABILITY AS SET FORTH IN THIS SECTION 2.2.1 (IT BEING
UNDERSTOOD THAT THE FOREGOING DISCLOSURE SHALL BE SUBJECT TO ANY CONFIDENTIALITY
OBLIGATIONS IMMUNOGEN MAY HAVE WITH ANY THIRD PARTY), PROVIDED, THAT, IMMUNOGEN
HEREBY ACKNOWLEDGES AND AGREES THAT IT MAY ONLY TREAT A PROPOSED TARGET THAT IS
IDENTIFIED IN AN OPTION REQUEST AS UNAVAILABLE (EACH, AN “EXCLUDED TARGET”) IF,
ON THE DATE OF THE OPTION REQUEST, (A) IMMUNOGEN IS PURSUING AN INTERNAL
DEVELOPMENT OR COMMERCIALIZATION PROGRAM WITH A MAY COMPOUNDCONJUGATED WITH AN
IMMUNOGEN ANTIBODY THAT IS DIRECTED AGAINST SUCH PROPOSED TARGET; (B) IMMUNOGEN
HAS, WITH RESPECT TO THE PROPOSED TARGET, GRANTED AN EXCLUSIVE OPTION OR LICENSE
TO A THIRD PARTY UNDER ANY PATENT RIGHTS CONTROLLED BY IMMUNOGEN THAT ARE
NECESSARY OR USEFUL FOR THE DEVELOPMENT, MANUFACTURE, USE OR SALE OF
ANTIBODY-MAY COMPOUND CONJUGATES (A “THIRD PARTY RIGHT”); OR (C) IMMUNOGEN IS IN
DISCUSSIONS WITH A THIRD PARTY RELATING TO A POTENTIAL GRANT OF A THIRD PARTY
RIGHT.  UPON THE GRANT OF AN OPTION TO A PROPOSED TARGET TO SANOFI-AVENTIS AS
PROVIDED IN THIS SECTION 2.2.1, THE PROPOSED TARGET SHALL BE DEEMED TO BE AN
OPTIONED TARGET FOR PURPOSES OF THIS AGREEMENT AND, FOR THE DURATION OF THE
OPTION PERIOD, (I) SANOFI-AVENTIS SHALL HAVE THE RIGHTS GRANTED IN SECTION 2.3.2
AND (II) IMMUNOGEN SHALL NOT INITIATE OR ENGAGE IN DISCUSSIONS WITH ANY THIRD
PARTY CONCERNING A THIRD PARTY RIGHT WITH RESPECT TO THE OPTIONED TARGET, OR
PURSUE INTERNALLY ANY DEVELOPMENT OR COMMERCIALIZATION PROGRAM CONCERNING AN
ANTIBODY-MAY COMPOUND CONJUGATE DIRECTED AGAINST THE OPTIONED TARGET. 
NOTWITHSTANDING ANYTHING TO THE CONTRARY SET FORTH IN THIS AGREEMENT, THE
PARTIES HEREBY AGREE THAT SANOFI-AVENTIS SHALL HAVE THE RIGHT TO SELECT AND
MAINTAIN NO MORE THAN [***] ([***]) OPTIONED TARGETS AT ANY GIVEN TIME DURING
THE TERM, PROVIDED, THAT, EXPIRED OPTIONS AND TERMINATED OPTIONS SHALL NOT COUNT
AS OPTIONED TARGETS FOR PURPOSES OF THIS LIMITATION.

2.2.2        EXERCISE OF OPTIONS.  SANOFI-AVENTIS SHALL HAVE THE RIGHT TO
EXERCISE ANY OPTION AT ANY TIME DURING THE PERIOD COMMENCING ON THE OPTION GRANT
DATE AND CONTINUING FOR A PERIOD OF [***] ([***]) MONTHS THEREAFTER (AS SUCH
PERIOD MAY BE EXTENDED AS PROVIDED IN SECTION 2.2.5 BELOW, THE “OPTION PERIOD”),
BY (A) DELIVERING WRITTEN NOTICE OF EXERCISE THEREOF, WHICH NOTICE SHALL SPECIFY
THE OPTIONED TARGET AND (B) EXECUTING A LICENSE AGREEMENT IN THE FORM OF
APPENDIX A ATTACHED HERETO.  UPON EXERCISE OF AN OPTION COVERING AN OPTIONED
TARGET AS PROVIDED IN THIS SECTION 2.2.2, SUCH OPTIONED TARGET SHALL BECOME A
LICENSED TARGET AND THE LICENSED PATENT RIGHTS AND LICENSED TECHNOLOGY (AS
DEFINED IN THE LICENSE AGREEMENT) SHALL BE

6

--------------------------------------------------------------------------------

EXCLUSIVELY LICENSED WITH RESPECT TO SUCH LICENSED TARGET TO SANOFI-AVENTIS ON
THE TERMS AND SUBJECT TO THE CONDITIONS SET FORTH IN THE RELEVANT LICENSE
AGREEMENT.

2.2.3        OPTION EXPIRATION.  IN THE EVENT THAT SANOFI-AVENTIS FAILS TO
EXERCISE ANY OPTION DURING THE APPLICABLE OPTION PERIOD (EACH, AN “EXPIRED
OPTION”), ALL RIGHTS GRANTED BY IMMUNOGEN TO SANOFI-AVENTIS PURSUANT TO SECTION
2.2.1 APPLICABLE TO SUCH EXPIRED OPTION SHALL TERMINATE AS OF SUCH EXPIRATION
DATE; PROVIDED, THAT, IF THE OPTION BECOMES AN EXPIRED OPTION PRIOR TO
EXPIRATION OF THE RESEARCH TERM, THE NON-EXCLUSIVE RESEARCH LICENSE GRANTED
PURSUANT TO SECTION 2.3.1 BELOW FOR THE OPTIONED TARGET THAT IS THE SUBJECT OF
SUCH EXPIRED OPTION SHALL AGAIN BE IN EFFECT AND SHALL SURVIVE, AND SUCH
NON-EXCLUSIVE LICENSE WILL CONTINUE UNTIL THE DATE ON WHICH IMMUNOGEN PROVIDES
WRITTEN NOTICE TO SANOFI-AVENTIS THAT SUCH TARGET HAS BECOME AN EXCLUDED
TARGET.  NOTWITHSTANDING THE FOREGOING, FOLLOWING THE EXPIRATION OF ANY OPTION
PERIOD WITH RESPECT TO AN OPTIONED TARGET, (A) IMMUNOGEN SHALL HAVE THE RIGHT TO
INITIATE OR ENGAGE IN DISCUSSIONS WITH ANY THIRD PARTY CONCERNING A THIRD PARTY
RIGHT OR PURSUE INTERNALLY ANY PROJECT CONCERNING, ANY RIGHTS REGARDING AN
ANTIBODY-MAY COMPOUND CONJUGATE DIRECTED TO THE TARGET COVERED BY SUCH EXPIRED
OPTION; (B) DURING THE PERIOD COMMENCING ON THE DATE OF EXPIRATION OF THE OPTION
PERIOD AND CONTINUING FOR A PERIOD OF [***] ([***]) MONTHS (THE “EXPIRED OPTION
TAIL PERIOD”), SANOFI-AVENTIS MAY NOT PROVIDE AN OPTION REQUEST TO IMMUNOGEN
WITH RESPECT TO THE TARGET THAT IS THE SUBJECT OF THE EXPIRED OPTION; AND (C) ON
AND AFTER THE EXPIRED OPTION TAIL PERIOD BUT PRIOR TO THE EXPIRATION OF THE
RESEARCH TERM, AND SUBJECT TO NOTICE, AVAILABILITY AND LIMITATIONS PURSUANT TO
THIS SECTION 2.2, SANOFI-AVENTIS SHALL HAVE THE RIGHT, UPON WRITTEN REQUEST, TO
PROVIDE AN OPTION REQUEST TO IMMUNOGEN WITH RESPECT TO THE TARGET COVERED BY
SUCH EXPIRED OPTION.

2.2.4        TERMINATION OF OPTIONS.  SANOFI-AVENTIS MAY TERMINATE ANY OPTION
THAT IS NOT AN EXPIRED OPTION AT ANY TIME ON AND AFTER [***] ([***]) MONTHS FROM
THE OPTION GRANT DATE BY PROVIDING WRITTEN NOTICE OF TERMINATION TO IMMUNOGEN,
WHICH NOTICE SHALL IDENTIFY THE OPTIONED TARGET TO BE TERMINATED (EACH, A
“TERMINATED OPTION”).  UPON TERMINATION OF AN OPTION AS PROVIDED IN THIS SECTION
2.2.4, SANOFI-AVENTIS SHALL HAVE THE RIGHTS SET FORTH IN SECTION 2.2.3 ABOVE, AS
IF THE TERMINATED OPTION WERE AN EXPIRED OPTION (SUBJECT TO NOTICE, AVAILABILITY
AND OTHER LIMITATIONS SET FORTH IN THIS SECTION 2.2), AND AT SUCH TIME OR
THEREAFTER SANOFI-AVENTIS MAY SELECT AND BE GRANTED ANOTHER OPTION TO REPLACE
THE TERMINATED OPTION, SUBJECT TO LIMITATIONS ON THE NUMBER OF OPTIONS SET FORTH
IN SECTION 2.2.1.

2.2.5        NON-OPTIONED TARGET: REQUEST FOR EXCLUSIVE LICENSE.
 NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, SANOFI-AVENTIS MAY
AT ANY TIME DURING THE RESEARCH TERM REQUEST THE GRANT BY IMMUNOGEN OF AN
EXCLUSIVE LICENSE TO ANY TARGET THAT IS NOT AN OPTIONED TARGET BY GIVING WRITTEN
NOTICE TO IMMUNOGEN (THE “LICENSE REQUEST”), WHICH LICENSE REQUEST SHALL SPECIFY
IN REASONABLE DETAIL THE TARGET.  IMMUNOGEN SHALL PROVIDE A WRITTEN RESPONSE
(THE “LICENSE RESPONSE”) TO SANOFI-AVENTIS WITHIN [***] ([***]) BUSINESS DAYS OF
ANY LICENSE REQUEST SPECIFYING WHETHER OR NOT THE TARGET SPECIFIED IN THE
LICENSE REQUEST IS AVAILABLE TO BE THE SUBJECT OF AN EXCLUSIVE LICENSE AND, IF
UNAVAILABLE, THE REASONS FOR SUCH UNAVAILABILITY AS SET FORTH IN SECTION 2.2.1. 
AS PROMPTLY AS POSSIBLE FOLLOWING THE ISSUANCE BY IMMUNOGEN OF A LICENSE
RESPONSE INDICATING THAT THE TARGET IS AVAILABLE TO BE THE SUBJECT OF AN
EXCLUSIVE LICENSE (A) THE PARTIES SHALL EXECUTE A LICENSE AGREEMENT IN THE FORM
OF APPENDIX A ATTACHED HERETO.  UPON EXECUTION OF SUCH LICENSE AGREEMENT, SUCH
TARGET SHALL BECOME A LICENSED TARGET AND THE LICENSED PATENT RIGHTS AND
LICENSED TECHNOLOGY (AS DEFINED IN THE

7

--------------------------------------------------------------------------------

LICENSE AGREEMENT) SHALL BE EXCLUSIVELY LICENSED WITH RESPECT TO SUCH LICENSED
TARGET TO SANOFI-AVENTIS ON THE TERMS AND SUBJECT TO THE CONDITIONS SET FORTH IN
THE RELEVANT LICENSE AGREEMENT.

2.2.6        DISCUSSIONS REGARDING TARGETS.  IMMUNOGEN AGREES, UPON THE REQUEST
OF SANOFI-AVENTIS, TO CONFER WITH SANOFI-AVENTIS ON WHETHER IMMUNOGEN REASONABLY
EXPECTS ANY TARGET IDENTIFIED BY SANOFI-AVENTIS WILL REMAIN AVAILABLE TO BECOME
AN OPTIONED TARGET AND/OR LICENSED TARGET, PROVIDED, THAT UNDER NO CIRCUMSTANCES
SHALL ANY SUCH DISCUSSIONS BE DEEMED BY SANOFI-AVENTIS TO BE A COMMITMENT BY
IMMUNOGEN WITH RESPECT TO ANY SUCH TARGET.

2.3           NON-EXCLUSIVE RESEARCH LICENSE; OPTION FOR EXCLUSIVE RESEARCH
LICENSE.

2.3.1        NON-EXCLUSIVE RESEARCH LICENSE.  IMMUNOGEN HEREBY GRANTS
SANOFI-AVENTIS A NON-EXCLUSIVE, ROYALTY-FREE LICENSE DURING THE RESEARCH TERM,
WITHOUT THE RIGHT TO GRANT SUBLICENSES, UNDER THE LICENSED TECHNOLOGY AND
LICENSED PATENT RIGHTS WITH RESPECT TO ANY TARGET THAT IS NOT AN OPTIONED TARGET
OR A LICENSED TARGET (INCLUDING ANY OPTIONED TARGET THAT IS THE SUBJECT OF AN
EXPIRED OPTION AND/OR TERMINATED OPTION), TO (A) CONDUCT SAFETY AND OTHER
PRECLINICAL STUDIES IN VITRO AND TOXICITY STUDIES IN VIVO IN ANY NON-HUMAN
SPECIES WITH ANY AB-MAY PRODUCT DIRECTED AT SUCH TARGET, (B) TO MANUFACTURE
AB-MAY PRODUCT SOLELY FOR USE IN SUCH STUDIES AND (C) TO MANUFACTURE AND
CONJUGATE MAY COMPOUNDS THAT DO NOT COMPRISE AN AB-MAY PRODUCT SOLELY FOR USE AS
A CONTROL FOR ANY AB-MAY PRODUCT THAT IS DIRECTED AT AN OPTIONED TARGET.  FOR
PURPOSES OF CLARITY, SANOFI-AVENTIS SHALL HAVE NO RIGHT UNDER THE LICENSE
DESCRIBED IN THIS SECTION 2.3.1 TO CONDUCT IN VIVO EFFICACY STUDIES OF ANY
AB-MAY PRODUCT TO ANY TARGET THAT IS NOT AN OPTIONED TARGET OR LICENSED TARGET.

2.3.2        EXCLUSIVE RESEARCH LICENSE.  IMMUNOGEN HEREBY GRANTS SANOFI-AVENTIS
AN EXCLUSIVE, ROYALTY-FREE LICENSE DURING THE RESEARCH TERM, WITHOUT THE RIGHT
TO GRANT SUBLICENSES, WITH RESPECT TO ANY OPTIONED TARGET, TO (A) CONDUCT ANY
AND ALL PRECLINICAL STUDIES (INCLUDING WITHOUT LIMITATION IN VIVO EFFICACY
STUDIES) ON ANY AB-MAY PRODUCT DIRECTED AT SUCH OPTIONED TARGET; AND (B)
MANUFACTURE AB-MAY PRODUCT SOLELY FOR USE IN SUCH STUDIES.

2.3.3        USE OF SUBCONTRACTORS; BONA FIDE COLLABORATORS.  SANOFI-AVENTIS
SHALL HAVE THE RIGHT TO ENGAGE ONE OR MORE THIRD PARTY SUBCONTRACTORS TO PERFORM
DESIGNATED FUNCTIONS, OR PARTICIPATE IN BONA FIDE COLLABORATIONS, RELATED TO THE
CONDUCT OF THE ACTIVITIES DESCRIBED IN SECTION 2.3.1 AND 2.3.2, PROVIDED, THAT
(I) SANOFI-AVENTIS SHALL REMAIN RESPONSIBLE FOR THE SATISFACTORY ACCOMPLISHMENT
OF SUCH ACTIVITIES IN ACCORDANCE WITH THE TERMS AND CONDITIONS OF THIS
AGREEMENT; AND (II) EACH SUCH THIRD PARTY SUBCONTRACTOR OR BONA FIDE
COLLABORATOR SHALL BE BOUND TO THE SAME EXTENT THAT SANOFI-AVENTIS IS OBLIGATED
TO IMMUNOGEN UNDER THIS AGREEMENT.

2.3.4        RESEARCH RECORDS.  SANOFI-AVENTIS SHALL MAINTAIN RECORDS OF ACCESS
TO AND USE OF THE LICENSED TECHNOLOGY AND LICENSED PATENT RIGHTS.  SUCH RECORDS
SHALL BE MADE AVAILABLE TO IMMUNOGEN UPON REASONABLE REQUEST DURING BUSINESS
HOURS AND PROVIDED THAT IMMUNOGEN SHALL MAKE SUCH REQUEST NO MORE THAN ONCE PER
CALENDAR YEAR.

2.3.5        RESEARCH TERM.  SUBJECT TO THE PAYMENT OF THE RESEARCH TERM
EXERCISE FEE AS PROVIDED IN SECTION 3.2 BELOW AND TO THE EXTENSION AS PROVIDED
IN SECTION 2.3.6 BELOW, THE RESEARCH TERM SHALL COMMENCE ON THE RESEARCH TERM
EXERCISE DATE AND CONTINUE UNTIL AUGUST 31, 2011 (THE “RESEARCH TERM”), UNLESS
THIS AGREEMENT IS EARLIER TERMINATED BY EITHER PARTY

8

--------------------------------------------------------------------------------

PURSUANT TO THE PROVISIONS OF SECTION 8.  UNLESS OTHERWISE PROVIDED IN A LICENSE
AGREEMENT OR OTHERWISE SET FORTH IN THIS AGREEMENT, UPON TERMINATION OR
EXPIRATION OF THE RESEARCH TERM, SANOFI-AVENTIS SHALL DISCONTINUE USE OF THE
LICENSED TECHNOLOGY AND LICENSED PATENT RIGHTS AND DESTROY ALL PORTIONS AND
COPIES OF THE LICENSED TECHNOLOGY AND LICENSED PATENT RIGHTS, PROVIDED, HOWEVER,
THAT SANOFI-AVENTIS SHALL HAVE THE RIGHT TO RETAIN ONE (1) COPY FOR ITS LEGAL
FILES.

2.3.6        EXTENSION OF RESEARCH TERM.  SANOFI-AVENTIS MAY EXTEND THE RESEARCH
TERM FOR ONE ADDITIONAL THREE (3) YEAR PERIOD (ENDING ON AUGUST 31, 2014) BY
PROVIDING WRITTEN NOTICE AND BY PAYING IMMUNOGEN A NON-REFUNDABLE,
NON-CREDITABLE FEE IN THE AMOUNT OF [***] [***] DOLLARS (US $[***]) BY WIRE
TRANSFER OF IMMEDIATELY AVAILABLE FUNDS AT ANY TIME PRIOR TO THE EXPIRATION OF
THE RESEARCH TERM.

2.4           GRANT OF IMPROVEMENT LICENSE TO IMMUNOGEN.  SANOFI-AVENTIS HEREBY
GRANTS IMMUNOGEN A NON-EXCLUSIVE, WORLDWIDE, FULLY-PAID, IRREVOCABLE,
ROYALTY-FREE LICENSE OF PERPETUAL DURATION, WITH THE RIGHT TO GRANT SUBLICENSES
AS DESCRIBED BELOW, UNDER SANOFI-AVENTIS’ INTEREST IN ANY SANOFI-AVENTIS
IMPROVEMENTS (A) TO MANUFACTURE PRECLINICAL MATERIALS PURSUANT TO THE TERMS OF
THIS AGREEMENT; (B) TO DEVELOP, MAKE, HAVE MADE, USE, SELL, HAVE SOLD, OFFER FOR
SALE, IMPORT, HAVE IMPORTED, EXPORT AND HAVE EXPORTED ANY PRODUCT THAT IS NOT
OTHERWISE RESTRICTED BY AN AGREEMENT BY AND BETWEEN SANOFI-AVENTIS AND
IMMUNOGEN; AND (C) TO OTHERWISE EXPLOIT SUCH SANOFI-AVENTIS IMPROVEMENTS FOR ALL
USES WITHIN THE FIELD THAT ARE NOT OTHERWISE RESTRICTED BY AN AGREEMENT BY AND
BETWEEN SANOFI-AVENTIS AND IMMUNOGEN, PROVIDED, THAT, (I) ANY GRANT BY IMMUNOGEN
OF A SUBLICENSE IS ONLY MADE IN CONNECTION WITH THE GRANT OF A LICENSE TO
TECHNOLOGY AND/OR PATENT RIGHTS CONTROLLED BY IMMUNOGEN AND USED IN THE
CONJUGATION OF MAY COMPOUNDS TO BINDING PROTEINS; AND (II) THE RIGHT OF
IMMUNOGEN TO GRANT ANY SUCH SUBLICENSE IS SUBJECT TO SANOFI-AVENTIS OBTAINING A
GRANT BACK OF A NON-EXCLUSIVE, FULLY PAID, IRREVOCABLE, ROYALTY-FREE LICENSE,
UNDER THAT SUBLICENSEE’S IMPROVEMENTS, ENHANCEMENTS OR MODIFICATIONS TO
TECHNOLOGY CONTROLLED BY IMMUNOGEN TO CONDUCT RESEARCH IN THE FIELD AND IN THE
TERRITORY IN ACCORDANCE WITH SECTIONS 2.3.1 AND/OR 2.3.2 OF THIS AGREEMENT.

2.5           NOTICE OF IMPROVEMENTS.  SANOFI-AVENTIS SHALL PROMPTLY NOTIFY
IMMUNOGEN OF THE CONCEPTION OR REDUCTION TO PRACTICE OF ANY SUCH SANOFI-AVENTIS
IMPROVEMENT. IMMUNOGEN SHALL PROMPTLY NOTIFY SANOFI-AVENTIS OF (A) THE
CONCEPTION OR REDUCTION TO PRACTICE BY IMMUNOGEN OF ANY IMPROVEMENT OR (B) ITS
RECEIPT OF WRITTEN NOTICE FROM ANY OF ITS THIRD PARTY COLLABORATORS OF ITS
CONCEPTION OR REDUCTION TO PRACTICE OF ANY IMPROVEMENT.

2.6           MANUFACTURE OF RESEARCH AND/OR PRECLINICAL MATERIALS.  SUBJECT TO
THIS SECTION 2.6, SANOFI-AVENTIS SHALL HAVE THE SOLE RIGHT, AT ITS SOLE COST AND
DISCRETION, FOR THE MANUFACTURE OF ALL MATERIALS (INCLUDING WITHOUT LIMITATION
ANY AB-MAY PRODUCTS AND/OR MAY COMPOUNDS) NECESSARY FOR SANOFI-AVENTIS TO
PRACTICE THE LICENSES GRANTED TO IT UNDER SECTIONS 2.3.1 AND/OR 2.3.2.  IN THE
EVENT THAT, DURING THE TERM, SANOFI-AVENTIS DESIRES IMMUNOGEN TO SUPPLY
SANOFI-AVENTIS WITH QUANTITIES OF PRECLINICAL MATERIALS, SANOFI-AVENTIS SHALL
PROVIDE IMMUNOGEN WITH WRITTEN NOTICE OF SAME.  IMMUNOGEN SHALL MANUFACTURE ALL
ORDERED AMOUNTS OF PRECLINICAL MATERIALS AT IMMUNOGEN’S CAMBRIDGE, MASSACHUSETTS
FACILITY OR ITS NORWOOD, MASSACHUSETTS FACILITY AND DELIVER SUCH ORDERED AMOUNTS
IN ACCORDANCE WITH FORECASTING PARAMETERS, ADVANCE ORDERING TIMEFRAMES AND
DELIVERY TIMEFRAMES TO BE AGREED UPON BY THE PARTIES.  SANOFI-AVENTIS MAY [***],
AT ITS SOLE DISCRETION, THE [***] [***] [***] IMMUNOGEN WILL SUPPLY THE
REQUESTED

9

--------------------------------------------------------------------------------

PRECLINICAL MATERIALS.  IN CONNECTION WITH ANY ORDERING OF PRECLINICAL MATERIALS
BY SANOFI-AVENTIS, (A) IMMUNOGEN SHALL PROVIDE SANOFI-AVENTIS WITH IMMUNOGEN’S
GOOD FAITH ESTIMATE OF THE MANUFACTURING COST FOR MANUFACTURE AND SUPPLY OF SUCH
PRECLINICAL MATERIALS; (B) IMMUNOGEN’S PRICE TO SUPPLY PRECLINICAL MATERIALS TO
SANOFI-AVENTIS MANUFACTURED AT IMMUNOGEN’S CAMBRIDGE, MASSACHUSETTS FACILITY
SHALL EQUAL [***]% OF IMMUNOGEN’S MANUFACTURING COST FOR SUCH PRECLINICAL
MATERIALS; AND (C) IMMUNOGEN’S PRICE TO SUPPLY PRECLINICAL MATERIALS
MANUFACTURED AT IMMUNOGEN’S NORWOOD, MASSACHUSETTS FACILITY SHALL EQUAL [***]%
OF IMMUNOGEN’S MANUFACTURING COST FOR SUCH PRECLINICAL MATERIALS; PROVIDED,
THAT, NOTHING IN THIS SECTION 2.6 SHALL PRECLUDE SANOFI-AVENTIS FROM MAKING ITS
OWN ARRANGEMENTS FOR MANUFACTURE AND SUPPLY OF PRECLINICAL MATERIALS ON ITS OWN
OR WITH THIRD PARTIES, SUBJECT TO THE LICENSES GRANTED HEREUNDER.

3.             FINANCIAL TERMS

3.1           UP-FRONT FEE.  IN CONSIDERATION OF THE RIGHTS GRANTED TO
SANOFI-AVENTIS UNDER THIS AGREEMENT, SANOFI-AVENTIS AGREES TO PAY IMMUNOGEN A
NON-REFUNDABLE, NON-CREDITABLE UP-FRONT FEE IN THE AMOUNT OF FIVE HUNDRED
THOUSAND DOLLARS ($500,000), PAYABLE IN IMMEDIATELY AVAILABLE FUNDS WITHIN [***]
([***]) DAYS OF THE EFFECTIVE DATE.

3.2           RESEARCH TERM EXERCISE FEE IN CONSIDERATION OF THE RIGHTS GRANTED
TO SANOFI-AVENTIS UNDER THIS AGREEMENT, SANOFI-AVENTIS AGREES TO PAY IMMUNOGEN A
NON-REFUNDABLE, NON-CREDITABLE EXERCISE FEE IN THE AMOUNT OF [***] [***] [***]
[***] [***] DOLLARS ($[***]) (THE “RESEARCH TERM EXERCISE FEE”), PAYABLE IN
IMMEDIATELY AVAILABLE FUNDS WITHIN [***] ([***]) BUSINESS DAYS OF THE RESEARCH
TERM EXERCISE DATE.

4.             TREATMENT OF CONFIDENTIAL INFORMATION

4.1           CONFIDENTIALITY.

4.1.1        CONFIDENTIALITY OBLIGATIONS.  IMMUNOGEN AND SANOFI-AVENTIS EACH
RECOGNIZES THAT THE OTHER PARTY’S CONFIDENTIAL INFORMATION CONSTITUTES HIGHLY
VALUABLE ASSETS OF SUCH OTHER PARTY.  IMMUNOGEN AND SANOFI-AVENTIS EACH AGREES
THAT, SUBJECT TO SECTION 4.1.2, (A) DURING THE TERM AND FOR AN ADDITIONAL [***]
([***]) YEARS THEREAFTER IT WILL NOT DISCLOSE, AND WILL CAUSE ITS AFFILIATES AND
SUBLICENSEES NOT TO DISCLOSE, ANY CONFIDENTIAL INFORMATION OF THE OTHER PARTY
AND (B) DURING AND AFTER THE TERM, IT WILL NOT USE, AND WILL CAUSE ITS
AFFILIATES NOT TO USE, ANY CONFIDENTIAL INFORMATION OF THE OTHER PARTY, IN
EITHER CASE, EXCEPT AS EXPRESSLY PERMITTED HEREUNDER.  WITHOUT LIMITING THE
GENERALITY OF THE FOREGOING, EACH PARTY SHALL TAKE SUCH ACTION, AND SHALL CAUSE
ITS AFFILIATES AND SUBLICENSEES TO TAKE SUCH ACTION, TO PRESERVE THE
CONFIDENTIALITY OF THE OTHER PARTY’S CONFIDENTIAL INFORMATION AS SUCH PARTY
WOULD CUSTOMARILY TAKE TO PRESERVE THE CONFIDENTIALITY OF ITS OWN CONFIDENTIAL
INFORMATION AND SHALL, IN ANY EVENT, USE AT LEAST REASONABLE CARE TO PRESERVE
THE CONFIDENTIALITY OF THE OTHER PARTY’S CONFIDENTIAL INFORMATION.

4.1.2        LIMITED DISCLOSURE.  IMMUNOGEN AND SANOFI-AVENTIS EACH AGREES THAT
DISCLOSURE OF ITS CONFIDENTIAL INFORMATION MAY BE MADE BY THE OTHER PARTY TO ANY
EMPLOYEE, CONSULTANT OR AFFILIATE OF SUCH OTHER PARTY TO ENABLE SUCH OTHER PARTY
TO EXERCISE ITS RIGHTS OR TO CARRY OUT ITS RESPONSIBILITIES UNDER THIS
AGREEMENT, PROVIDED THAT ANY SUCH DISCLOSURE OR TRANSFER SHALL ONLY BE MADE TO
PERSONS WHO ARE BOUND BY WRITTEN OBLIGATIONS AS DESCRIBED IN SECTION 4.1.3.

10

--------------------------------------------------------------------------------

IN ADDITION, IMMUNOGEN AND SANOFI-AVENTIS EACH AGREES THAT THE OTHER PARTY MAY
DISCLOSE ITS CONFIDENTIAL INFORMATION (A) ON A NEED-TO-KNOW BASIS TO SUCH OTHER
PARTY’S LEGAL AND FINANCIAL ADVISORS AND (B) AS REASONABLY NECESSARY IN
CONNECTION WITH AN ACTUAL OR POTENTIAL (I) PERMITTED SUBLICENSE OF SUCH OTHER
PARTY’S RIGHTS HEREUNDER, (II) DEBT OR EQUITY FINANCING OF SUCH OTHER PARTY OR
(III) PURCHASE BY ANY THIRD PARTY OF ALL OF THE CAPITAL STOCK OR ALL OR
SUBSTANTIALLY ALL OF THE ASSETS OF SUCH OTHER PARTY OR ANY MERGER OR
CONSOLIDATION INVOLVING SUCH OTHER PARTY; IF, IN EACH CASE, THE PERSON RECEIVING
SUCH CONFIDENTIAL INFORMATION OF THE OTHER PARTY AGREES IN WRITING TO MAINTAIN
THE CONFIDENTIALITY OF SUCH CONFIDENTIAL INFORMATION OF THE OTHER PARTY WITH
TERMS AT LEAST AS RESTRICTIVE AS THOSE CONTAINED IN SECTION 4.1.1.  IN ADDITION,
EACH PARTY AGREES THAT THE OTHER PARTY MAY DISCLOSE SUCH PARTY’S CONFIDENTIAL
INFORMATION (A) AS REASONABLY NECESSARY TO FILE, PROSECUTE OR MAINTAIN PATENTS
OR PATENT APPLICATIONS, OR TO FILE, PROSECUTE OR DEFEND LITIGATION RELATED TO
PATENTS OR PATENT APPLICATIONS, IN ACCORDANCE WITH THIS AGREEMENT; OR (B) AS
REQUIRED BY APPLICABLE LAWS, PROVIDED THAT, IN THE CASE OF ANY DISCLOSURE UNDER
THIS CLAUSE (B), THE DISCLOSING PARTY SHALL (1) IF PRACTICABLE, PROVIDE THE
OTHER PARTY WITH REASONABLE ADVANCE NOTICE OF AND AN OPPORTUNITY TO COMMENT ON
ANY SUCH REQUIRED DISCLOSURE, (2) IF REQUESTED BY THE OTHER PARTY, COOPERATE IN
ALL REASONABLE RESPECTS WITH THE OTHER PARTY’S EFFORTS TO OBTAIN CONFIDENTIAL
TREATMENT OR A PROTECTIVE ORDER WITH RESPECT TO ANY SUCH DISCLOSURE, AT THE
OTHER PARTY’S EXPENSE AND (3) USE GOOD FAITH EFFORTS TO INCORPORATE THE COMMENTS
OF SUCH OTHER PARTY IN ANY SUCH DISCLOSURE OR REQUEST FOR CONFIDENTIAL TREATMENT
OR A PROTECTIVE ORDER.

4.1.3        EMPLOYEES AND CONSULTANTS.  IMMUNOGEN AND SANOFI-AVENTIS EACH
HEREBY REPRESENTS THAT ALL OF ITS EMPLOYEES AND CONSULTANTS, AND ALL OF THE
EMPLOYEES AND CONSULTANTS OF ITS AFFILIATES, WHO PARTICIPATE IN THE ACTIVITIES
CONTEMPLATED BY THIS AGREEMENT OR HAVE ACCESS TO CONFIDENTIAL INFORMATION OF THE
OTHER PARTY ARE OR WILL, PRIOR TO THEIR PARTICIPATION OR ACCESS, BE BOUND BY
WRITTEN OBLIGATIONS TO MAINTAIN SUCH CONFIDENTIAL INFORMATION IN CONFIDENCE AND
NOT TO USE SUCH INFORMATION EXCEPT AS EXPRESSLY PERMITTED HEREUNDER.  EACH PARTY
AGREES TO USE, AND TO CAUSE ITS AFFILIATES TO USE, REASONABLE EFFORTS TO ENFORCE
SUCH OBLIGATIONS.

4.2           PUBLICITY.  THE PARTIES ACKNOWLEDGE THAT THE TERMS OF THIS
AGREEMENT CONSTITUTE CONFIDENTIAL INFORMATION OF EACH PARTY AND MAY NOT BE
DISCLOSED EXCEPT AS PERMITTED BY SECTION 4.1.2.  NOTWITHSTANDING ANYTHING TO THE
CONTRARY IN SECTION 4.1, THE PARTIES, UPON THE EXECUTION OF THIS AGREEMENT,
SHALL MUTUALLY AGREE TO A PRESS RELEASE WITH RESPECT TO THIS AGREEMENT AND
EITHER PARTY MAY MAKE SUBSEQUENT PUBLIC DISCLOSURE OF THE CONTENTS OF SUCH PRESS
RELEASE WITHOUT FURTHER APPROVAL OF THE OTHER PARTY.  AFTER ISSUANCE OF SUCH
PRESS RELEASE, EXCEPT AS REQUIRED BY APPLICABLE LAWS, NEITHER PARTY SHALL ISSUE
A PRESS OR NEWS RELEASE OR MAKE ANY SIMILAR PUBLIC ANNOUNCEMENT (OTHER THAN
PUBLICATION IN SCIENTIFIC JOURNALS, IN ADVERTISING MATERIALS AND BROCHURES, OR
PRESENTATION AT SCIENTIFIC CONFERENCES AND MEETINGS AND THE LIKE THAT ARE
INTENDED TO BE COVERED BY, AND ARE ISSUED IN COMPLIANCE WITH, SECTION 4.3)
RELATED TO EVENTS ARISING UNDER THIS AGREEMENT WITHOUT THE PRIOR WRITTEN CONSENT
OF THE OTHER PARTY, PROVIDED THAT NOTWITHSTANDING THE FOREGOING, IMMUNOGEN
SHALL BE EXPRESSLY PERMITTED TO PUBLICLY ANNOUNCE THE EXERCISE OF AN OPTION
UNDER SECTION 2.1.3, PROVIDED, HOWEVER, THAT THE TEXT OF SUCH ANNOUNCEMENT SHALL
BE MUTUALLY AGREED TO BY THE PARTIES.

4.3           PUBLICATIONS AND PRESENTATIONS.  THE PARTIES ACKNOWLEDGE THAT
SCIENTIFIC PUBLICATIONS AND PRESENTATIONS MUST BE STRICTLY MONITORED TO PREVENT
ANY ADVERSE EFFECT FROM PREMATURE PUBLICATION OR DISSEMINATION OF RESULTS OF THE
ACTIVITIES HEREUNDER.  EACH PARTY AGREES THAT, EXCEPT AS REQUIRED BY APPLICABLE
LAWS, IT SHALL NOT PUBLISH OR PRESENT, OR PERMIT TO BE

11

--------------------------------------------------------------------------------

PUBLISHED OR PRESENTED, THE RESULTS OF THE RESEARCH CONDUCTED BY SANOFI-AVENTIS
UNDER OR PURSUANT TO THIS AGREEMENT TO THE EXTENT SUCH RESULTS REFER TO OR
OTHERWISE RELATE TO THE LICENSED TECHNOLOGY OR LICENSED PATENT RIGHTS (THE
“COVERED RESULTS”) WITHOUT THE PRIOR REVIEW BY AND APPROVAL OF THE OTHER PARTY. 
EACH PARTY SHALL PROVIDE TO THE OTHER PARTY THE OPPORTUNITY TO REVIEW EACH OF
THE SUBMITTING PARTY’S PROPOSED ABSTRACTS, MANUSCRIPTS OR PRESENTATIONS
(INCLUDING, WITHOUT LIMITATION, INFORMATION TO BE PRESENTED VERBALLY) THAT
RELATE TO THE COVERED RESULTS AT LEAST [***] ([***]) DAYS PRIOR TO ITS INTENDED
PRESENTATION OR SUBMISSION FOR PUBLICATION, AND SUCH SUBMITTING PARTY AGREES,
UPON WRITTEN REQUEST FROM THE OTHER PARTY GIVEN WITHIN SUCH [***]-[***] PERIOD,
NOT TO SUBMIT SUCH ABSTRACT OR MANUSCRIPT FOR PUBLICATION OR TO MAKE SUCH
PRESENTATION UNTIL THE OTHER PARTY IS GIVEN UP TO [***] ([***]) DAYS FROM THE
DATE OF SUCH WRITTEN REQUEST TO SEEK APPROPRIATE PATENT PROTECTION FOR ANY
COVERED RIGHTS IN SUCH PUBLICATION OR PRESENTATION THAT IT REASONABLY BELIEVES
MAY BE PATENTABLE.  ONCE SUCH ABSTRACTS, MANUSCRIPTS OR PRESENTATIONS HAVE BEEN
REVIEWED AND APPROVED BY EACH PARTY, THE SAME ABSTRACTS, MANUSCRIPTS OR
PRESENTATIONS DO NOT HAVE TO BE PROVIDED AGAIN TO THE OTHER PARTY FOR REVIEW FOR
A LATER SUBMISSION FOR PUBLICATION.  EACH PARTY ALSO SHALL HAVE THE RIGHT TO
REQUIRE THAT ANY OF ITS CONFIDENTIAL INFORMATION THAT IS DISCLOSED IN ANY SUCH
PROPOSED PUBLICATION OR PRESENTATION BE DELETED PRIOR TO SUCH PUBLICATION OR
PRESENTATION.  IN ANY PERMITTED PUBLICATION OR PRESENTATION BY A PARTY, THE
OTHER PARTY’S CONTRIBUTION SHALL BE DULY RECOGNIZED, AND CO-AUTHORSHIP SHALL BE
DETERMINED IN ACCORDANCE WITH CUSTOMARY INDUSTRY STANDARDS.

5.             INTELLECTUAL PROPERTY RIGHTS

EXCEPT AS OTHERWISE EXPRESSLY PROVIDED HEREIN, ALL INVENTIONS AND DISCOVERIES
GOVERNED BY THIS AGREEMENT SHALL BE OWNED BASED ON INVENTORSHIP, AS INVENTORSHIP
IS DETERMINED IN ACCORDANCE WITH UNITED STATES PATENT LAW.  NOTWITHSTANDING
ANYTHING TO THE CONTRARY IN THIS AGREEMENT, SANOFI-AVENTIS IMPROVEMENTS SHALL BE
SOLELY OWNED BY SANOFI-AVENTIS, AND LICENSED TECHNOLOGY AND LICENSED PATENT
RIGHTS SHALL BE SOLELY OWNED BY IMMUNOGEN.

6.             PROVISIONS CONCERNING THE FILING, PROSECUTION AND MAINTENANCE OF
PATENT RIGHTS

6.1           APPLICABILITY.  THE PROVISIONS OF THIS SECTION 6 SHALL BE
APPLICABLE TO ALL PATENTS COVERING LICENSED TECHNOLOGY AND LICENSED PATENT
RIGHTS UNLESS AND UNTIL THEY BECOME SUBJECT TO A LICENSE AGREEMENT, WHEREUPON
THE LICENSE AGREEMENT WILL GOVERN THE RIGHTS OF THE PARTIES WITH RESPECT TO THE
SUBJECT MATTER THEREOF.

6.2           PATENT FILING.

6.2.1        LICENSED TECHNOLOGY.  IMMUNOGEN, ACTING THROUGH PATENT COUNSEL OR
AGENTS OF ITS CHOICE, SHALL BE RESPONSIBLE, AT ITS SOLE COST AND EXPENSE, FOR
THE PREPARATION, FILING, PROSECUTION AND MAINTENANCE OF ALL LICENSED PATENT
RIGHTS.  ALL COSTS AND EXPENSES INCURRED BY IMMUNOGEN IN CONNECTION WITH THE
PREPARATION, FILING, PROSECUTION AND MAINTENANCE OF LICENSED PATENT RIGHTS SHALL
BE THE SOLE RESPONSIBILITY OF IMMUNOGEN.  AT IMMUNOGEN’S REQUEST, SANOFI-AVENTIS
SHALL COOPERATE WITH IMMUNOGEN IN ALL REASONABLE RESPECTS IN CONNECTION WITH
SUCH PREPARATION, FILING, PROSECUTION AND MAINTENANCE OF LICENSED PATENT RIGHTS.

12

--------------------------------------------------------------------------------

6.2.2        SANOFI-AVENTIS IMPROVEMENTS. SANOFI-AVENTIS, ACTING THROUGH PATENT
COUNSEL OR AGENTS OF ITS CHOICE, SHALL BE RESPONSIBLE, AT ITS SOLE COST AND
EXPENSE, FOR THE PREPARATION, FILING, PROSECUTION AND MAINTENANCE OF PATENT
APPLICATIONS AND PATENTS CONSTITUTING PATENT RIGHTS CLAIMING SANOFI-AVENTIS
IMPROVEMENTS.  SANOFI-AVENTIS (I) WILL PROVIDE IMMUNOGEN WITH A COPY OF ANY SUCH
PROPOSED PATENT APPLICATION FOR REVIEW AND COMMENT REASONABLY IN ADVANCE OF
FILING, AND (II) WILL KEEP IMMUNOGEN REASONABLY INFORMED OF THE STATUS OF SUCH
FILING, PROSECUTION AND MAINTENANCE, INCLUDING, WITHOUT LIMITATION, (A) BY
PROVIDING IMMUNOGEN WITH COPIES OF ALL COMMUNICATIONS RECEIVED FROM OR FILED IN
PATENT OFFICE(S) WITH RESPECT TO SUCH FILING, AND (B) BY PROVIDING IMMUNOGEN A
REASONABLE TIME PRIOR TO TAKING OR FAILING TO TAKE ANY ACTION THAT WOULD AFFECT
THE SCOPE OR VALIDITY OF ANY SUCH FILING (INCLUDING THE SUBSTANTIALLY NARROWING,
CANCELLATION OR ABANDONMENT OF ANY CLAIM(S) WITHOUT RETAINING THE RIGHT TO
PURSUE SUCH SUBJECT MATTER IN A SEPARATE APPLICATION, OR THE FAILURE TO FILE OR
PERFECT THE FILING OF ANY CLAIM(S) IN ANY COUNTRY), WITH PRIOR WRITTEN NOTICE OF
SUCH PROPOSED ACTION OR INACTION SO THAT IMMUNOGEN HAS A REASONABLE OPPORTUNITY
TO REVIEW AND COMMENT.  IF SANOFI-AVENTIS FAILS TO UNDERTAKE THE FILING(S) OF
ANY SUCH PATENT APPLICATION WITH RESPECT TO ANY SUCH INVENTION WITHIN [***]
([***]) DAYS AFTER RECEIPT OF WRITTEN NOTICE FROM IMMUNOGEN THAT IMMUNOGEN
BELIEVES FILING(S) OF SUCH AN APPLICATION BY SANOFI-AVENTIS IS APPROPRIATE,
IMMUNOGEN MAY UNDERTAKE SUCH FILING(S) AT ITS OWN EXPENSE, IN WHICH CASE
SANOFI-AVENTIS WILL ASSIGN ALL OF ITS RIGHTS TO SUCH IMPROVEMENTS TO IMMUNOGEN
AND ANY SUBSEQUENTLY ISSUED PATENT THEREON WILL BE OWNED SOLELY BY IMMUNOGEN.

6.2.3        COOPERATION.  EACH PARTY AGREES TO COOPERATE REASONABLY WITH THE
OTHER PARTY IN THE PREPARATION, FILING, AND PROSECUTION OF ANY PATENT
APPLICATIONS PURSUANT TO THIS SECTION 6.2.  SUCH COOPERATION INCLUDES, BUT IS
NOT LIMITED TO, EXECUTING ALL PAPERS AND INSTRUMENTS, OR REQUIRING ITS EMPLOYEES
OR AGENTS TO EXECUTE SUCH PAPERS AND INSTRUMENTS, SO AS TO EFFECTUATE THE
OWNERSHIP OF SUCH PATENT APPLICATIONS AND ANY PATENTS THEREON AND TO ENABLE THE
FILING AND PROSECUTION OF APPLICATIONS IN ANY COUNTRY.

6.3           INFRINGEMENT.

6.3.1        SANOFI-AVENTIS IMPROVEMENTS.  SANOFI-AVENTIS SHALL HAVE ALL RIGHTS,
AT ITS OWN EXPENSE, TO BRING SUIT (OR OTHER APPROPRIATE LEGAL ACTION) AGAINST
ANY ACTUAL OR SUSPECTED INFRINGEMENT OF PATENT RIGHTS CLAIMING SANOFI-AVENTIS
IMPROVEMENTS.

6.3.2        IMMUNOGEN TECHNOLOGY.  IMMUNOGEN SHALL HAVE ALL RIGHTS, AT ITS OWN
EXPENSE, TO BRING SUIT (OR OTHER APPROPRIATE LEGAL ACTION) AGAINST ANY ACTUAL OR
SUSPECTED INFRINGEMENT OF THE LICENSED PATENT RIGHTS.

6.4           COOPERATION.  EACH PARTY SHALL GIVE NOTICE TO THE OTHER PARTY OF
ANY POTENTIAL INFRINGEMENT OR ACTUAL INFRINGEMENT BY A THIRD PARTY OF ANY
PATENTS RIGHTS COVERING LICENSED TECHNOLOGY AND SHALL EXECUTE ALL PAPERS AND
PERFORM SUCH OTHER ACTS (OTHER THAN MONETARY) AS MAY BE REASONABLY REQUIRED TO
MAINTAIN ANY INFRINGEMENT SUIT BROUGHT IN ACCORDANCE WITH SECTION 6.3 ABOVE
(INCLUDING GIVING LEGAL CONSENT FOR BRINGING SUCH SUIT, AND AGREEING TO BE NAMED
AS A PLAINTIFF OR OTHERWISE JOINED IN SUCH SUIT), AND AT ITS OPTION AND EXPENSE,
MAY BE REPRESENTED IN SUCH SUIT BY COUNSEL OF ITS CHOICE.  IN ADDITION, THE
PARTIES SHALL REASONABLY COOPERATE WITH EACH OTHER IN OBTAINING PATENT TERM
RESTORATION OR SUPPLEMENTAL PROTECTION

13

--------------------------------------------------------------------------------

CERTIFICATES OR THEIR EQUIVALENTS IN ANY COUNTRY IN THE TERRITORY WHERE
APPLICABLE TO LICENSED PATENT RIGHTS.

6.5           NO OBLIGATION.  NO PARTY SHALL HAVE ANY OBLIGATION TO THE OTHER
PARTY UNDER THIS AGREEMENT TO PAY ANY FEES OR COSTS: (I) FOR THAT PARTY’S
BRINGING A LAWSUIT OR OTHER ACTION TO ENFORCE ANY LICENSED PATENT RIGHTS, OR ANY
OTHER PATENT OWNED BY A PARTY AGAINST AN ACTUAL OR SUSPECTED INFRINGEMENT OR
(II) FOR ANY OTHER PARTY TO OBTAIN FOR ITS OWN BENEFIT INDEPENDENT BUSINESS OR
LEGAL ADVICE CONCERNING ANY OF THE PATENT RIGHTS SET FORTH IN CLAUSE (I) HEREOF.

7.             TERM AND TERMINATION

7.1           TERM.  UNLESS EARLIER TERMINATED AS PROVIDED IN THIS SECTION 7,
THE TERM OF THIS AGREEMENT SHALL EXPIRE UPON THE LATER OF THE EXPIRATION OF THE
RESEARCH TERM OR THE LAST TO EXPIRE OF THE OPTION PERIODS (THE “TERM”).

7.2           TERMINATION.  THIS AGREEMENT AND THE RIGHTS AND OPTIONS GRANTED
HEREIN MAY BE TERMINATED BY EITHER PARTY UPON ANY MATERIAL BREACH BY THE OTHER
PARTY OF ANY MATERIAL OBLIGATION OR CONDITION, EFFECTIVE [***] ([***]) DAYS
AFTER GIVING WRITTEN NOTICE TO THE BREACHING PARTY OF SUCH TERMINATION IN THE
CASE OF A PAYMENT BREACH AND [***] ([***]) DAYS AFTER GIVING WRITTEN NOTICE TO
THE BREACHING PARTY OF SUCH TERMINATION IN THE CASE OF ANY OTHER BREACH, WHICH
NOTICE SHALL DESCRIBE SUCH BREACH IN REASONABLE DETAIL.  THE FOREGOING
NOTWITHSTANDING, IF SUCH DEFAULT OR BREACH IS CURED OR SHOWN TO BE NON-EXISTENT
WITHIN THE AFORESAID [***] ([***]) OR [***] ([***]) DAY PERIOD, THE NOTICE SHALL
BE AUTOMATICALLY WITHDRAWN AND OF NO EFFECT.  HOWEVER, PRIOR TO GIVING ANY
NOTICE FOR BREACH, THE PARTIES SHALL FIRST ATTEMPT TO RESOLVE ANY DISPUTES AS TO
THE EXISTENCE OF ANY BREACH AS SET FORTH IN SECTION 8.14.  ADDITIONALLY, UNTIL
SUCH TIME AS SANOFI-AVENTIS HAS EXERCISED THE RESEARCH TERM OPTION,
SANOFI-AVENTIS SHALL HAVE THE FURTHER RIGHT TO TERMINATE THIS AGREEMENT UPON
PROVIDING NOT LESS THAN [***] ([***]) DAYS’ WRITTEN NOTICE TO IMMUNOGEN OF SUCH
TERMINATION.

7.3           REMEDIES.  IF EITHER PARTY SHALL FAIL TO PERFORM OR OBSERVE OR
OTHERWISE BREACHES ANY OF ITS MATERIAL OBLIGATIONS UNDER THIS AGREEMENT, IN
ADDITION TO ANY RIGHT TO TERMINATE THIS AGREEMENT, THE NON-DEFAULTING PARTY MAY
ELECT TO OBTAIN OTHER RELIEF AND REMEDIES AVAILABLE UNDER LAW.

7.4           SURVIVING PROVISIONS.  NOTWITHSTANDING ANY PROVISION HEREIN TO THE
CONTRARY, THE RIGHTS AND OBLIGATIONS SET FORTH IN SECTIONS 2.3.6, 4, 5, 6.2,
7.4, 8.4, 8.5, 8.6, 8.16 AND 8.17 HEREOF SHALL SURVIVE THE EXPIRATION OF THE
TERM OR THE TERMINATION OF THIS AGREEMENT.  ALL OTHER RIGHTS AND LICENSES OF THE
PARTIES SET FORTH IN THIS AGREEMENT SHALL TERMINATE.

8.             REPRESENTATIONS, WARRANTIES AND COVENANTS

8.1           MUTUAL REPRESENTATIONS AND WARRANTIES.  IMMUNOGEN AND
SANOFI-AVENTIS EACH REPRESENTS AND WARRANTS TO THE OTHER, AS OF THE EFFECTIVE
DATE, AS FOLLOWS:

8.1.1        ORGANIZATION.  IT IS A CORPORATION DULY ORGANIZED, VALIDLY EXISTING
AND IN GOOD STANDING UNDER THE LAWS OF THE JURISDICTION OF ITS ORGANIZATION, AND
HAS ALL REQUISITE POWER AND AUTHORITY, CORPORATE OR OTHERWISE, TO EXECUTE,
DELIVER AND PERFORM THIS AGREEMENT.

14

--------------------------------------------------------------------------------

8.1.2        AUTHORIZATION.  THE EXECUTION AND DELIVERY OF THIS AGREEMENT AND
THE PERFORMANCE BY IT OF THE TRANSACTIONSCONTEMPLATED HEREBY HAVE BEEN DULY
AUTHORIZED BY ALL NECESSARY CORPORATE ACTION AND WILL NOT VIOLATE (A) SUCH
PARTY’S CERTIFICATE OF INCORPORATION OR BYLAWS, (B) ANY AGREEMENT, INSTRUMENT OR
CONTRACTUAL OBLIGATION TO WHICH SUCH PARTY IS BOUND IN ANY MATERIAL RESPECT, (C)
ANY REQUIREMENT OF ANY APPLICABLE LAW, OR (D) ANY ORDER, WRIT, JUDGMENT,
INJUNCTION, DECREE, DETERMINATION OR AWARD OF ANY COURT OR GOVERNMENTAL AGENCY
PRESENTLY IN EFFECT APPLICABLE TO SUCH PARTY.

8.1.3        BINDING AGREEMENT.  THIS AGREEMENT IS A LEGAL, VALID AND BINDING
OBLIGATION OF SUCH PARTY ENFORCEABLE AGAINST IT IN ACCORDANCE WITH ITS TERMS AND
CONDITIONS.

8.1.4        NO INCONSISTENT OBLIGATION.  IT IS NOT UNDER ANY OBLIGATION,
CONTRACTUAL OR OTHERWISE, TO ANY PERSON THAT CONFLICTS WITH OR IS INCONSISTENT
IN ANY RESPECT WITH THE TERMS OF THIS AGREEMENT OR THAT WOULD IMPEDE THE
DILIGENT AND COMPLETE FULFILLMENT OF ITS OBLIGATIONS HEREUNDER.

8.2           ADDITIONAL REPRESENTATIONS OF IMMUNOGEN.  IMMUNOGEN FURTHER
REPRESENTS AND WARRANTS TO SANOFI-AVENTIS, AS OF THE EFFECTIVE DATE, AS FOLLOWS:

8.2.1        LICENSED PATENT RIGHTS.  ALL LICENSED PATENT RIGHTS EXISTING AS OF
THE EFFECTIVE DATE ARE EXISTING AND, TO IMMUNOGEN’S KNOWLEDGE, NO SUCH LICENSED
PATENT RIGHTS ARE INVALID OR UNENFORCEABLE.

8.2.2        CLAIMS OR JUDGMENTS.  THERE ARE NO CLAIMS, JUDGMENT OR SETTLEMENTS
AGAINST IMMUNOGEN PENDING, OR TO IMMUNOGEN’S KNOWLEDGE, THREATENED, THAT
INVALIDATE OR SEEK TO INVALIDATE THE LICENSED PATENT RIGHTS EXISTING AS OF THE
EFFECTIVE DATE.

8.2.3        RIGHT TO TECHNOLOGY.  IMMUNOGEN HAS THE RIGHT TO (A) USE THE
LICENSED TECHNOLOGY AND LICENSED PATENT RIGHTS EXISTING AS OF THE EFFECTIVE DATE
AS IS NECESSARY TO FULFILL ITS OBLIGATIONS UNDER THIS AGREEMENT; AND (B) GRANT
THE LICENSES UNDER THE LICENSED PATENT RIGHTS GRANTED PURSUANT TO THIS
AGREEMENT.

8.2.4        NO INFRINGEMENT.  TO IMMUNOGEN’S KNOWLEDGE, NO THIRD PARTY IS
INFRINGING, OR THREATENING TO INFRINGE, THE LICENSED PATENT RIGHTS.

8.2.5        NO LITIGATION.  TO IMMUNOGEN’S KNOWLEDGE, THERE IS NO PENDING OR
THREATENED LITIGATION THAT ALLEGES THAT IMMUNOGEN’S PROPOSED ACTIVITIES UNDER
THIS AGREEMENT WOULD INFRINGE OR MISAPPROPRIATE ANY INTELLECTUAL PROPERTY RIGHTS
OF ANY THIRD PARTY.

8.3           COVENANT.  IMMUNOGEN AGREES TO USE COMMERCIALLY REASONABLE EFFORTS
TO MAINTAIN THE RIGHT, TO (A) USE THE LICENSED TECHNOLOGY AND LICENSED PATENT
RIGHTS EXISTING AS OF THE EFFECTIVE DATE AS IS NECESSARY TO FULFILL ITS
OBLIGATIONS UNDER THIS AGREEMENT; AND (B) GRANT THE LICENSES UNDER THE LICENSED
PATENT RIGHTS GRANTED PURSUANT TO THIS AGREEMENT.

9.             INDEMNIFICATION

9.1           INDEMNIFICATION OF SANOFI-AVENTIS BY IMMUNOGEN.  IMMUNOGEN SHALL
INDEMNIFY, DEFEND AND HOLD HARMLESS SANOFI-AVENTIS, ITS AFFILIATES, THEIR
RESPECTIVE DIRECTORS,

15

--------------------------------------------------------------------------------

OFFICERS, EMPLOYEES AND AGENTS, AND THEIR RESPECTIVE SUCCESSORS, HEIRS AND
ASSIGNS (COLLECTIVELY, THE “SANOFI-AVENTIS INDEMNITEES”), AGAINST ALL
LIABILITIES, DAMAGES, LOSSES AND EXPENSES (INCLUDING, WITHOUT LIMITATION,
REASONABLE ATTORNEYS’ FEES AND EXPENSES OF LITIGATION) (COLLECTIVELY, “LOSSES”)
INCURRED BY OR IMPOSED UPON THE SANOFI-AVENTIS INDEMNITEES, OR ANY ONE OF THEM,
AS A DIRECT RESULT OF CLAIMS, SUITS, ACTIONS, DEMANDS OR JUDGMENTS OF THIRD
PARTIES, INCLUDING WITHOUT LIMITATION PERSONAL INJURY AND PRODUCT LIABILITY
CLAIMS AND CLAIMS OF SUPPLIERS AND IMMUNOGEN EMPLOYEES (COLLECTIVELY, “CLAIMS”),
ARISING OUT OF THE MATERIAL BREACH BY IMMUNOGEN OF THIS AGREEMENT, EXCEPT WITH
RESPECT TO ANY CLAIM OR LOSSES THAT RESULT FROM A MATERIAL BREACH OF THIS
AGREEMENT BY, OR THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF, SANOFI-AVENTIS,
PROVIDED THAT, WITH RESPECT TO ANY CLAIM FOR WHICH IMMUNOGEN HAS AN OBLIGATION
TO ANY SANOFI-AVENTIS INDEMNITEE PURSUANT TO THIS SECTION 9.1 AND SANOFI-AVENTIS
HAS AN OBLIGATION TO ANY IMMUNOGEN INDEMNITEE PURSUANT TO SECTION 9.2, EACH
PARTY SHALL INDEMNIFY EACH OF THE OTHER PARTY’S INDEMNITEES FOR ITS LOSSES TO
THE EXTENT OF ITS RESPONSIBILITY, RELATIVE TO THE OTHER PARTY, FOR THE FACTS
UNDERLYING THE CLAIM.

9.2           INDEMNIFICATION OF IMMUNOGEN BY SANOFI-AVENTIS.  SANOFI-AVENTIS
SHALL INDEMNIFY, DEFEND AND HOLD HARMLESS IMMUNOGEN, ITS AFFILIATES, THEIR
RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS, AND THEIR RESPECTIVE
SUCCESSORS, HEIRS AND ASSIGNS (THE “IMMUNOGEN INDEMNITEES”), AGAINST ANY LOSSES
INCURRED BY OR IMPOSED UPON THE IMMUNOGEN INDEMNITEES, OR ANY ONE OF THEM, AS A
DIRECT RESULT OF CLAIMS ARISING OUT OF (A) THE MATERIAL BREACH BY SANOFI-AVENTIS
OF THIS AGREEMENT; (B) THE DEVELOPMENT OR COMMERCIALIZATION (INCLUDING, WITHOUT
LIMITATION, THE PRODUCTION, MANUFACTURE, PROMOTION, IMPORT, SALE OR USE BY ANY
PERSON) OF ANY MAY COMPOUND OR AB-MAY PRODUCT BY SANOFI-AVENTIS OR ANY OF ITS
AFFILIATES, SUBLICENSEES, DISTRIBUTORS OR AGENTS, EXCEPT WITH RESPECT TO ANY
CLAIM OR LOSSES THAT RESULT FROM A BREACH OF THIS AGREEMENT BY, OR THE GROSS
NEGLIGENCE OR WILLFUL MISCONDUCT OF, IMMUNOGEN, PROVIDED THAT WITH RESPECT TO
ANY CLAIM FOR WHICH IMMUNOGEN HAS AN OBLIGATION TO ANY SANOFI-AVENTIS INDEMNITEE
PURSUANT TO SECTION 9.1 AND SANOFI-AVENTIS HAS AN OBLIGATION TO ANY IMMUNOGEN
INDEMNITEE PURSUANT TO THIS SECTION 9.2, EACH PARTY SHALL INDEMNIFY EACH OF THE
OTHER PARTY’S INDEMNITEES FOR ITS LOSSES TO THE EXTENT OF ITS RESPONSIBILITY,
RELATIVE TO THE OTHER PARTY, FOR THE FACTS UNDERLYING THE CLAIM.

9.3           CONDITIONS TO INDEMNIFICATION.  A PERSON SEEKING RECOVERY UNDER
SECTIONS 9.1 OR 9.2(THE “INDEMNIFIED PARTY”) IN RESPECT OF A CLAIM SHALL GIVE
PROMPT NOTICE OF SUCH CLAIM TO THE PARTY FROM WHICH RECOVERY IS SOUGHT (THE
“INDEMNIFYING PARTY”) AND, PROVIDED THAT THE INDEMNIFYING PARTY IS NOT
CONTESTING ITS OBLIGATION UNDER SECTIONS 9.1 OR 9.2, SHALL PERMIT THE
INDEMNIFYING PARTY TO CONTROL ANY LITIGATION RELATING TO SUCH CLAIM AND THE
DISPOSITION OF SUCH CLAIM, PROVIDED THAT THE INDEMNIFYING PARTY SHALL (A) ACT
REASONABLY AND IN GOOD FAITH WITH RESPECT TO ALL MATTERS RELATING TO THE
SETTLEMENT OR DISPOSITION OF SUCH CLAIM AS THE SETTLEMENT OR DISPOSITION RELATES
TO SUCH INDEMNIFIED PARTY AND (B) NOT SETTLE OR OTHERWISE RESOLVE SUCH CLAIM
WITHOUT THE PRIOR WRITTEN CONSENT OF SUCH INDEMNIFIED PARTY (WHICH CONSENT SHALL
NOT BE UNREASONABLY WITHHELD, CONDITIONED OR DELAYED).  EACH INDEMNIFIED PARTY
SHALL COOPERATE WITH THE INDEMNIFYING PARTY IN ITS DEFENSE OF ANY SUCH CLAIM IN
ALL REASONABLE RESPECTSAND SHALL HAVE THE RIGHT TO BE PRESENT IN PERSON OR
THROUGH COUNSEL AT ALL LEGAL PROCEEDINGS WITH RESPECT TO SUCH CLAIM.

9.4           WARRANTY DISCLAIMER.  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN
THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT

16

--------------------------------------------------------------------------------

TO ANY TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS
AGREEMENT AND EACH PARTY HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED,
INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A
PARTICULAR PURPOSE AND NONINFRINGEMENT.

9.5           LIMITED LIABILITY.  NOTWITHSTANDING ANYTHING TO THE CONTRARY IN
THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS
AFFILIATES FOR (I) ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL
DAMAGES, INCLUDING WITHOUT LIMITATION LOST PROFITS OR LOST REVENUES, OR (II)
COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES, WHETHER UNDER
ANY CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE
THEORY.

10.          MISCELLANEOUS

10.1         NOTICES.  ANY NOTICES, REQUESTS, DELIVERIES, APPROVALS OR CONSENTS
REQUIRED OR PERMITTED TO BE GIVEN UNDER THIS AGREEMENT TO SANOFI-AVENTIS OR
IMMUNOGEN SHALL BE IN WRITING AND SHALL BE EFFECTIVE ON RECEIPT WHEN DELIVERED
TO THE APPLICABLE ADDRESS SPECIFIED BELOW (OR TO SUCH OTHER ADDRESS AS MAY BE
SPECIFIED IN WRITING TO THE OTHER PARTY HERETO):

If to ImmunoGen:

ImmunoGen, Inc.

 

128 Sidney Street

 

Cambridge, MA 02139

 

Attn: Chief Executive Officer

 

 

With a copy to:

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

 

One Financial Center

 

Boston, MA 02111

 

Attn: [***] [***] [***], Esq

 

Telecopy: 617-542-2241

 

 

If to sanofi-aventis:

sanofi-aventis U.S. Inc.

 

1041 Rt.202-206

 

Bridgewater, NJ 08807

 

Attn: Head, US Alliance & Partnerships

 

 

With a copy to:

 

 

Attn: Head, US R&D Legal

 

Except as otherwise expressly provided in this Agreement or mutually agreed in
writing, any notice, communication or document (excluding payment) required to
be given or made shall be deemed given or made and effective upon actual receipt
or, if earlier, (a) three (3) business days after deposit with an
internationally-recognized overnight express courier with changes prepaid, or
(b) five (5) business days after mailed by certified, registered or regular
mail, postage prepaid, in each case addressed to a Parties at its address stated
above or to such other address as such Party may designate by written notice
given in accordance with this Section 10.1.

17

--------------------------------------------------------------------------------

10.2         GOVERNING LAW.  THIS AGREEMENT WILL BE CONSTRUED, INTERPRETED AND
APPLIED IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE (EXCLUDING ITS BODY
OF LAW CONTROLLING CONFLICTS OF LAW).

10.3         LIMITATIONS.  EXCEPT AS SET FORTH ELSEWHERE IN THIS AGREEMENT,
NEITHER PARTY GRANTS TO THE OTHER PARTY ANY RIGHT OR LICENSE TO ANY OF ITS
INTELLECTUAL PROPERTY.

10.4         ENTIRE AGREEMENT.  THIS IS THE ENTIRE AGREEMENT BETWEEN THE PARTIES
WITH RESPECT TO THE SUBJECT MATTER HEREOF AND SUPERSEDES ALL PRIOR
REPRESENTATIONS, UNDERSTANDINGS AND AGREEMENTS BETWEEN THE PARTIES WITH RESPECT
TO THE SUBJECT MATTER HEREOF, INCLUDING WITHOUT LIMITATION THE OPTION
AGREEMENT.  NO MODIFICATION SHALL BE EFFECTIVE UNLESS IN WRITING WITH SPECIFIC
REFERENCE TO THIS AGREEMENT AND SIGNED BY THE PARTIES.

10.5         WAIVER.  THE TERMS OR CONDITIONS OF THIS AGREEMENT MAY BE WAIVED
ONLY BY A WRITTEN INSTRUMENT EXECUTED BY THE PARTY WAIVING COMPLIANCE.  THE
FAILURE OF EITHER PARTY AT ANY TIME OR TIMES TO REQUIRE PERFORMANCE OF ANY
PROVISION HEREOF SHALL IN NO MANNER AFFECT ITS RIGHTS AT A LATER TIME TO ENFORCE
THE SAME.  NO WAIVER BY EITHER PARTY OF ANY CONDITION OR TERM SHALL BE DEEMED AS
A CONTINUING WAIVER OF SUCH CONDITION OR TERM OR OF ANOTHER CONDITION OR TERM.

10.6         HEADINGS.  SECTION AND SUBSECTION HEADINGS ARE INSERTED FOR
CONVENIENCE OF REFERENCE ONLY AND DO NOT FORM PART OF THIS AGREEMENT.

10.7         ASSIGNMENT.  NEITHER THIS AGREEMENT NOR ANY OBLIGATION OF A PARTY
HEREUNDER MAY BE ASSIGNED BY EITHER PARTY WITHOUT THE CONSENT OF THE OTHER WHICH
SHALL NOT BE UNREASONABLY WITHHELD, EXCEPT THAT EACH PARTY MAY ASSIGN THIS
AGREEMENT AND THE RIGHTS, OBLIGATIONS AND INTERESTS OF SUCH PARTY, IN WHOLE OR
IN PART, TO ANY OF ITS AFFILIATES, AND TO ANY THIRD PARTY PURCHASER OF ALL OF
THE CAPITAL STOCK OF SUCH PARTY OR ALL OR SUBSTANTIALLY ALL OF ITS ASSETS IN THE
LINE OF BUSINESS TO WHICH THIS AGREEMENT PERTAINS OR TO ANY SUCCESSOR
CORPORATION RESULTING FROM ANY MERGER OR CONSOLIDATION OF SUCH PARTY WITH OR
INTO SUCH CORPORATION.

10.8         FORCE MAJEURE.  NEITHER PARTY SHALL BE LIABLE FOR FAILURE OF OR
DELAY IN PERFORMING OBLIGATIONS SET FORTH IN THIS AGREEMENT, AND NEITHER SHALL
BE DEEMED IN BREACH OF ITS OBLIGATIONS, IF SUCH FAILURE OR DELAY IS DUE TO
NATURAL DISASTERS OR ANY CAUSES BEYOND THE REASONABLE CONTROL OF SUCH PARTY.  IN
THE EVENT OF SUCH FORCE MAJEURE, THE PARTY AFFECTED THEREBY SHALL USE REASONABLE
EFFORTS TO CURE OR OVERCOME THE SAME AND RESUME PERFORMANCE OF ITS OBLIGATIONS
HEREUNDER.

10.9         CONSTRUCTION.  THE PARTIES HERETO ACKNOWLEDGE AND AGREE THAT EACH
PARTY AND ITS COUNSEL REVIEWED AND NEGOTIATED THE TERMS AND PROVISIONS OF THIS
AGREEMENT AND HAVE CONTRIBUTED TO ITS REVISION.

10.10       SEVERABILITY.  IF ANY PROVISION(S) OF THIS AGREEMENT ARE OR BECOME
INVALID, ARE RULED ILLEGAL BY ANY COURT OF COMPETENT JURISDICTION OR ARE DEEMED
UNENFORCEABLE UNDER THEN CURRENT APPLICABLE LAW FROM TIME TO TIME IN EFFECT
DURING THE TERM HEREOF, IT IS THE INTENTION OF THE PARTIES THAT THE REMAINDER OF
THIS AGREEMENT SHALL NOT BE AFFECTED THEREBY PROVIDED THAT A PARTY’S RIGHTS
UNDER THIS AGREEMENT ARE NOT MATERIALLY AFFECTED.  THE PARTIES HERETO COVENANT
AND AGREE TO RENEGOTIATE ANY SUCH TERM, COVENANT OR APPLICATION THEREOF IN GOOD
FAITH IN ORDER TO PROVIDE A REASONABLY ACCEPTABLE ALTERNATIVE TO THE TERM,
COVENANT OR CONDITION OF THIS AGREEMENT

18

--------------------------------------------------------------------------------

OR THE APPLICATION THEREOF THAT IS INVALID, ILLEGAL OR UNENFORCEABLE, IT BEING
THE INTENT OF THE PARTIES THAT THE BASIC PURPOSES OF THIS AGREEMENT ARE TO BE
EFFECTUATED.

10.11       STATUS.  NOTHING IN THIS AGREEMENT IS INTENDED OR SHALL BE DEEMED TO
CONSTITUTE A PARTNER, AGENCY, EMPLOYER-EMPLOYEE, OR JOINT VENTURE RELATIONSHIP
BETWEEN THE PARTIES.

10.12       SECTION 365(N).  ALL LICENSES GRANTED UNDER THIS AGREEMENT ARE
DEEMED TO BE, FOR PURPOSES OF SECTION 365(N) OF THE U.S. BANKRUPTCY CODE,
LICENSES OF RIGHT TO “INTELLECTUAL PROPERTY” AS DEFINED IN SECTION 101 OF SUCH
CODE.  THE PARTIES AGREE THAT THE LICENSEE MAY FULLY EXERCISE ALL OF ITS RIGHTS
AND ELECTIONS UNDER THE U.S. BANKRUPTCY CODE, REGARDLESS OF WHETHER EITHER PARTY
FILES FOR BANKRUPTCY IN THE UNITED STATES OR OTHER JURISDICTION.  THE PARTIES
FURTHER AGREE THAT, IN THE EVENT A LICENSEE ELECTS TO RETAIN ITS RIGHTS AS A
LICENSEE UNDER SUCH CODE, THE LICENSEE SHALL BE ENTITLED TO COMPLETE ACCESS TO
ANY TECHNOLOGY LICENSED TO IT HEREUNDER AND ALL EMBODIMENTS OF SUCH TECHNOLOGY. 
SUCH EMBODIMENTS OF THE TECHNOLOGY SHALL BE DELIVERED TO THE LICENSEE NOT LATER
THAN (A) THE COMMENCEMENT OF BANKRUPTCY PROCEEDINGS AGAINST THE LICENSOR, UPON
WRITTEN REQUEST, UNLESS THE LICENSOR ELECTS TO PERFORM ITS OBLIGATIONS UNDER THE
AGREEMENT, OR (B) IF NOT DELIVERED UNDER SECTION 10.12(A) ABOVE, UPON THE
REJECTION OF THIS AGREEMENT BY OR ON BEHALF OF THE LICENSOR, UPON WRITTEN
REQUEST.

10.13       FURTHER ASSURANCES.  EACH PARTY AGREES TO EXECUTE, ACKNOWLEDGE AND
DELIVER SUCH FURTHER INSTRUCTIONS, AND TO DO ALL SUCH OTHER ACTS, AS MAY BE
NECESSARY OR APPROPRIATE IN ORDER TO CARRY OUT THE PURPOSES AND INTENT OF THIS
AGREEMENT.

10.14       COUNTERPARTS.  THIS AGREEMENT MAY BE EXECUTED SIMULTANEOUSLY IN ONE
OR MORE COUNTERPARTS, EACH OF WHICH SHALL BE DEEMED AN ORIGINAL, BUT ALL OF
WHICH TOGETHER SHALL CONSTITUTE ONE AND THE SAME INSTRUMENT.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK.]

19

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by
their duly authorized representative in two (2) originals.

 

IMMUNOGEN, INC.

 

 

 

 

 

By:

 

 

 

Name:

 

 

 

Title:

 

 

 

 

 

 

 

SANOFI-AVENTIS U.S. LLC

 

 

 

 

 

By:

 

 

 

Name:

 

 

 

Title:

 

 

 

 

 

 

 

SANOFI-AVENTIS U.S. LLC

 

 

 

 

 

By:

 

 

 

Name:

 

 

 

Title:

 

 

 

20

--------------------------------------------------------------------------------

APPENDIX A

FORM OF EXCLUSIVE LICENSE AGREEMENT

This EXCLUSIVE LICENSE AGREEMENT (this “Agreement”) is entered into as of
                 ,         , by and between ImmunoGen, Inc., a Massachusetts
corporation having a principal place of business at 128 Sidney Street,
Cambridge, Massachusetts 02139 (“ImmunoGen”), and sanofi-aventis U.S. LLC, a
limited liability company organized and existing under the laws of Delaware with
offices at 1041 Rt.202-206, Bridgewater, NJ 08807 (“sanofi-aventis”).  Each of
sanofi-aventis and ImmunoGen is sometimes referred to individually herein as a
“Party” and collectively as the “Parties.”

WHEREAS, the Parties executed an Option and License Agreement (as hereinafter
defined) pursuant to which ImmunoGen granted sanofi-aventis certain options to
license certain Technology Controlled by ImmunoGen; and

WHEREAS, ImmunoGen has entered into agreements based on the so-called
“Revolving-Door” structure with a number of Third Parties whereby such Third
Parties are obligated to grant back to ImmunoGen the right to such Third
Parties’ improvements to Technology and Patent Rights, and pursuant to which
ImmunoGen has the right to grant access to such Third Party Improvements to
sanofi-aventis; and

WHEREAS, sanofi-aventis exercised an Option (as hereinafter defined) pursuant to
the Option and License Agreement, pursuant to which the Parties have agreed to
enter into this Agreement in accordance with the terms thereof.

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and
for other good and valuable consideration, the Parties hereto, intending to be
legally bound, hereby agree as follows:

1.             DEFINITIONS

Whenever used in this Agreement with an initial capital letter, the terms
defined in this Section 1 shall have the meanings specified.

1.1           “AB-MAY PRODUCT” MEANS ANY PRODUCT CONTAINING A CONJUGATE OF A
SANOFI-AVENTIS ANTIBODY WITH A MAY COMPOUND.

1.2           “AFFILIATE” MEANS, WITH RESPECT TO ANY PARTY, ANY PERSON THAT,
DIRECTLY OR THROUGH ONE OR MORE AFFILIATES, CONTROLS, OR IS CONTROLLED BY, OR IS
UNDER COMMON CONTROL WITH, SUCH PARTY.  FOR PURPOSES OF THIS DEFINITION,
“CONTROL” MEANS (A) OWNERSHIP OF MORE THAN FIFTY PERCENT (50%) OF THE SHARES OF
STOCK ENTITLED TO VOTE FOR THE ELECTION OF DIRECTORS IN THE CASE OF A
CORPORATION, OR MORE THAN FIFTY PERCENT (50%) OF THE EQUITY INTERESTS IN THE
CASE OF ANY OTHER TYPE OF LEGAL ENTITY, (B) STATUS AS A GENERAL PARTNER IN ANY
PARTNERSHIP, OR (C) ANY OTHER ARRANGEMENT WHEREBY A PERSON CONTROLS OR HAS THE
RIGHT TO CONTROL THE BOARD OF DIRECTORS OF A CORPORATION OR EQUIVALENT GOVERNING
BODY OF AN ENTITY OTHER THAN A CORPORATION.

1.3           “ANNUAL NET SALES” MEANS THE AGGREGATE NET SALES DURING A
PARTICULAR CALENDAR YEAR.

A-1

--------------------------------------------------------------------------------

1.4           “ANTIBODY” MEANS A POLYCLONAL OR MONOCLONAL ANTIBODY, WHETHER
MULTIPLE OR SINGLE CHAIN, RECOMBINANT OR NATURALLY OCCURRING, WHOLE OR FRAGMENT,
AND ANY VARIANTS, DERIVATIVES OR CONSTRUCTS THEREOF, INCLUDING BUT NOT LIMITED
TO, ANTIGEN BINDING PORTIONS INCLUDING FAB, FAB’, F(AB’)2, FV, DAB AND CDR
FRAGMENTS, SINGLE CHAIN ANTIBODIES (SCFV), CHIMERIC ANTIBODIES, DIABODIES AND
POLYPEPTIDES (INCLUDING ANY HUMANIZED VERSIONS THEREOF) THAT CONTAIN AT LEAST A
PORTION OF AN IMMUNOGLOBULIN THAT IS SUFFICIENT TO CONFER SPECIFIC ANTIGEN
BINDING TO THE POLYPEPTIDE.

1.5           “ANTIBODY-MAY COMPOUND CONJUGATE” MEANS ANY COMPOUND CONTAINING A
CONJUGATE OF AN ANTIBODY WITH A MAY COMPOUND.

1.6           “APPLICABLE LAWS” MEANS FEDERAL, STATE, LOCAL, NATIONAL AND
SUPRA-NATIONAL LAWS, STATUTES, RULES AND REGULATIONS, INCLUDING ANY RULES,
REGULATIONS, GUIDANCE, GUIDELINES OR REQUIREMENTS OF REGULATORY AUTHORITIES,
NATIONAL SECURITIES EXCHANGES OR SECURITIES LISTING ORGANIZATIONS, THAT MAY BE
IN EFFECT FROM TIME TO TIME DURING THE TERM AND APPLICABLE TO A PARTICULAR
ACTIVITY HEREUNDER.

1.7           “BUSINESS DAY” MEANS A DAY ON WHICH BANKING INSTITUTIONS IN NEW
YORK, NEW YORK ARE OPEN FOR BUSINESS.

1.8           “CALENDAR QUARTER” MEANS THE PERIOD BEGINNING ON THE EFFECTIVE
DATE AND ENDING ON THE LAST DAY OF THE CALENDAR QUARTER IN WHICH THE EFFECTIVE
DATE FALLS, AND THEREAFTER EACH SUCCESSIVE PERIOD OF THREE (3) CONSECUTIVE
CALENDAR MONTHS ENDING ON MARCH 31, JUNE 30, SEPTEMBER 30 OR DECEMBER 31.

1.9           “CALENDAR YEAR” MEANS EACH SUCCESSIVE PERIOD OF TWELVE (12) MONTHS
COMMENCING ON JANUARY 1 AND ENDING ON DECEMBER 31.

1.10         “CLINICAL MATERIALS” MEANS ANY SUPPLIES OF MAY COMPOUND OR LICENSED
PRODUCT MANUFACTURED BY IMMUNOGEN IN ACCORDANCE WITH ALL APPLICABLE LAWS
(INCLUDING GMP) AND APPLICABLE SPECIFICATIONS FOR USE IN HUMAN CLINICAL TESTING
UP TO AND INCLUDING NON-PIVOTAL PHASE IIB STUDIES.

1.11         “COLLABORATION AGREEMENT” MEANS THAT CERTAIN COLLABORATION AND
LICENSE AGREEMENT DATED AS OF JULY 30, 2003, AS AMENDED, BY AND BETWEEN
IMMUNOGEN AND AVENTIS PHARMACEUTICALS, INC., THE PREDECESSOR IN INTEREST TO
SANOFI-AVENTIS.

1.12         “COMMERCIALIZATION” OR “COMMERCIALIZE” MEANS ANY AND ALL ACTIVITIES
DIRECTED TO THE COMMERCIALIZATION OF A LICENSED PRODUCT, INCLUDING PRE-LAUNCH
AND LAUNCH ACTIVITIES, MARKETING, MANUFACTURING FOR COMMERCIAL SALE, PROMOTING,
DETAILING, DISTRIBUTING, OFFERING TO SELL AND SELLING A LICENSED PRODUCT,
IMPORTING A LICENSED PRODUCT FOR SALE, CONDUCTING ADDITIONAL HUMAN CLINICAL
TRIALS AND INTERACTING WITH REGULATORY AUTHORITIES REGARDING THE FOREGOING. 
WHEN USED AS A VERB, “COMMERCIALIZING” MEANS TO ENGAGE IN COMMERCIALIZATION AND
“COMMERCIALIZED” HAS A CORRESPONDING MEANING.

1.13         “COMMERCIALLY REASONABLE EFFORTS” MEANS, WITH RESPECT TO
SANOFI-AVENTIS, THE EFFORTS AT LEAST EQUAL TO THOSE CUSTOMARILY USED BY
SANOFI-AVENTIS WITH RESPECT TO A PRODUCT OR POTENTIAL PRODUCT OF SIMILAR NATURE
AT A SIMILAR STAGE IN ITS DEVELOPMENT OR PRODUCT LIFE AND OF

A-2

--------------------------------------------------------------------------------

SIMILAR MARKET POTENTIAL, IN VIEW OF CONDITIONS PREVAILING AT THE TIME, AND
EVALUATED TAKING INTO ACCOUNT ALL RELEVANT FACTORS, INCLUDING WITHOUT
LIMITATION, THE MECHANISM OF ACTION, EFFICACY, SAFETY, THE ANTICIPATED
REGULATORY AUTHORITY APPROVED LABELING, THE COMPETITIVENESS OF ALTERNATIVE
PRODUCTS THAT ARE IN THE MARKETPLACE OR UNDER DEVELOPMENT, THE PATENT AND OTHER
PROPRIETARY POSITION OF THE PRODUCT, THE LIKELIHOOD OF REGULATORY APPROVAL, THE
PROFITABILITY OF THE PRODUCT AND OTHER TECHNICAL, SCIENTIFIC, LEGAL, MEDICAL,
MARKETING AND COMPETITIVE FACTORS.

1.14       “COMMERCIALIZATION REGULATORY APPROVAL” MEANS, WITH RESPECT TO ANY
LICENSED PRODUCT, THE GRANTING OF APPROVAL BY A REGULATORY AUTHORITY OF (A) AN
NDA IN THE UNITED STATES, OR (B) THE EQUIVALENT OF AN NDA REQUIRED BY APPLICABLE
LAWS IN ANY COUNTRY OR REGION IN THE TERRITORY OUTSIDE OF THE UNITED STATES TO
SELL SUCH LICENSED PRODUCT FOR USE IN THE FIELD IN SUCH COUNTRY OR REGION.

1.15       “COMPARABLE PRODUCT” MEANS A PRODUCT, OTHER THAN ANY PRODUCT BEING
MARKETED AND/OR SOLD AS OF THE EFFECTIVE DATE, THAT (A) INCORPORATES OR IS
COMPRISED OF AN ANTIBODY-DRUG CONJUGATE, (B) IS DIRECTED AGAINST THE SAME TARGET
AS A LICENSED PRODUCT AND (C) IS MARKETED AND SOLD BY A THIRD PARTY FOR USE IN
THE FIELD.

1.16       “CONFIDENTIAL INFORMATION” MEANS (A) WITH RESPECT TO IMMUNOGEN, ALL
TANGIBLE EMBODIMENTS OF LICENSED TECHNOLOGY AND LICENSED PATENT; (B) WITH
RESPECT TO SANOFI-AVENTIS, ALL INFORMATION AND TECHNOLOGY RELATED TO THE
SANOFI-AVENTIS ANTIBODY AND OTHERWISE INCLUDED IN ANY REGULATORY FILINGS MADE,
AND REGULATORY APPROVALS RECEIVED, BY SANOFI-AVENTIS WITH RESPECT TO LICENSED
PRODUCTS; AND (C) WITH RESPECT TO EACH PARTY, ALL INFORMATION AND TECHNOLOGY
DISCLOSED OR PROVIDED BY OR ON BEHALF OF SUCH PARTY (THE “DISCLOSING PARTY”) TO
THE OTHER PARTY (THE “RECEIVING PARTY”) OR TO ANY OF THE RECEIVING PARTY’S
EMPLOYEES, CONSULTANTS, AFFILIATES OR SUBLICENSEES, PROVIDED, THAT, NONE OF THE
FOREGOING SHALL BE CONFIDENTIAL INFORMATION IF: (I) AS OF THE DATE OF
DISCLOSURE, IT IS KNOWN TO THE RECEIVING PARTY OR ITS AFFILIATES AS DEMONSTRATED
BY CREDIBLE CONTEMPORANEOUS WRITTEN DOCUMENTATION, OTHER THAN BY VIRTUE OF A
PRIOR CONFIDENTIAL DISCLOSURE TO SUCH RECEIVING PARTY; (II) AS OF THE DATE OF
DISCLOSURE IT IS IN THE PUBLIC DOMAIN, OR IT SUBSEQUENTLY ENTERS THE PUBLIC
DOMAIN THROUGH NO FAULT OF THE RECEIVING PARTY; (III) IT IS OBTAINED BY THE
RECEIVING PARTY FROM A THIRD PARTY HAVING A LAWFUL RIGHT TO MAKE SUCH DISCLOSURE
FREE FROM ANY OBLIGATION OF CONFIDENTIALITY TO THE DISCLOSING PARTY; OR (IV) IT
IS INDEPENDENTLY DEVELOPED BY OR FOR THE RECEIVING PARTY WITHOUT REFERENCE TO OR
USE OF ANY CONFIDENTIAL INFORMATION OF THE DISCLOSING PARTY AS DEMONSTRATED BY
CREDIBLE CONTEMPORANEOUS WRITTEN DOCUMENTATION.  FOR PURPOSES OF CLARITY, THE
TERMS OF THIS AGREEMENT SHALL CONSTITUTE CONFIDENTIAL INFORMATION OF EACH PARTY.

1.17       “CONTROL” OR “CONTROLLED” MEANS WITH RESPECT TO TECHNOLOGY OR PATENT
RIGHTS, THE POSSESSION BY A PARTY OF THE RIGHT TO GRANT A LICENSE OR SUBLICENSE
TO SUCH TECHNOLOGY OR PATENT RIGHTS AS PROVIDED HEREIN WITHOUT THE PAYMENT OF
ADDITIONAL CONSIDERATION TO, AND WITHOUT VIOLATING THE TERMS OF ANY AGREEMENT OR
ARRANGEMENT WITH, ANY THIRD PARTY.

1.18       “DERIVED” MEANS OBTAINED, DEVELOPED, CREATED, SYNTHESIZED, DESIGNED,
DERIVED OR RESULTING OR GENERATED FROM, BASED UPON, OR OTHERWISE CONTAINING
(WHETHER DIRECTLY OR INDIRECTLY, OR IN WHOLE OR IN PART).

A-3

--------------------------------------------------------------------------------

1.19       “DESIGNATED SENIOR OFFICER” MEANS, WITH RESPECT TO A PARTY, THE
SENIOR OFFICER OF SUCH PARTY OR ITS AFFILIATE DESIGNATED BY SUCH PARTY TO HAVE
FINAL DECISION MAKING AUTHORITY OVER DISPUTED MATTERS.

1.20       “DEVELOPMENT” OR “DEVELOP” MEANS, WITH RESPECT TO EACH LICENSED
PRODUCT, ALL NON-CLINICAL AND CLINICAL ACTIVITIES REQUIRED TO OBTAIN REGULATORY
APPROVAL OF SUCH LICENSED PRODUCT.  FOR PURPOSES OF CLARITY, THESE ACTIVITIES
INCLUDE, WITHOUT LIMITATION, TEST METHOD DEVELOPMENT AND STABILITY TESTING,
REGULATORY TOXICOLOGY STUDIES, FORMULATION, PROCESS DEVELOPMENT, MANUFACTURING,
MANUFACTURING SCALE-UP, DEVELOPMENT-STAGE MANUFACTURING, QUALITY
ASSURANCE/QUALITY CONTROL DEVELOPMENT, STATISTICAL ANALYSIS AND REPORT WRITING,
CLINICAL TRIAL DESIGN AND OPERATIONS, PREPARING AND FILING DRUG APPROVAL
APPLICATIONS, AND ALL REGULATORY AFFAIRS RELATED TO THE FOREGOING.  WHEN USED AS
A VERB, “DEVELOPING” MEANS TO ENGAGE IN DEVELOPMENT AND “DEVELOPED” HAS A
CORRESPONDING MEANING.

1.21       “DRUG APPROVAL APPLICATION” MEANS, WITH RESPECT TO A LICENSED PRODUCT
IN A PARTICULAR COUNTRY OR REGION, AN APPLICATION FOR COMMERCIALIZATION
REGULATORY APPROVAL FOR SUCH LICENSED PRODUCT IN SUCH COUNTRY OR REGION,
INCLUDING WITHOUT LIMITATION: (A) AN NDA OR SNDA; (B) A COUNTERPART OF AN NDA OR
SNDA, INCLUDING ANY MAA, IN ANY COUNTRY OR REGION IN THE TERRITORY; AND (C) ALL
SUPPLEMENTS AND AMENDMENTS TO ANY OF THE FOREGOING.

1.22       “EFFECTIVE DATE” MEANS THE DATE FIRST SET FORTH ABOVE IN THE
INTRODUCTORY PARAGRAPH TO THIS AGREEMENT.

1.23       “FDA” MEANS THE UNITED STATES FOOD AND DRUG ADMINISTRATION OR ANY
SUCCESSOR AGENCY OR AUTHORITY THERETO.

1.24       “FDCA” MEANS THE UNITED STATES FEDERAL FOOD, DRUG, AND COSMETIC ACT,
AS AMENDED.

1.25       “FIELD” MEANS ALL HUMAN THERAPEUTIC, PROPHYLACTIC AND DIAGNOSTIC
USES.

1.26       “FIRST COMMERCIAL SALE” MEANS, WITH RESPECT TO A LICENSED PRODUCT IN
ANY COUNTRY IN THE TERRITORY, THE FIRST SALE, TRANSFER OR DISPOSITION FOR VALUE
OR FOR END USE OR CONSUMPTION OF SUCH LICENSED PRODUCT IN SUCH COUNTRY,
PROVIDED, THAT, ANY SALE TO AN AFFILIATE OR SUBLICENSEE WILL NOT CONSTITUTE A
FIRST COMMERCIAL SALE UNLESS THE AFFILIATE OR SUBLICENSEE IS THE LAST ENTITY IN
THE DISTRIBUTION CHAIN OF THE LICENSED PRODUCT.

1.27       “FORCE MAJEURE EVENT” MEANS ANY OCCURRENCE BEYOND THE REASONABLE
CONTROL OF A PARTY THAT (A) PREVENTS OR SUBSTANTIALLY INTERFERES WITH THE
PERFORMANCE BY SUCH PARTY OF ANY OF ITS OBLIGATIONS HEREUNDER AND (B) OCCURS BY
REASON OF ANY ACT OF GOD, FLOOD, FIRE, EXPLOSION, EARTHQUAKE, STRIKE, LOCKOUT,
LABOR DISPUTE, CASUALTY OR ACCIDENT, OR WAR, REVOLUTION, CIVIL COMMOTION, ACT OF
TERRORISM, BLOCKAGE OR EMBARGO, OR ANY INJUNCTION, LAW, ORDER, PROCLAMATION,
REGULATION, ORDINANCE, DEMAND OR REQUIREMENT OF ANY GOVERNMENT OR OF ANY
SUBDIVISION, AUTHORITY OR REPRESENTATIVE OF ANY SUCH GOVERNMENT.

1.28       “GENERIC PRODUCT” MEANS A PHARMACEUTICAL PRODUCT THAT (A) CONTAINS
THE SAME ACTIVE INGREDIENT AS A LICENSED PRODUCT; (B) IS BIOEQUIVALENT TO SUCH
LICENSED PRODUCT; AND (C) IS DIRECTED AGAINST THE SAME TARGET AS A LICENSED
PRODUCT.

A-4

--------------------------------------------------------------------------------

1.29       “GLP” MEANS THE THEN CURRENT GOOD LABORATORY PRACTICE STANDARDS
PROMULGATED OR ENDORSED BY THE FDA OR IN THE CASE OF FOREIGN JURISDICTIONS,
COMPARABLE REGULATORY STANDARDS PROMULGATED OR ENDORSED BY THE APPLICABLE
REGULATORY AUTHORITY, INCLUDING THOSE PROCEDURES EXPRESSED OR IMPLIED IN THE
REGULATORY FILINGS.

1.30       “GMP” MEANS ALL GOOD MANUFACTURING PRACTICES UNDER TITLE 21 OF THE
UNITED STATES CODE OF FEDERAL REGULATIONS, AS AMENDED FROM TIME TO TIME.

1.31       “HATCH-WAXMAN ACT” MEANS THE DRUG PRICE COMPETITION AND PATENT TERM
RESTORATION ACT OF 1984, AS AMENDED.

1.32       “IMPROVEMENT” MEANS ANY ENHANCEMENT, IMPROVEMENT OR MODIFICATION TO
THE LICENSED TECHNOLOGY OR THE LICENSED PATENT RIGHTS.

1.33       “IND” MEANS: (A) AN INVESTIGATIONAL NEW DRUG APPLICATION (AS DEFINED
IN THE FDCA AND REGULATIONS PROMULGATED THEREUNDER) OR ANY SUCCESSOR APPLICATION
OR PROCEDURE REQUIRED TO INITIATE CLINICAL TESTING OF A LICENSED PRODUCT IN
HUMANS IN THE UNITED STATES; (B) A COUNTERPART OF AN INVESTIGATIONAL NEW DRUG
APPLICATION THAT IS REQUIRED IN ANY OTHER COUNTRY OR REGION IN THE TERRITORY
BEFORE BEGINNING CLINICAL TESTING OF A LICENSED PRODUCT IN HUMANS IN SUCH
COUNTRY OR REGION; AND (C) ALL SUPPLEMENTS AND AMENDMENTS TO ANY OF THE
FOREGOING.

1.34       “INITIATION” MEANS, WITH RESPECT TO ANY CLINICAL TRIAL, THE FIRST
DATE THAT A HUMAN SUBJECT IS DOSED IN SUCH CLINICAL TRIAL.

1.35       “LICENSED PATENT RIGHTS” MEANS ANY OF THE PATENTS AND PATENT
APPLICATIONS DESCRIBED IN SCHEDULE 1 ATTACHED HERETO, AND ANY DIVISIONALS,
CONTINUATIONS, CONTINUATIONS-IN-PART (TO THE EXTENT THAT ANY
CONTINUATIONS-IN-PART ARE ENTITLED TO THE PRIORITY DATE OF AN INITIAL PATENT OR
PATENT APPLICATION WHICH IS THE SUBJECT OF THIS AGREEMENT), REISSUES,
REEXAMINATIONS, CONFIRMATIONS, REVALIDATIONS, REGISTRATIONS, PATENTS OF
ADDITION, RENEWALS, EXTENSIONS OR SUBSTITUTES THEREOF, OR ANY PATENTS ISSUING
THEREFROM OR ANY SUPPLEMENTARY PROTECTION CERTIFICATES RELATED THERETO,
INCLUDING ANY IMPROVEMENT RELATED THERETO THAT IS CONCEIVED OR REDUCED TO
PRACTICE BY IMMUNOGEN OR ITS THIRD PARTY COLLABORATORS, THAT ARE CONTROLLED BY
IMMUNOGEN AND THAT INCLUDE ONE OR MORE CLAIMS THAT COVER LICENSED TECHNOLOGY.

1.36       “LICENSED PRODUCT” MEANS ANY PRODUCT DIRECTED AGAINST THE LICENSED
TARGET (A) THAT IS COMPRISED OF, INCORPORATES OR IS DERIVED FROM AN AB-MAY
PRODUCT, OR (B) THE MANUFACTURE, USE OR SALE OF WHICH WOULD, ABSENT THE LICENSE
GRANTED TO SANOFI-AVENTIS HEREUNDER, INFRINGE ANY VALID CLAIM INCLUDED IN THE
LICENSED PATENT RIGHTS.

1.37       “LICENSED TARGET” MEANS THE TARGET SET FORTH ON EXHIBIT A ATTACHED
HERETO AND INCORPORATED HEREIN BY REFERENCE.

1.38       “LICENSED TECHNOLOGY” MEANS ANY TECHNOLOGY CONTROLLED BY IMMUNOGEN AS
OF THE EFFECTIVE DATEORTHAT IS CONTROLLED BY IMMUNOGEN AT ANY TIME DURING THE
TERM INCLUDING, WITHOUT LIMITATION, ANY IMPROVEMENT RELATED THERETO THAT IS
CONCEIVED OR REDUCED TO PRACTICE BY IMMUNOGEN OR ITS THIRD PARTY COLLABORATORS
AND THAT IS, IN ANY CASE, NECESSARY OR USEFUL FOR SANOFI-AVENTIS TO EXERCISE THE
LICENSES GRANTED TO IT PURSUANT TO SECTION 2.1.1.

A-5

--------------------------------------------------------------------------------

1.39       “MAA” MEANS ANY APPLICATION FILED WITH THE RELEVANT REGULATORY
AUTHORITY SEEKING REGULATORY APPROVAL TO MARKET AND SELL A LICENSED PRODUCT
OUTSIDE THE UNITED STATES FOR A PARTICULAR INDICATION IN THE FIELD.

1.40          “MANUFACTURING COST” MEANS, WITH RESPECT TO ANY PRECLINICAL
MATERIALS OR CLINICAL MATERIALS MANUFACTURED BY IMMUNOGEN, IMMUNOGEN’S
FULLY-BURDENED COSTS (INCLUDING THE COSTS ASSOCIATED WITH PRODUCT TESTING AND
RELEASE ACTIVITIES) OF PRODUCING AND PACKAGING SUCH PRECLINICAL MATERIALS OR
CLINICAL MATERIALS, INCLUDING THE SUM OF THE FOLLOWING COMPONENTS: (A) DIRECT
COSTS, INCLUDING (1) MATERIALS DIRECTLY USED IN PRODUCING AND PACKAGING SUCH
PRECLINICAL MATERIALS OR CLINICAL MATERIALS AND (2) WITH RESPECT TO ANY
PRECLINICAL MATERIALS OR CLINICAL MATERIALS OBTAINED BY IMMUNOGEN FROM A THIRD
PARTY AND SUPPLIED TO SANOFI-AVENTIS WITHOUT MODIFICATION, THE AMOUNT PAID BY
IMMUNOGEN TO SUCH THIRD PARTY FOR THE SAME; (B) MANUFACTURING OVERHEAD COSTS
ATTRIBUTABLE TO THE COST OF GOODS UNDER THE FOREGOING CLAUSE (A) (1), INCLUDING
MANUFACTURING AND QUALITY LABOR AND MANUFACTURING AND QUALITY SUPERVISORY
SERVICES, OPERATING AND ADMINISTRATIVE COSTS OF THE MANUFACTURING AND QUALITY
DEPARTMENTS AND OCCUPANCY COSTS WHICH ARE ALLOCABLE TO COMPANY DEPARTMENTS BASED
ON SPACE OCCUPIED OR HEADCOUNT OR ANOTHER REASONABLE ACTIVITY-BASED METHOD; FOR
THE PURPOSE OF CLARITY, ANY COST ALLOCATION SHALL BE (I) IN ANY CASE, APPLIED IN
ACCORDANCE WITH GAAP, AND (II) APPLIED CONSISTENTLY BY IMMUNOGEN IN RELATION TO
ALL OTHER THIRD PARTIES FOR WHICH IMMUNOGEN MANUFACTURES COMPARABLE MATERIALS;
(C) ANY OTHER REASONABLE AND CUSTOMARY OUT-OF-POCKET COSTS BORNE BY IMMUNOGEN
FOR THE TESTING, TRANSPORT, CUSTOMS CLEARANCE, DUTY, INSURANCE AND/OR STORAGE OF
SUCH PRECLINICAL MATERIALS OR CLINICAL MATERIALS; AND (D) IMMUNOGEN’S GENERAL
AND ADMINISTRATIVE COSTS, INCLUDING PURCHASING, HUMAN RESOURCES, PAYROLL,
INFORMATION SYSTEM AND ACCOUNTING, WHICH ARE DIRECTLY ATTRIBUTABLE OR REASONABLY
ALLOCABLE TO COMPANY DEPARTMENTS BASED ON SPACE OCCUPIED OR HEADCOUNT.

1.41       “MAY COMPOUND” MEANS ANY AND ALL MAYTANSINOID COMPOUNDS (INCLUDING,
WITHOUT LIMITATION, MAYTANSINOL, ANSAMITOCINS DM1 AND DM4), WHETHER PRODUCED BY
A BOTANICAL SOURCE, NATURAL FERMENTATION, CHEMICAL SYNTHESIS OR OTHERWISE, AND
SHALL INCLUDE, WITHOUT LIMITATION, ALL VARIANTS, FRAGMENTS OR DERIVATIVES OF ANY
OF THE FOREGOING, IN EACH CASE CONTROLLED BY IMMUNOGEN.

1.42       “NDA” MEANS A NEW DRUG APPLICATION, AS DEFINED IN THE FDCA AND
REGULATIONS PROMULGATED THEREUNDER, OR ANY SUCCESSOR APPLICATION OR PROCEDURE
REQUIRED TO SELL A LICENSED PRODUCT IN THE UNITED STATES FOR A PARTICULAR
INDICATION IN THE FIELD.

1.43       “NET SALES” MEANS THE GROSS AMOUNT INVOICED BY SANOFI-AVENTIS OR ITS
AFFILIATES OR SUBLICENSEES TO THIRD PARTIES IN EACH COUNTRY IN THE TERRITORY FOR
SALES OF EACH LICENSED PRODUCT IN SUCH COUNTRY DURING THE PERIOD IN WHICH
ROYALTIES ARE PAYABLE HEREUNDER WITH RESPECT TO SALES OF SUCH LICENSED PRODUCT
IN SUCH COUNTRY, LESS THE FOLLOWING DEDUCTIONS FROM SUCH GROSS AMOUNTS ABSORBED
OR ACCRUED WITH RESPECT TO SUCH GROSS AMOUNTS: (A) TRADE, CASH AND/OR QUANTITY
DISCOUNTS ALLOWED AND TAKEN DIRECTLY WITH RESPECT TO SUCH SALES, OR REFLECTED IN
THE INVOICED AMOUNT; (B) EXCISE, SALES AND OTHER CONSUMPTION TAXES (INCLUDING
VAT ON THE SALE OF LICENSED PRODUCTS AND EXCLUDING TAXES BASED ON INCOME) AND
CUSTOM DUTIES IMPOSED UPON AND PAID DIRECTLY BY SANOFI-AVENTIS WITH RESPECT TO
THE LICENSED PRODUCTS, TO THE EXTENT INCLUDED IN THE INVOICE PRICE; (C) FREIGHT,
INSURANCE AND OTHER TRANSPORTATION CHARGES, TO THE EXTENT INCLUDED IN THE
INVOICE PRICE; (D) AMOUNTS REPAID OR CREDITED BY REASON OF RETURNS, REJECTIONS,
DEFECTS OR RECALLS, CHARGEBACKS, RETROACTIVE PRICE REDUCTIONS, REFUNDS AND
BILLING ERRORS; AND (E) COMPULSORY

A-6

--------------------------------------------------------------------------------

PAYMENTS AND REBATES DIRECTLY RELATED TO THE SALE OF LICENSED PRODUCTS, ACCRUED,
PAID OR DEDUCTED, PURSUANT TO AGREEMENTS (INCLUDING, BUT NOT LIMITED TO, MANAGED
CARE AGREEMENTS) OR GOVERNMENTAL REGULATIONS.

USE OF LICENSED PRODUCTS FOR PROMOTIONAL OR SAMPLING PURPOSES AND FOR USE IN
CLINICAL TRIALS CONTEMPLATED UNDER THIS AGREEMENT SHALL NOT BE CONSIDERED IN
DETERMINING NET SALES.  IN THE CASE OF ANY SALE OF A LICENSED PRODUCTS BETWEEN
OR AMONG SANOFI-AVENTIS AND ITS AFFILIATES OR SUBLICENSEES FOR RESALE, NET SALES
SHALL BE CALCULATED AS ABOVE ONLY ON THE FIRST ARM’S LENGTH SALE THEREAFTER TO A
THIRD PARTY.

IN THE EVENT A LICENSED PRODUCT IS SOLD AS A COMPONENT OF A COMBINATION OR
BUNDLED PRODUCT THAT CONSISTS OF A LICENSED PRODUCT TOGETHER WITH ANOTHER
THERAPEUTICALLY ACTIVE PRODUCT FOR THE SAME INDICATION (A “COMBINATION
PRODUCT”), THE NET SALES FROM THE COMBINATION PRODUCT, FOR THE PURPOSES OF
DETERMINING ROYALTY PAYMENTS, SHALL BE DETERMINED BY MULTIPLYING THE NET SALES
OF THE COMBINATION PRODUCT (AS DEFINED IN THE STANDARD NET SALES DEFINITION
ABOVE), DURING THE APPLICABLE ROYALTY REPORTING PERIOD, BY THE FRACTION, A/A+B,
WHERE A IS THE AVERAGE PER UNIT SALE PRICE OF THE LICENSED PRODUCT WHEN SOLD
SEPARATELY IN FINISHED FORM IN THE COUNTRY IN WHICH THE COMBINATION PRODUCT IS
SOLD DURING THE SAME ROYALTY REPORTING PERIOD IN SIMILAR VOLUMES AND OF THE SAME
CLASS, PURITY AND POTENCY AND B IS THE AVERAGE PER UNIT SALE PRICE OF THE OTHER
PRODUCT(S) INCLUDED IN THE COMBINATION PRODUCT WHEN SOLD SEPARATELY IN FINISHED
FORM IN THE COUNTRY DURING THE SAME ROYALTY REPORTING PERIOD IN SIMILAR VOLUMES
AND OF THE SAME CLASS, PURITY AND POTENCY IN WHICH THE COMBINATION PRODUCT IS
SOLD, IN EACH CASE DURING THE APPLICABLE ROYALTY REPORTING PERIOD OR, IF SALES
OF THE LICENSED PRODUCT ALONE DID NOT OCCUR IN SUCH PERIOD, THEN IN THE MOST
RECENT ROYALTY REPORTING PERIOD IN WHICH ARMS LENGTH FAIR MARKET SALES OF SUCH
LICENSED PRODUCT OCCURRED.  IN THE EVENT THAT SUCH AVERAGE SALE PRICE CANNOT BE
DETERMINED FOR THE LICENSED PRODUCT, ON THE ONE HAND, AND ALL OTHER PRODUCT(S)
INCLUDED IN THE COMBINATION PRODUCT, ON THE OTHER, NET SALES FOR THE PURPOSES OF
DETERMINING ROYALTY PAYMENTS SHALL BE MUTUALLY AGREED UPON BY THE PARTIES BASED
ON THE RELATIVE VALUE CONTRIBUTED BY EACH COMPONENT, SUCH AGREEMENT TO BE
NEGOTIATED IN GOOD FAITH.

1.44       “OPTION” SHALL HAVE THE MEANING SET FORTH IN THE OPTION AND LICENSE
AGREEMENT.

1.45       “OPTION AND LICENSE AGREEMENT” MEANS THAT CERTAIN OPTION AND LICENSE
AGREEMENT DATED AS OF DECEMBER 21, 2006, BY AND BETWEEN IMMUNOGEN AND
SANOFI-AVENTIS.

1.46       “PATENT RIGHTS” MEANS THE RIGHTS AND INTERESTS IN AND TO ISSUED
PATENTS AND PENDING PATENT APPLICATIONS (INCLUDING INVENTOR’S CERTIFICATES AND
UTILITY MODELS) IN ANY COUNTRY OR JURISDICTION WITHIN THE TERRITORY, INCLUDING
ALL PROVISIONALS, SUBSTITUTIONS, CONTINUATIONS, CONTINUATIONS-IN-PART,
DIVISIONALS, SUPPLEMENTARY PROTECTION CERTIFICATES, RENEWALS, ALL LETTERS PATENT
GRANTED THEREON, AND ALL REISSUES, REEXAMINATIONS, EXTENSIONS, CONFIRMATIONS,
REVALIDATIONS, REGISTRATIONS, PATENTS OF ADDITION THEREOF, PCTS AND FOREIGN
COUNTERPARTS.

1.47       “PERSON” MEANS AN INDIVIDUAL, SOLE PROPRIETORSHIP, PARTNERSHIP,
LIMITED PARTNERSHIP, LIMITED LIABILITY PARTNERSHIP, CORPORATION, LIMITED
LIABILITY COMPANY, BUSINESS TRUST, JOINT STOCK COMPANY, TRUST, INCORPORATED
ASSOCIATION, JOINT VENTURE OR SIMILAR ENTITY OR ORGANIZATION, INCLUDING A
GOVERNMENT OR POLITICAL SUBDIVISION, DEPARTMENT OR AGENCY OF A GOVERNMENT.

A-7

--------------------------------------------------------------------------------

1.48       “PHASE I STUDY” MEANS A CLINICAL STUDY IN SUBJECTS TO EVALUATE THE
PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES, MAXIMUM TOLERATED DOSE, DOSING
INTERVAL, AND ABSORPTION, DISTRIBUTION, METABOLISM AND EXCRETION (ADME) OF A
LICENSED PRODUCT.

1.49       “PHASE IIB STUDY”MEANS A CONTROLLED DOSE RANGING CLINICAL TRIAL TO
EVALUATE FURTHER THE EFFICACY AND SAFETY OF A LICENSED PRODUCT IN THE TARGETED
PATIENT POPULATION AND TO DEFINE THE OPTIMAL DOSING REGIMEN.

1.50       “PHASE III STUDY” MEANS, AS TO A PARTICULAR LICENSED PRODUCT FOR A
PARTICULAR INDICATION, A CONTROLLED AND LAWFUL STUDY IN HUMANS OF THE SAFETY AND
EFFICACY OF SUCH PRODUCT FOR SUCH INDICATION, WHICH IS PROSPECTIVELY DESIGNED TO
DEMONSTRATE STATISTICALLY WHETHER SUCH LICENSED PRODUCT IS SAFE AND EFFECTIVE
FOR USE IN SUCH INDICATION IN A MANNER SUFFICIENT TO FILE A DRUG APPROVAL
APPLICATION TO OBTAIN REGULATORY APPROVAL TO MARKET AND SELL THAT LICENSED
PRODUCT FOR THE INDICATION UNDER INVESTIGATION IN SUCH STUDY.

1.51       “PRECLINICAL MATERIALS” MEANS ANY SUPPLIES OF MAY COMPOUND OR
LICENSED PRODUCT MANUFACTURED BY IMMUNOGEN IN ACCORDANCE WITH APPLICABLE LAWS
AND ALL APPLICABLE SPECIFICATIONS FOR USE IN PRECLINICAL TESTING.

1.52       “REGULATORY APPROVAL” MEANS, WITH RESPECT TO ANY COUNTRY OR REGION IN
THE TERRITORY, ANY APPROVAL, PRODUCT AND ESTABLISHMENT LICENSE, REGISTRATION OR
AUTHORIZATION OF ANY REGULATORY AUTHORITY REQUIRED FOR THE MANUFACTURE, USE,
STORAGE, IMPORTATION, EXPORTATION, TRANSPORT OR SALE OF A LICENSED PRODUCT FOR
USE IN THE FIELD IN SUCH COUNTRY OR REGION.

1.53       “REGULATORY AUTHORITY” MEANS THE FDA OR ANY COUNTERPART OF THE FDA
OUTSIDE THE UNITED STATES, OR OTHER NATIONAL, SUPRA-NATIONAL, REGIONAL, STATE OR
LOCAL REGULATORY AGENCY, DEPARTMENT, BUREAU, COMMISSION, COUNCIL OR OTHER
GOVERNMENTAL ENTITY WITH AUTHORITY OVER THE DISTRIBUTION, IMPORTATION,
EXPORTATION, MANUFACTURE, PRODUCTION, USE, STORAGE, TRANSPORT, CLINICAL TESTING
OR SALE OF A LICENSED PRODUCT.

1.54       “REGULATORY FILINGS” MEANS, COLLECTIVELY: (A) ALL INDS, NDAS,
ESTABLISHMENT LICENSE APPLICATIONS, DRUG MASTER FILES, APPLICATIONS FOR
DESIGNATION AS AN “ORPHAN PRODUCT” UNDER THE ORPHAN DRUG ACT, FOR “FAST TRACK”
STATUS UNDER SECTION 506 OF THE FDCA (21 U.S.C. § 356) OR FOR A SPECIAL PROTOCOL
ASSESSMENT UNDER SECTION 505(B)(4)(B) AND (C) OF THE FDCA (21 U.S.C.
§ 355(B)(4)(B)) OR ALL OTHER SIMILAR FILINGS (INCLUDING MAAS AND, COUNTERPARTS
OF ANY OF THE FOREGOING IN ANY COUNTRY OR REGION IN THE TERRITORY) AS MAY BE
REQUIRED BY ANY REGULATORY AUTHORITY FOR THE DEVELOPMENT OR COMMERCIALIZATION OF
A LICENSED PRODUCT IN THE TERRITORY; (B) ALL SUPPLEMENTS AND AMENDMENTS TO ANY
OF THE FOREGOING; AND (C) ALL DATA AND OTHER INFORMATION CONTAINED IN, AND
CORRESPONDENCE RELATING TO, ANY OF THE FOREGOING.

1.55       “REPORTABLE EVENT” MEANS ANY SERIOUS ADVERSE EVENT OR MEDICAL
OCCURRENCE IN A PATIENT OR SUBJECT WHO IS ADMINISTERED A LICENSED PRODUCT,
WHETHER OR NOT CONSIDERED RELATED TO THE LICENSED PRODUCT, INCLUDING, WITHOUT
LIMITATION, ANY UNDESIRABLE SIGN (INCLUDING ABNORMAL LABORATORY FINDINGS OF
CLINICAL CONCERN), SYMPTOM OR DISEASE TEMPORALLY ASSOCIATED WITH THE USE OF SUCH
LICENSED PRODUCT.

1.56       “ROYALTY TERM” MEANS, WITH RESPECT TO EACH LICENSED PRODUCT IN EACH
COUNTRY IN THE TERRITORY, THE PERIOD BEGINNING ON THE DATE OF FIRST COMMERCIAL
SALE OF SUCH LICENSED

A-8

--------------------------------------------------------------------------------

PRODUCT IN SUCH COUNTRY AND CONTINUING UNTIL THE LATER OF (A) THE EXPIRATION OF
THE LAST TO EXPIRE VALID CLAIM OF THE LICENSED PATENT RIGHTS IN SUCH COUNTRY
THAT COVERS SUCH LICENSED PRODUCT OR ITS USE, METHOD OF DELIVERY OR MANUFACTURE
OR (B) [***] ([***]) YEARS FROM THE DATE OF THE FIRST COMMERCIAL SALE OF SUCH
LICENSED PRODUCT IN SUCH COUNTRY.  FOR PURPOSES OF CLARITY, TO THE EXTENT A
LICENSED PRODUCT IS COVERED IN A GIVEN COUNTRY SOLELY BY A VALID CLAIM THAT
RELATES TO AN IMMUNOGEN OR THIRD PARTY IMPROVEMENT, THE ROYALTY TERM APPLICABLE
TO SUCH LICENSED PRODUCT IN SUCH COUNTRY WILL ONLY BE EXTENDED UNTIL THE
EXPIRATION OF SUCH VALID CLAIM IF  THE IMMUNOGEN OR THIRD PARTY IMPROVEMENT
COVERS A USE, METHOD OF DELIVERY OR MANUFACTURE OF SUCH LICENSED PRODUCT THAT IS
BEING EXPLOITED IN SUCH COUNTRY.

1.57       “SANOFI-AVENTIS ANTIBODY” MEANS ANY ANTIBODY CONTROLLED BY
SANOFI-AVENTIS.

1.58       “SANOFI-AVENTIS IMPROVEMENT” MEANS ANY IMPROVEMENT THAT IS CONCEIVED
OR FIRST REDUCED TO PRACTICE BY SANOFI-AVENTIS IN CONNECTION WITH THE
DEVELOPMENT OR COMMERCIALIZATION OF ANY LICENSED PRODUCT.

1.59       “SNDA” MEANS A SUPPLEMENTAL NEW DRUG APPLICATION, AS DEFINED IN THE
FDCA AND APPLICABLE REGULATIONS PROMULGATED THEREUNDER.

1.60       “SPECIFICATIONS” MEANS ANY SPECIFICATIONS PREPARED BY SANOFI-AVENTIS
AND AGREED TO BY THE PARTIES IN WRITING RELATING TO THE MANUFACTURE AND SUPPLY
OF ANY PRECLINICAL MATERIALS OR CLINICAL MATERIALS HEREUNDER.

1.61       “SUBLICENSEE” MEANS ANY THIRD PARTY (OTHER THAN AN AFFILIATE) TO
WHICH SANOFI-AVENTIS GRANTS A LICENSE OR SUBLICENSE PURSUANT TO SECTION 2.1.2.

1.62       “TECHNOLOGY” MEANS, COLLECTIVELY, ALL INVENTIONS, DISCOVERIES,
IMPROVEMENTS, TRADE SECRETS AND PROPRIETARY METHODS, WHETHER OR NOT PATENTABLE,
INCLUDING WITHOUT LIMITATION, MACROMOLECULAR SEQUENCES, DATA, FORMULATIONS,
PROCESSES, TECHNIQUES, KNOW-HOW AND RESULTS (INCLUDING ANY NEGATIVE RESULTS).

1.63       “TERRITORY” MEANSALL COUNTRIES OF THE WORLD.

1.64       “THIRD PARTY” MEANS ANY PERSON OTHER THAN SANOFI-AVENTIS AND
IMMUNOGEN AND THEIR RESPECTIVE AFFILIATES.

1.65       “VALID CLAIM” MEANS ANY CLAIM OF A PENDING PATENT APPLICATION OR AN
ISSUED UNEXPIRED PATENT WITHIN THE LICENSED PATENT RIGHTS THAT (A) HAS NOT BEEN
FINALLY CANCELLED, WITHDRAWN, ABANDONED OR REJECTED BY ANY ADMINISTRATIVE AGENCY
OR OTHER BODY OF COMPETENT JURISDICTION, (B) HAS NOT BEEN PERMANENTLY REVOKED,
HELD INVALID, OR DECLARED UNPATENTABLE OR UNENFORCEABLE IN A DECISION OF A COURT
OR OTHER BODY OF COMPETENT JURISDICTION THAT IS UNAPPEALABLE OR UNAPPEALED
WITHIN THE TIME ALLOWED FOR APPEAL, (C) HAS NOT BEEN RENDERED UNENFORCEABLE
THROUGH DISCLAIMER OR OTHERWISE, AND (D) IS NOT LOST THROUGH AN INTERFERENCE
PROCEEDING.

ADDITIONAL DEFINITIONS.  IN ADDITION, EACH OF THE FOLLOWING DEFINITIONS SHALL
HAVE THE RESPECTIVE MEANINGS SET FORTH IN THE SECTION OF THIS AGREEMENT
INDICATED BELOW:

A-9

--------------------------------------------------------------------------------

 

Definition

 

Section

 

 

 

Agreement

 

Recitals

Claims

 

9.1

Covered Results

 

5.3

Disputed Matters

 

10.3.1

ImmunoGen

 

Recitals

ImmunoGen Indemnitees

 

9.2

Indemnified Party

 

9.3

Indemnifying Party

 

9.3

Infringement

 

6.3.1(a)

Infringement Notice

 

6.3.1(a)

Losses

 

9.1

sanofi-aventis

 

Recitals

sanofi-aventis Indemnitees

 

9.1

Party/Parties

 

Recitals

Supply Agreement

 

2.7.2

Term

 

7.1

Third Party Payments

 

4.3.3

Threshold Market Share

 

4.3.4

Withholding Taxes

 

4.3.8

 

2.             LICENSE GRANTS; TECHNOLOGY TRANSFER

2.1           LICENSE GRANTS.

2.1.1        LICENSE TO SANOFI-AVENTIS.  SUBJECT TO THE OTHER TERMS OF THIS
AGREEMENT, IMMUNOGEN HEREBY GRANTS TO SANOFI-AVENTIS AND ITS AFFILIATES AN
EXCLUSIVE (EVEN AS TO IMMUNOGEN) LICENSE WITHIN THE TERRITORY, INCLUDING THE
RIGHT TO GRANT SUBLICENSES AS DESCRIBED IN SECTION 2.1.2 BELOW, UNDER THE
LICENSED PATENT RIGHTS AND LICENSED TECHNOLOGY TO RESEARCH, DEVELOP, HAVE
DEVELOPED, COMMERCIALIZE AND HAVE COMMERCIALIZED LICENSED PRODUCTS, FOR ANY AND
ALL USES WITHIN THE FIELD.

2.1.2        RIGHT TO SUBLICENSE.  SANOFI-AVENTIS AND ITS AFFILIATES SHALL HAVE
THE RIGHT TO GRANT SUBLICENSES UNDER THE LICENSE GRANTED TO IT UNDER SECTION
2.1.1WITH RESPECT TO ANY LICENSED PRODUCT TO ANY THIRD PARTY, PROVIDED, THAT:
(A) IT SHALL BE A CONDITION OF ANY SUCH SUBLICENSE THAT SUCH SUBLICENSEE AGREES
TO BE BOUND BY ALL TERMS OF THIS AGREEMENT APPLICABLE TO THE DEVELOPMENT AND
COMMERCIALIZATION OF LICENSED PRODUCTS IN THE FIELD IN THE TERRITORY (INCLUDING,
WITHOUT LIMITATION, SECTIONS 3.2, 3.3 AND 3.4); (B) SANOFI-AVENTIS SHALL PROVIDE
WRITTEN NOTICE TO IMMUNOGEN OF ANY SUCH PROPOSED SUBLICENSE AT LEAST [***]
([***]) DAYS PRIOR TO SUCH EXECUTION AND PROVIDE REDACTED COPIES TO IMMUNOGEN OF
EACH SUCH SUBLICENSE WITHIN [***] ([***]) DAYS OF SUCH EXECUTION; (C)
SANOFI-AVENTIS SHALL BE DEEMED TO HAVE GUARANTEED THAT EACH SUCH SUBLICENSEE
WILL FULFILL ALL OF SANOFI-AVENTIS’ OBLIGATIONS UNDER THIS AGREEMENT APPLICABLE
TO THE SUBJECT MATTER OF SUCH SUBLICENSE; AND (D) SANOFI-AVENTIS SHALL NOT BE
RELIEVED OF ITS OBLIGATIONS PURSUANT TO THIS AGREEMENT AS A RESULT OF ANY SUCH
SUBLICENSE.

2.2           RETAINED RIGHTS OF IMMUNOGEN; RESTRICTED ACTIVITIES.  SUBJECT TO
THE OTHER TERMS OF THIS AGREEMENT, IMMUNOGEN RETAINS THE RIGHT TO USE THE
LICENSED TECHNOLOGY AND

A-10

--------------------------------------------------------------------------------

PRACTICE THE LICENSED PATENT RIGHTS (A) TO PERFORM ITS OBLIGATIONS UNDER THIS
AGREEMENT, (B) TO DEVELOP, HAVE DEVELOPED, MAKE, HAVE MADE, USE, HAVE USED,
SELL, HAVE SOLD, OFFER FOR SALE, IMPORT, HAVE IMPORTED, EXPORT AND HAVE EXPORTED
ANY PRODUCT THAT IS NOT A LICENSED PRODUCT, AND (C) FOR ANY AND ALL USES OUTSIDE
OF THE FIELD.  NOTWITHSTANDING THE FOREGOING, DURING THE TERM, IMMUNOGEN SHALL
NOT, AND SHALL CAUSE EACH OF ITS AFFILIATES TO NOT, DEVELOP OR COMMERCIALIZE, OR
GRANT ANY LICENSE OR RIGHT TO ANY THIRD PARTY TO UTILIZE, ANY TECHNOLOGY OR
PATENT RIGHTS CONTROLLED BY IMMUNOGEN OR ANY OF ITS AFFILIATES AT ANY TIME
DURING THE TERM FOR THE DEVELOPMENT OR COMMERCIALIZATION OF AN ANTIBODY-MAY
COMPOUND CONJUGATE THAT IS DIRECTED AGAINST THE LICENSED TARGET.

2.3           LICENSE TO IMMUNOGEN.  SANOFI-AVENTIS HEREBY GRANTS IMMUNOGEN A
NON-EXCLUSIVE, WORLDWIDE, FULLY-PAID, IRREVOCABLE, ROYALTY-FREE LICENSE OF
PERPETUAL DURATION UNDER SANOFI-AVENTIS’ INTEREST IN ANY SANOFI-AVENTIS
IMPROVEMENTS (A) TO MANUFACTURE CLINICAL MATERIALS AND/OR PRECLINICAL MATERIALS
PURSUANT TO THE TERMS OF THIS AGREEMENT AND/OR EACH APPLICABLE SUPPLY AGREEMENT;
(B) TO DEVELOP, MAKE, HAVE MADE, USE, SELL, HAVE SOLD, OFFER FOR SALE, IMPORT,
HAVE IMPORTED, EXPORT AND HAVE EXPORTED ANY PRODUCT THAT IS NOT A LICENSED
PRODUCT; AND (C) TO OTHERWISE EXPLOIT SUCH IMPROVEMENTS FOR ALL USES WITHIN THE
FIELD THAT ARE NOT OTHERWISE RESTRICTED BY AN AGREEMENT BY AND BETWEEN
SANOFI-AVENTIS AND IMMUNOGEN, PROVIDED, THAT, (I) ANY GRANT BY IMMUNOGEN OF A
SUBLICENSE IS ONLY MADE IN CONNECTION WITH THE GRANT OF A LICENSE TO TECHNOLOGY
CONTROLLED BY IMMUNOGEN AND USED IN THE CONJUGATION OF MAY COMPOUNDS TO BINDING
PROTEINS; AND (II) THE RIGHT OF IMMUNOGEN TO GRANT ANY SUCH SUBLICENSE IS
SUBJECT TO SANOFI-AVENTIS OBTAINING A GRANT BACK OF A NON-EXCLUSIVE, FULLY PAID,
IRREVOCABLE, ROYALTY-FREE LICENSE, INCLUDING THE RIGHT TO GRANT SUBLICENSES,
UNDER THAT SUBLICENSEE’S IMPROVEMENTS, ENHANCEMENTS OR MODIFICATIONS TO
TECHNOLOGY CONTROLLED BY IMMUNOGEN, TO DEVELOP AND COMMERCIALIZE LICENSED
PRODUCTS IN THE FIELD AND IN THE TERRITORY IN ACCORDANCE WITH SECTION 2.1.1 OF
THIS AGREEMENT.

2.4           NOTICE OF IMPROVEMENTS.  SANOFI-AVENTIS SHALL PROMPTLY NOTIFY
IMMUNOGEN OF THE CONCEPTION OR REDUCTION TO PRACTICE OF ANY SUCH SANOFI-AVENTIS
IMPROVEMENT. IMMUNOGEN SHALL PROMPTLY NOTIFY SANOFI-AVENTIS OF (A) THE
CONCEPTION OR REDUCTION TO PRACTICE BY IMMUNOGEN OF ANY IMPROVEMENT OR (B) ITS
RECEIPT OF WRITTEN NOTICE FROM ANY OF ITS THIRD PARTY COLLABORATORS OF ITS
CONCEPTION OR REDUCTION TO PRACTICE OF ANY IMPROVEMENT.

2.5           NO OTHER RIGHTS.  SANOFI-AVENTIS SHALL HAVE NO RIGHTS TO USE OR
OTHERWISE EXPLOIT ANY TECHNOLOGY CONTROLLED BY IMMUNOGEN EXCEPT AS EXPRESSLY SET
FORTH HEREIN.

2.6           USE OF LICENSED TECHNOLOGY.  IN CONNECTION WITH ANY LICENSED
TECHNOLOGY TRANSFERRED TO SANOFI-AVENTIS PURSUANT TO THIS AGREEMENT,
SANOFI-AVENTIS HEREBY AGREES THAT (A) IT SHALL NOT USE SUCH LICENSED TECHNOLOGY
FOR ANY PURPOSE OTHER THAN EXERCISING ITS RIGHTS OR PERFORMING ITS OBLIGATIONS
HEREUNDER; (B) IT SHALL USE SUCH LICENSED TECHNOLOGY ONLY IN COMPLIANCE WITH ALL
APPLICABLE LAWS; (C) IT SHALL NOT TRANSFER ANY SUCH LICENSED TECHNOLOGY TO ANY
THIRD PARTY WITHOUT THE PRIOR WRITTEN CONSENT OF IMMUNOGEN, EXCEPT AS EXPRESSLY
PERMITTED HEREBY; AND (D) EXCEPT FOR THE RIGHTS EXPRESSLY SET FORTH HEREIN,
SANOFI-AVENTIS SHALL NOT ACQUIRE ANY OTHER RIGHTS, TITLE OR INTEREST IN OR TO
SUCH LICENSED TECHNOLOGY AS A RESULT OF SUCH TRANSFER BY IMMUNOGEN.

A-11

--------------------------------------------------------------------------------

2.7           COMPLIANCE.  SANOFI-AVENTIS SHALL PERFORM ITS OBLIGATIONS TO
DEVELOP LICENSED PRODUCTS IN GOOD SCIENTIFIC MANNER AND IN COMPLIANCE IN ALL
MATERIAL RESPECTS WITH ALL APPLICABLE LAWS, PROVIDED, THAT, WITH RESPECT TO EACH
ACTIVITY SO PERFORMED THAT WILL OR WOULD REASONABLY BE EXPECTED TO BE SUBMITTED
TO A REGULATORY AUTHORITY IN SUPPORT OF A REGULATORY FILING OR DRUG APPROVAL
APPLICATION, SANOFI-AVENTIS SHALL COMPLY IN ALL MATERIAL RESPECTS WITH THE
REGULATIONS AND GUIDANCE OF THE FDA THAT CONSTITUTE GLP OR GMP (OR, IF AND AS
APPROPRIATE UNDER THE CIRCUMSTANCES, OR OTHER COMPARABLE REGULATION AND GUIDANCE
OF ANY APPLICABLE REGULATORY AUTHORITY IN ANY COUNTRY OR REGION IN THE
TERRITORY).

2.8           MANUFACTURE OF MATERIALS FOR DEVELOPMENT.  AS BETWEEN THE PARTIES,
SANOFI-AVENTIS SHALL HAVE THE SOLE RIGHT, AT ITS SOLE COST AND DISCRETION, TO
MANUFACTURE ALL MATERIALS (INCLUDING WITHOUT LIMITATION ANY LICENSED PRODUCTS)
TO ENABLE IT TO DEVELOP OR COMMERCIALIZE LICENSED PRODUCTS (INCLUDING AS
REQUIRED FOR ANY PRE-CLINICAL, CLINICAL AND COMMERCIAL USE OF LICENSED PRODUCTS,
INCLUDING PROCESS DEVELOPMENT AND SCALE-UP). IN THE EVENT THAT, DURING THE TERM,
SANOFI-AVENTIS DESIRES IMMUNOGEN TO SUPPLY TO SANOFI-AVENTIS WITH QUANTITIES OF
PRECLINICAL MATERIALS OR CLINICAL MATERIALS TO ENABLE IT TO DEVELOP OR
COMMERCIALIZE LICENSED PRODUCTS, SANOFI-AVENTIS SHALL PROVIDE IMMUNOGEN WITH
WRITTEN NOTICE OF SAME AND THE FOLLOWING PROVISION SHALL APPLY, AS APPLICABLE:

2.8.1        PRECLINICAL MATERIALS.  TO THE EXTENT THE SANOFI-AVENTIS NOTICE IS
WITH RESPECT TO PRECLINICAL MATERIALS, (A) IMMUNOGEN SHALL DELIVER ALL ORDERED
AMOUNTS OF PRECLINICAL MATERIALS IN ACCORDANCE WITH FORECASTING PARAMETERS,
ADVANCE ORDERING TIMEFRAMES AND DELIVERY TIMEFRAMES TO BE AGREED UPON BY THE
PARTIES; (B) IN CONNECTION WITH ANY ORDERING OF PRECLINICAL MATERIALS BY
SANOFI-AVENTIS, IMMUNOGEN SHALL PROVIDE SANOFI-AVENTIS WITH IMMUNOGEN’S GOOD
FAITH ESTIMATE OF THE MANUFACTURING COST FOR MANUFACTURE AND SUPPLY OF SUCH
PRECLINICAL MATERIALS; (C) IMMUNOGEN’S PRICE TO SUPPLY PRECLINICAL MATERIALS TO
SANOFI-AVENTIS MANUFACTURED AT IMMUNOGEN’S CAMBRIDGE, MASSACHUSETTS FACILITY
SHALL EQUAL [***] OF IMMUNOGEN’S MANUFACTURING COST FOR SUCH PRECLINICAL
MATERIALS; (D) IMMUNOGEN’S PRICE TO SUPPLY PRECLINICAL MATERIALS MANUFACTURED AT
IMMUNOGEN’S NORWOOD, MASSACHUSETTS FACILITY SHALL EQUAL [***] OF IMMUNOGEN’S
MANUFACTURING COST FOR SUCH PRECLINICAL MATERIALS; AND (E) SUBJECT TO (A) ABOVE,
SANOFI-AVENTIS MAY [***]%, AT ITS SOLE DISCRETION, THE [***] [***] [***]
IMMUNOGEN WILL SUPPLY THE REQUESTED PRECLINICAL MATERIALS, PROVIDED, THAT,
NOTHING IN THIS SECTION 2.7.1 SHALL PRECLUDE SANOFI-AVENTIS FROM MAKING ITS OWN
ARRANGEMENTS FOR MANUFACTURE AND SUPPLY OF PRECLINICAL MATERIALS ON ITS OWN OR
WITH THIRD PARTIES, SUBJECT TO THE LICENSES GRANTED HEREUNDER.  SUBJECT TO THE
FOREGOING, AS BETWEEN THE PARTIES, SANOFI-AVENTIS SHALL HAVE THE SOLE RIGHT, AT
ITS SOLE COST AND DISCRETION, TO MANUFACTURE ALL LICENSED PRODUCTS REQUIRED FOR
THE CONDUCT OF DEVELOPMENT ACTIVITIES UNDER THIS AGREEMENT.

2.8.2        CLINICAL MATERIALS.  TO THE EXTENT THE SANOFI-AVENTIS NOTICE IS
WITH RESPECT TO CLINICAL MATERIALS, THE PARTIES SHALL NEGOTIATE IN GOOD FAITH
AND EXECUTE A SUPPLY AGREEMENT PROVIDING FOR SUCH SUPPLY (EACH, A “SUPPLY
AGREEMENT”).  THE SUPPLY AGREEMENT SHALL PROVIDE, INTER ALIA, THAT (A) IMMUNOGEN
SHALL DELIVER ALL ORDERED AMOUNTS OF CLINICAL MATERIALS IN ACCORDANCE WITH
FORECASTING PARAMETERS, ADVANCE ORDERING TIMEFRAMES AND DELIVERY TIMEFRAMES TO
BE AGREED UPON BY THE PARTIES IN SUCH SUPPLY AGREEMENT; (B) IN CONNECTION WITH
ANY ORDERING OF CLINICAL MATERIALS BY SANOFI-AVENTIS, IMMUNOGEN SHALL PROVIDE
SANOFI-AVENTIS WITH IMMUNOGEN’S GOOD FAITH ESTIMATE OF THE MANUFACTURING COST
FOR MANUFACTURE AND SUPPLY OF SUCH CLINICAL MATERIALS; (C) IMMUNOGEN’S PRICE TO
SUPPLY CLINICAL MATERIALS TO SANOFI-AVENTIS SHALL

A-12

--------------------------------------------------------------------------------

EQUAL [***] OF IMMUNOGEN’S MANUFACTURING COST FOR SUCH CLINICAL MATERIALS; AND
(D) SANOFI-AVENTIS SHALL USE SUCH CLINICAL MATERIALS SOLELY FOR HUMAN CLINICAL
TESTING UP TO AND INCLUDING THE CONDUCT OF NON-PIVOTAL PHASE IIB STUDIES,
PROVIDED, THAT, NOTHING HEREIN SHALL PRECLUDE SANOFI-AVENTIS FROM MAKING ITS OWN
ARRANGEMENTS FOR MANUFACTURE AND SUPPLY OF CLINICAL MATERIALS ON ITS OWN OR WITH
THIRD PARTIES, SUBJECT TO THE LICENSES GRANTED HEREUNDER.    THE SUPPLY
AGREEMENT MAY TAKE THE FORM OF A MASTER SUPPLY AGREEMENT, TOGETHER WITH A WORK
ORDER SPECIFICALLY RELATED TO THE SUPPLY OF CLINICAL MATERIALS.  FURTHER, THE
PARTIES SHALL EXECUTE SUCH ADDITIONAL AGREEMENTS RELATED TO GMP, QUALITY AND
TECHNICAL TERMS AS ARE NECESSARY FOR REGULATORY PURPOSES.

3.             DEVELOPMENT AND COMMERCIALIZATION OF LICENSED PRODUCTS

3.1           RESPONSIBILITY FOR DEVELOPMENT AND COMMERCIALIZATION.  ON AND
AFTER THE EFFECTIVE DATE, SANOFI-AVENTIS SHALL HAVE THE SOLE RIGHT, AT ITS SOLE
EXPENSE, FOR ALL ASPECTS OF THE DEVELOPMENT AND COMMERCIALIZATION OF LICENSED
PRODUCTS IN THE FIELD IN THE TERRITORY, INCLUDING, WITHOUT LIMITATION, THE
CONDUCT OF: (A) ALL IND-ENABLING NON-CLINICAL STUDIES; (B) ALL ACTIVITIES
RELATED TO HUMAN CLINICAL TRIALS; (C) ALL ACTIVITIES RELATING TO THE MANUFACTURE
AND SUPPLY OF LICENSED PRODUCTS (INCLUDING ALL REQUIRED PROCESS DEVELOPMENT AND
SCALE UP WORK WITH RESPECT THERETO); AND (D) ALL PRE-MARKETING, MARKETING,
PROMOTION, SALES, DISTRIBUTION, IMPORT AND EXPORT ACTIVITIES (INCLUDING SECURING
REIMBURSEMENT, SALES AND MARKETING AND CONDUCTING ANY POST-MARKETING TRIALS OR
DATABASES AND POST-MARKETING SAFETY SURVEILLANCE).  WITHOUT LIMITING THE
GENERALITY OF THE FOREGOING, SANOFI-AVENTIS SHALL HAVE THE SOLE RIGHT, AT ITS
SOLE EXPENSE, FOR (I) MAKING ALL REGULATORY FILINGS FOR LICENSED PRODUCTS AND
FILING ALL DRUG APPROVAL APPLICATIONS AND OTHERWISE SEEKING ALL REGULATORY
APPROVALS FOR LICENSED PRODUCTS, AS WELL AS ALL CORRESPONDENCE AND
COMMUNICATIONS WITH REGULATORY AUTHORITIES REGARDING SUCH MATTERS, AND (II)
REPORTING OF ALL ADVERSE EVENTS TO REGULATORY AUTHORITIES IF AND TO THE EXTENT
REQUIRED BY APPLICABLE LAWS.  THE PARTIES HEREBY AGREE THAT SUBJECT TO SECTION
2.3, [***] SHALL [***]ALL DATA, RESULTS AND ALL OTHER INFORMATION ARISING FROM
ANY SUCH ACTIVITIES UNDER THIS AGREEMENT SPECIFICALLY RELATING TO LICENSED
PRODUCTS, INCLUDING, WITHOUT LIMITATION, ALL [***] [***] AND [***] [***]
RELATING TO LICENSED PRODUCTS, AND ALL OF THE FOREGOING INFORMATION,
DOCUMENTATION AND MATERIALS SHALL BE CONSIDERED CONFIDENTIAL
INFORMATION OF [***].

3.2           DILIGENCE.  SANOFI-AVENTIS SHALL USE COMMERCIALLY REASONABLE
EFFORTS DURING THE TERM TO DEVELOP AND COMMERCIALIZE LICENSED PRODUCTS IN THE
FIELD IN THE TERRITORY.

3.3           UPDATES AND REPORTS.  SANOFI-AVENTIS SHALL PROVIDE IMMUNOGEN WITH
BRIEF WRITTEN REPORTS NO LESS FREQUENTLY THAN ANNUALLY DURING THE TERM
(COMMENCING WITH THE FIRST ANNIVERSARY OF THE EFFECTIVE DATE) SUMMARIZING
SANOTI-AVENTIS’ EFFORTS TO DEVELOP AND COMMERCIALIZE LICENSED PRODUCTS
HEREUNDER.  IN ADDITION, SANOFI-AVENTIS SHALL PROVIDE IMMUNOGEN WITH PROMPT
WRITTEN NOTICE OF THE OCCURRENCE OF THE FIRST COMMERCIAL SALE OF ANY LICENSED
PRODUCT IN ANY COUNTRY.

3.4           REPORTABLE EVENTS.  SANOFI-AVENTIS SHALL PROMPTLY PROVIDE
IMMUNOGEN WITH NOTICE OF ANY REPORTABLE EVENT WITHIN TIME FRAMES CONSISTENT WITH
ANY REPORTING OBLIGATIONS UNDER APPLICABLE LAWS.

3.5           MANUFACTURE OF LICENSED PRODUCTS FOR COMMERCIAL SALE.  UNLESS
OTHERWISE AGREED TO BY THE PARTIES IN THE SUPPLY AGREEMENT, SANOFI-AVENTIS SHALL
HAVE THE SOLE OBLIGATION

A-13

--------------------------------------------------------------------------------

AND RESPONSIBILITY, AT ITS SOLE COST AND EXPENSE, FOR THE MANUFACTURE OF ALL
LICENSED PRODUCTS (INCLUDING WITHOUT LIMITATION THE ACTIVE PHARMACEUTICAL
INGREDIENTS IN ANY LICENSED PRODUCT) FOR COMMERCIAL SALE.

3.6           PRODUCT RECALLS.  IN THE EVENT THAT ANY REGULATORY AUTHORITY
ISSUES OR REQUESTS A RECALL OR TAKES SIMILAR ACTION IN CONNECTION WITH A
LICENSED PRODUCT THAT SANOFI-AVENTIS REASONABLY BELIEVES IS ATTRIBUTABLE TO OR
OTHERWISE RELATES TO THE LICENSED TECHNOLOGY OR LICENSED PATENT RIGHTS, OR IN
THE EVENT A PARTY REASONABLY BELIEVES THAT AN EVENT, INCIDENT OR CIRCUMSTANCE
HAS OCCURRED THAT MAY RESULT IN THE NEED FOR SUCH A RECALL, SUCH PARTY SHALL
PROMPTLY ADVISE THE OTHER PARTY THEREOF BY TELEPHONE OR FACSIMILE.  FOLLOWING
SUCH NOTIFICATION, SANOFI-AVENTIS SHALL DECIDE AND HAVE CONTROL OF WHETHER TO
CONDUCT A RECALL OR MARKET WITHDRAWAL (EXCEPT IN THE EVENT OF A RECALL OR MARKET
WITHDRAWAL MANDATED BY A REGULATORY AUTHORITY, IN WHICH CASE IT SHALL BE
REQUIRED) OR TO TAKE OTHER CORRECTIVE ACTION IN ANY COUNTRY AND THE MANNER IN
WHICH ANY SUCH RECALL, MARKET WITHDRAWAL OR CORRECTIVE ACTION SHALL BE
CONDUCTED, PROVIDED THAT SANOFI-AVENTIS SHALL KEEP IMMUNOGEN REGULARLY INFORMED
REGARDING ANY SUCH RECALL, MARKET WITHDRAWAL OR CORRECTIVE ACTION. 
SANOFI-AVENTIS SHALL BEAR ALL EXPENSES OF ANY SUCH RECALL, MARKET WITHDRAWAL OR
CORRECTIVE ACTION (INCLUDING, WITHOUT LIMITATION, EXPENSES FOR NOTIFICATION,
DESTRUCTION AND RETURN OF THE AFFECTED LICENSED PRODUCT AND ANY REFUND TO
CUSTOMERS OF AMOUNTS PAID FOR SUCH LICENSED PRODUCT).

4.             PAYMENTS

4.1           LICENSE FEE.  SANOFI-AVENTIS SHALL PAY IMMUNOGEN A LICENSE FEE IN
THE AMOUNT OF [***] [***] DOLLARS (US $[***]), WHICH AMOUNT SHALL BE
NON-REFUNDABLE AND NON-CREDITABLE, PAYABLE IN IMMEDIATELY AVAILABLE FUNDS WITHIN
[***] ([***]) BUSINESS DAYS OF THE EFFECTIVE DATE.

4.2           MILESTONE PAYMENTS.

4.2.1        MILESTONES.  SANOFI-AVENTIS SHALL MAKE THE FOLLOWING NONREFUNDABLE,
NON-CREDITABLE MILESTONE PAYMENTS TO IMMUNOGEN WITHIN [***] ([***]) DAYS AFTER
THE ACHIEVEMENT BY SANOFI-AVENTIS AND/OR SANOFI-AVENTIS’ AFFILIATES AND
SUBLICENSEES OF EACH EVENT FOR EACH LICENSED PRODUCT AS SET FORTH BELOW:  

Milestone Event

 

Milestone Payment

 

[***] of [***] [***] [***] [***] for a [***] [***]

 

$

[***

]

 

 

 

 

[***] of [***] [***] [***] [***] for a [***] [***]

 

$

[***

]

 

 

 

 

[***] of [***] [***] [***] [***] for a [***] [***]

 

$

[***

]

 

 

 

 

[***] of [***] in the [***] [***] for a [***] [***]

 

$

[***

]

 

 

 

 

[***] of [***] [***] [***] in the [***] [***] for a [***] [***]

 

$

[***

]

 

 

 

 

[***] of [***] [***] [***] in [***] [***] for a [***] [***]

 

$

[***

]

 

 

 

 

[***] of [***] [***] [***] in [***] for a [***] [***]

 

$

[***

]

 

A-14

--------------------------------------------------------------------------------

For purposes of clarity, (a) any milestone payment shall be made only once, with
respect to the first achievement of the relevant milestone for the first
Licensed Product, regardless of how many times such milestones are achieved by
Licensed Products and regardless of how many times a particular Licensed Product
achieves such milestones and (b) if a milestone payment is made for any
milestone event with respect to any Licensed Product and any milestone payments
for any preceding milestone events have not been made with respect to
such Licensed Product, then such earlier milestone payments shall be made
concurrently with such later milestone payment (for example, if the
milestone payment with respect to an [***] [***] in the [***] is due and
payable, but the milestone payment with respect to the [***] of a [***] [***]
[***] was not previously paid (because a [***] [***] [***] was not conducted
with respect to such Licensed Product), then milestone payments for both
milestone events shall both be made on the basis of the achievement of the
milestone event with respect to the [***] of the [***] for that Licensed
Product).  Notwithstandingthe foregoing, after the last to expire of the
Licensed Patent Rights covering a Licensed Product, any milestone event achieved
by such Licensed Product after such expiration shall result in a milestone
payment to ImmunoGen in an amount equal to [***] percent ([***]%) of the
corresponding milestone payment amounts listed in Section 4.2.1 above.

4.2.2        MILESTONE NOTICES.  SANOFI-AVENTIS SHALL PROVIDE IMMUNOGEN WITH
PROMPT WRITTEN NOTICE UPON EACH OCCURRENCE OF A MILESTONE EVENT SET FORTH IN
SECTION 4.2.1.  IN THE EVENT THAT, NOTWITHSTANDING THE FACT THAT SANOFI-AVENTIS
HAS NOT GIVEN SUCH A NOTICE, IMMUNOGEN BELIEVES ANY SUCH MILESTONE EVENT HAS
OCCURRED, IT SHALL SO NOTIFY SANOFI-AVENTIS IN WRITING AND SHALL PROVIDE TO
SANOFI-AVENTIS DATA, DOCUMENTATION OR OTHER INFORMATION THAT SUPPORTS ITS
BELIEF.

4.3           PAYMENT OF ROYALTIES; ROYALTY RATES; ACCOUNTING AND RECORDS.

4.3.1        PAYMENT OF ROYALTIES.

(A)           PATENT COVERAGE.  FOR EACH LICENSED PRODUCT COVERED BY A VALID
CLAIM OF THE LICENSED PATENT RIGHTS IN ANY COUNTRY IN THE TERRITORY IN WHICH IT
IS SOLD, SANOFI-AVENTIS SHALL PAY IMMUNOGEN A ROYALTY BASED ON ANNUAL NET SALES
OF SUCH LICENSED PRODUCT IN EACH CALENDAR YEAR (OR PARTIAL CALENDAR YEAR)
COMMENCING WITH THE FIRST COMMERCIAL SALE OF SUCH LICENSED PRODUCT IN SUCH
COUNTRY AND ENDING UPON THE EXPIRATION OF THE ROYALTY TERM FOR SUCH LICENSED
PRODUCT, AT THE FOLLOWING RATES:

Annual Net Sales

 

Royalty Rate (%)

 

Up to and including $[***] [***]

 

[***

]%

 

 

 

 

Above $[***] [***] and up to and including $[***] [***]

 

[***

]%

 

 

 

 

Above $[***] [***]

 

[***

]%

 

A-15

--------------------------------------------------------------------------------

(B)           NO PATENT COVERAGE.  FOR EACH LICENSED PRODUCT THAT IS NOT COVERED
BY A VALID CLAIM OF THE LICENSED PATENT RIGHTS IN ANY COUNTRY IN THE TERRITORY
IN WHICH IT IS SOLD OR THAT IS [***] [***] BY A [***][***] [***] UNDER A [***]
[***] [***] TO [***] UNDER SECTION [***], SANOFI-AVENTIS SHALL PAY IMMUNOGEN A
ROYALTY BASED ON ANNUAL NET SALES OF SUCH LICENSED PRODUCT IN EACH CALENDAR YEAR
(OR PARTIAL CALENDAR YEAR) COMMENCING WITH THE FIRST COMMERCIAL SALE OF SUCH
LICENSED PRODUCT IN SUCH COUNTRY (INCLUDING WITHOUT LIMITATION THE FIRST
COMMERCIAL SALE FOLLOWING THE TERMINATION OR EXPIRATION OF ANY VALID CLAIM IN
SUCH COUNTRY COVERING SUCH LICENSED PRODUCT)AND ENDING ON THE EXPIRATION OF THE
ROYALTY TERM FOR SUCH LICENSED PRODUCT, AT THE FOLLOWING RATES:

Annual Net Sales

 

Royalty Rate (%)

 

Up to and including $[***] [***]

 

[***

]%

Above $[***] [***] and up to and including $[***] [***]

 

[***

]%

Above $[***] [***]

 

[***

]%

 

THE PARTIES HEREBY ACKNOWLEDGE AND AGREE THAT ROYALTIES MAY BE PAYABLE HEREUNDER
FOR A LICENSED PRODUCT FOR WHICH NO ISSUED PATENTS WITHIN LICENSED PATENT RIGHTS
EXIST AND UNDER SUCH CIRCUMSTANCES, SUCH ROYALTIES SHALL BE IN CONSIDERATION OF
THE COMMERCIAL ADVANTAGE, KNOW-HOW AND BACKGROUND INFORMATION GAINED FROM THE
LICENSED TECHNOLOGY.

(C)           APPLICABILITY OF ROYALTY RATES. FOR PURPOSES OF CLARITY, (I) IF A
LICENSED PRODUCT IS COVERED BY A VALID CLAIM IN A COUNTRY WITHIN THE TERRITORY
SUCH THAT ROYALTIES ARE PAID BY SANOFI-AVENTIS PURSUANT TO SECTION 4.3.1(A) AND,
PRIOR TO THE [***] ([***]) ANNIVERSARY OF THE DATE OF FIRST COMMERCIAL SALE OF
SUCH LICENSED PRODUCT IN SUCH COUNTRY, THE LICENSED PRODUCT IS NO LONGER COVERED
BY A VALID CLAIM IN SUCH COUNTRY, SANOFI-AVENTIS SHALL PAY IMMUNOGEN A ROYALTY
AT THE RATES SET FORTH IN SECTION 4.3.1(B) FOR THAT PORTION OF THE ROYALTY TERM
DURING WHICH NO SUCH VALID CLAIM EXISTS IN SUCH COUNTRY; AND (II) IF A LICENSED
PRODUCT IS NOT COVERED BY A VALID CLAIM IN A COUNTRY WITHIN THE TERRITORY SUCH
THAT ROYALTIES ARE PAID BY SANOFI-AVENTIS PURSUANT TO SECTION 4.3.1(B) AND,
PRIOR TO THE [***] ([***]) ANNIVERSARY OF THE DATE OF FIRST COMMERCIAL SALE OF
SUCH LICENSED PRODUCT, THE LICENSED PRODUCT BECOMES COVERED BY A VALID CLAIM IN
SUCH COUNTRY, SANOFI-AVENTIS SHALL PAY IMMUNOGEN A ROYALTY AT THE RATES SET
FORTH IN SECTION 4.3.1(A) FOR THAT PORTION OF THE ROYALTY TERM DURING WHICH SUCH
VALID CLAIM EXISTS IN SUCH COUNTRY.

4.3.2        ROYALTY TERM.  SANOFI-AVENTIS SHALL PAY THE ROYALTIES SET FORTH IN
SECTION 4.3.1 WITH RESPECT TO EACH LICENSED PRODUCT ON A COUNTRY-BY-COUNTRY AND
PRODUCT-BY-PRODUCT BASIS UNTIL EXPIRATION OF THE ROYALTY TERM WITH RESPECT
THERETO.  UPON THE EXPIRATION OF THE ROYALTY TERM FOR EACH LICENSED PRODUCT IN
EACH COUNTRY IN THE TERRITORY, SANOFI-AVENTIS SHALL HAVE A WORLDWIDE, PERPETUAL,
FULLY PAID-UP LICENSE, WITH THE RIGHT TO SUBLICENSE, UNDER ANY AND ALL LICENSED
PATENTS COVERING SUCH LICENSED PRODUCT TO DEVELOP, MAKE, HAVE MADE, USE, IMPORT,
OFFER FOR SALE, DISTRIBUTE AND SELL SUCH LICENSED PRODUCT IN THE FIELD AND IN
SUCH COUNTRY.

4.3.3        PAYMENTS TO THIRD PARTIES.  IF, DURING ANY CALENDAR QUARTER,
SANOFI-AVENTIS ACTUALLY MAKES ANY ROYALTY PAYMENTS TO ONE OR MORE THIRD PARTIES
IN CONSIDERATION FOR A LICENSE, IN THE ABSENCE OF WHICH SANOFI-AVENTIS COULD NOT
PRACTICE THE LICENSED PATENT RIGHTS NECESSARY TO MAKE, USE OR SELL THE MAY
COMPOUND PORTION OF ANY LICENSED PRODUCT WITHOUT

A-16

--------------------------------------------------------------------------------

INFRINGING AN ISSUED PATENT OR PATENTS OWNED BY SUCH THIRD PARTY IN ANY COUNTRY
(COLLECTIVELY, “THIRD PARTY PAYMENTS”), THEN SANOFI-AVENTIS SHALL HAVE THE RIGHT
TO REDUCE THE ROYALTIES OTHERWISE DUE TO IMMUNOGEN PURSUANT TO SECTION 4.3.1
HEREOF WITH RESPECT TO SALES IN SUCH COUNTRY OF SUCH LICENSED PRODUCT IN SUCH
CALENDAR QUARTER OR ANY SUBSEQUENT CALENDAR QUARTER BY AN AMOUNT EQUAL TO UP TO
[***] PERCENT ([***]%) OF THE AMOUNT OF SUCH THIRD PARTY PAYMENTS. 
NOTWITHSTANDING THE FOREGOING, SUCH REDUCTIONS SHALL IN NO EVENT REDUCE THE
ROYALTY RATES OTHERWISE DUE TO IMMUNOGEN PURSUANT TO SECTION 4.3.1 HEREOF WITH
RESPECT TO THE SALES OF SUCH LICENSED PRODUCT IN SUCH COUNTRY TO A ROYALTY RATE
THAT IS LESS THAN THE RESPECTIVE RATES SET FORTH IN SECTION 4.3.1(B) ABOVE.

4.3.4        COMPETITIVE PRODUCTS.  NOTWITHSTANDING ANYTHING TO THE CONTRARY
CONTAINED IN THIS AGREEMENT, IF DURING ANY CALENDAR QUARTER, SANOFI-AVENTIS
SELLS LICENSED PRODUCTS IN A COUNTRY IN WHICH A THIRD PARTY IS SELLING (A) A
GENERIC PRODUCT OR (B) A COMPARABLE PRODUCT AND SUCH THIRD PARTY HAS SALES OF
SUCH COMPARABLE PRODUCT IN SUCH COUNTRY THAT IS GREATER THAN [***] PERCENT
([***]%) OF SANOFI-AVENTIS’ REVENUE-BASED OR UNIT-BASED MARKET SHARE OF SUCH
LICENSED PRODUCT IN SUCH COUNTRY (THE “THRESHOLD MARKET SHARE”), THEN, SUBJECT
TO THE FINAL SENTENCE OF THIS SECTION 4.3.4, ON AND AFTER THE DATE OF FIRST
COMMERCIAL SALE OF SUCH GENERIC PRODUCT OR DATE OF ACHIEVEMENT OF THE THRESHOLD
MARKET SHARE, AS THE CASE MAY BE, ALL APPLICABLE ROYALTIES IN EFFECT WITH
RESPECT TO SUCH LICENSED PRODUCT IN SUCH COUNTRY AS SPECIFIED IN SECTION 4.5.1
SHALL BE REDUCED TO [***] PERCENT ([***]%).  NOTWITHSTANDING THE FOREGOING,
SANOFI-AVENTIS’ OBLIGATION TO PAY THE FULL ROYALTY RATE SHALL BE REINSTATED ON
THE FIRST DAY OF THE CALENDAR QUARTER IMMEDIATELY FOLLOWING THE CALENDAR QUARTER
IN WHICH (A) SALES OF SUCH GENERIC PRODUCT CEASE OR (B) SALES OF SUCH COMPARABLE
PRODUCT ACCOUNT FOR LESS THAN THE THRESHOLD MARKET SHARE IN SUCH COUNTRY.

4.3.5        PAYMENT DATES AND REPORTS.  ROYALTY PAYMENTS SHALL BE MADE BY
SANOFI-AVENTIS WITHIN [***] ([***]) DAYS AFTER THE END OF EACH CALENDAR QUARTER
COMMENCING WITH THE CALENDAR QUARTER IN WHICH THE FIRST COMMERCIAL SALE OF A
LICENSED PRODUCT OCCURS.  ALL PAYMENTS SHALL BE MADE BY WIRE TRANSFER IN
ACCORDANCE WITH INSTRUCTIONS GIVEN IN WRITING FROM TIME TO TIME BY IMMUNOGEN. 
SANOFI-AVENTIS SHALL ALSO PROVIDE, AT THE SAME TIME EACH SUCH PAYMENT IS MADE, A
REPORT SHOWING: (A) THE NET SALES OF EACH LICENSED PRODUCT BY COUNTRY IN THE
TERRITORY;(B) THE BASIS FOR ANY DEDUCTIONS FROM GROSS AMOUNTS BILLED OR INVOICED
TO DETERMINE NET SALES; (C) THE APPLICABLE ROYALTY RATES FOR SUCH LICENSED
PRODUCT; (D) THE EXCHANGE RATES USED IN CALCULATING ANY OF THE FOREGOING; AND
(E) A CALCULATION OF THE AMOUNT OF ROYALTY DUE TO IMMUNOGEN.

4.3.6        RECORDS; AUDIT RIGHTS.  FOR A PERIOD OF [***] ([***]) YEARS,
SANOFI-AVENTIS SHALL KEEP AND MAINTAIN, AND SHALL REQUIRE ITS RESPECTIVE
AFFILIATES AND SUBLICENSEES TO KEEP AND MAINTAIN, SUCH ACCURATE AND COMPLETE
BOOKS AND RECORDS IN CONNECTION WITH THE SALE OF LICENSED PRODUCTS HEREUNDER, AS
ARE NECESSARY TO ALLOW THE ACCURATE CALCULATION CONSISTENT WITH GENERALLY
ACCEPTED ACCOUNTING PRINCIPLES OF THE ROYALTIES DUE TO IMMUNOGEN, INCLUDING ANY
RECORDS REQUIRED TO CALCULATE ANY ROYALTY ADJUSTMENTS HEREUNDER.   ONCE PER
CALENDAR YEAR, IMMUNOGEN SHALL HAVE THE RIGHT TO ENGAGE AN INDEPENDENT CERTIFIED
PUBLIC ACCOUNTING FIRM OF NATIONALLY RECOGNIZED STANDING AND REASONABLY
ACCEPTABLE TO SANOFI-AVENTIS, WHICH SHALL HAVE THE RIGHT TO EXAMINE IN
CONFIDENCE THE RELEVANT BOOKS AND RECORDS OF SANOFI-AVENTIS AND ITS RESPECTIVE
AFFILIATES AND SUBLICENSEES AS MAY BE REASONABLY NECESSARY TO DETERMINE AND/OR
VERIFY THE AMOUNT OF ROYALTY PAYMENTS DUE HEREUNDER.  SUCH EXAMINATION SHALL BE
CONDUCTED, AND SANOFI-AVENTIS

A-17

--------------------------------------------------------------------------------

SHALL MAKE ITS RECORDS AVAILABLE, DURING NORMAL BUSINESS HOURS, AFTER AT LEAST
[***] ([***]) DAYS PRIOR WRITTEN NOTICE TO SANOFI-AVENTIS, AS APPLICABLE, AND
SHALL TAKE PLACE AT THE FACILITY(IES) WHERE SUCH RECORDS ARE MAINTAINED.  EACH
SUCH EXAMINATION SHALL BE LIMITED TO PERTINENT BOOKS AND RECORDS FOR ANY YEAR
ENDING NOT MORE THAN [***] ([***]) MONTHS PRIOR TO THE DATE OF REQUEST,
PROVIDED, THAT, IMMUNOGEN SHALL NOT BE PERMITTED TO AUDIT THE SAME PERIOD OF
TIME MORE THAN ONCE.  BEFORE PERMITTING SUCH INDEPENDENT ACCOUNTING FIRM TO HAVE
ACCESS TO SUCH BOOKS AND RECORDS, SANOFI-AVENTIS MAY REQUIRE SUCH INDEPENDENT
ACCOUNTING FIRM AND ITS PERSONNEL INVOLVED IN SUCH AUDIT, TO SIGN A
CONFIDENTIALITY AGREEMENT (IN FORM AND SUBSTANCE REASONABLY ACCEPTABLE TO EACH
OF THE PARTIES) AS TO ANY CONFIDENTIAL INFORMATION WHICH IS TO BE PROVIDED TO
SUCH ACCOUNTING FIRM OR TO WHICH SUCH ACCOUNTING FIRM WILL HAVE ACCESS, WHILE
CONDUCTING THE AUDIT UNDER THIS PARAGRAPH.  THE IMMUNOGEN INDEPENDENT ACCOUNTING
FIRM WILL PREPARE AND PROVIDE TO EACH PARTY A WRITTEN REPORT STATING WHETHER THE
ROYALTY REPORTS SUBMITTED AND ROYALTIES PAID ARE CORRECT OR INCORRECT AND THE
SPECIFIC DETAILS CONCERNING ANY DISCREPANCIES.  SUCH ACCOUNTING FIRM MAY NOT
REVEAL TO IMMUNOGEN ANY INFORMATION LEARNED IN THE COURSE OF SUCH AUDIT OTHER
THAN THE AMOUNT OF ANY SUCH DISCREPANCIES.  IMMUNOGEN AGREES TO HOLD IN STRICT
CONFIDENCE ALL INFORMATION DISCLOSED TO IT, EXCEPT TO THE EXTENT NECESSARY FOR
IMMUNOGEN TO ENFORCE ITS RIGHTS UNDER THIS AGREEMENT OR IF DISCLOSURE IS
REQUIRED BY LAW.  IN THE EVENT THERE WAS AN UNDERPAYMENT BY SANOFI-AVENTIS
HEREUNDER, SANOFI-AVENTIS SHALL PROMPTLY (BUT IN NO EVENT LATER THAN [***]
([***]) DAYS AFTER SUCH PARTY’S RECEIPT OF THE INDEPENDENT AUDITOR’S REPORT SO
CORRECTLY CONCLUDING) MAKE PAYMENT TO IMMUNOGEN OF ANY SHORTFALL.  IN THE EVENT
THAT THERE WAS AN OVERPAYMENT BY SANOFI-AVENTIS HEREUNDER, IMMUNOGEN SHALL
PROMPTLY (BUT IN NO EVENT LATER THAN [***] ([***]) DAYS AFTER IMMUNOGEN’S
RECEIPT OF THE INDEPENDENT AUDITOR’S REPORT SO CORRECTLY CONCLUDING) REFUND TO
SANOFI-AVENTIS THE EXCESS AMOUNT.  IMMUNOGEN SHALL BEAR THE FULL COST OF SUCH
AUDIT UNLESS SUCH AUDIT DISCLOSES AN UNDERREPORTING BY SANOFI-AVENTIS OF MORE
THAN [***] PERCENT ([***]%) OF THE AGGREGATE AMOUNT OF ROYALTIES IN ANY TWELVE
(12) MONTH PERIOD, IN WHICH CASE, SANOFI-AVENTIS SHALL REIMBURSE IMMUNOGEN FOR
ALL COSTS INCURRED BY IMMUNOGEN IN CONNECTION WITH SUCH EXAMINATION AND AUDIT.

4.3.7        OVERDUE PAYMENTS.  ALL ROYALTY PAYMENTS NOT MADE WITHIN THE TIME
PERIOD SET FORTH IN SECTION 4.3.1, AND ALL MILESTONE PAYMENTS NOT MADE WITHIN
THE TIME PERIOD SPECIFIED IN SECTION 4.2.1, SHALL BEAR INTEREST AT A RATE OF ONE
PERCENT (1%) PER MONTH FROM THE DUE DATE UNTIL PAID IN FULL OR, IF LESS, THE
MAXIMUM INTEREST RATE PERMITTED BY APPLICABLE LAWS.  ANY SUCH OVERDUE ROYALTY OR
MILESTONE PAYMENT SHALL, WHEN MADE, BE ACCOMPANIED BY, AND CREDITED FIRST TO,
ALL INTEREST SO ACCRUED.

4.3.8        WITHHOLDING TAXES.  ANY PAYMENTS MADE BY SANOFI-AVENTIS TO
IMMUNOGEN UNDER THIS AGREEMENT SHALL BE FREE AND CLEAR OF ANY TAXES, DUTIES,
LEVIES, FEES OR CHARGES, AND SUCH AMOUNTS SHALL BE REDUCED BY THE AMOUNT
REQUIRED TO BE PAID OR WITHHELD PURSUANT TO ANY APPLICABLE LAW, INCLUDING, BUT
NOT LIMITED TO, UNITED STATES FEDERAL, STATE OR LOCAL TAX LAW (“WITHHOLDING
TAXES”).  ANY SUCH WITHHOLDING TAXES REQUIRED BY LAW TO BE PAID OR WITHHELD
SHALL BE AN EXPENSE OF, AND BORNE SOLELY BY, IMMUNOGEN.  SANOFI-AVENTIS, AS
APPLICABLE, SHALL SUBMIT TO IMMUNOGEN REASONABLE PROOF OF PAYMENT OF THE
WITHHOLDING TAXES, TOGETHER WITH AN ACCOUNTING OF THE CALCULATIONS OF SUCH
TAXES, WITHIN [***] ([***]) DAYS AFTER SUCH WITHHOLDING TAXES ARE REMITTED TO
THE PROPER AUTHORITY.  THE PARTIES WILL COOPERATE REASONABLY IN COMPLETING AND
FILING DOCUMENTS REQUIRED UNDER THE PROVISIONS OF ANY APPLICABLE TAX LAWS OR
UNDER ANY OTHER APPLICABLE LAW IN CONNECTION WITH THE MAKING OF ANY REQUIRED TAX
PAYMENT OR WITHHOLDING PAYMENT, OR IN CONNECTION WITH ANY CLAIM TO A REFUND OF
OR CREDIT FOR ANY SUCH PAYMENT.

A-18

--------------------------------------------------------------------------------

4.3.9        FOREIGN CURRENCY EXCHANGE.  WITH RESPECT TO NET SALES INVOICED OR
EXPENSES INCURRED IN U.S. DOLLARS, THE NET SALES OR EXPENSE AMOUNTS AND THE
AMOUNTS DUE TO IMMUNOGEN HEREUNDER SHALL BE EXPRESSED IN U.S. DOLLARS.  WITH
RESPECT TO NET SALES INVOICED OR EXPENSES INCURRED IN A CURRENCY OTHER THAN U.S.
DOLLARS, THE NET SALES OR EXPENSE SHALL BE EXPRESSED IN THE DOMESTIC CURRENCY OF
THE ENTITY MAKING THE SALE OR INCURRING THE EXPENSE, TOGETHER WITH THE U.S.
DOLLAR EQUIVALENT, CALCULATED USING THE ARITHMETIC AVERAGE OF THE SPOT RATES ON
THE LAST BUSINESS DAY OF EACH MONTH OF THE CALENDAR QUARTER IN WHICH THE NET
SALES WERE MADE OR THE EXPENSE WAS INCURRED.  THE “CLOSING MID-POINT RATES”
FOUND IN THE “EXCHANGE RATES” TABLE PUBLISHED BY THE WALL STREET JOURNAL, OR ANY
OTHER PUBLICATION AS AGREED TO BY THE PARTIES, SHALL BE USED AS THE SOURCE OF
SPOT RATES TO CALCULATE THE AVERAGE AS DEFINED IN THE PRECEDING SENTENCE.  ALL
PAYMENTS SHALL BE MADE BY WIRE TRANSFER IN U.S. DOLLARS TO THE CREDIT OF SUCH
BANK ACCOUNT AS SHALL BE DESIGNATED AT LEAST [***] ([***]) BUSINESS DAYS IN
ADVANCE BY IMMUNOGEN IN WRITING TO SANOFI-AVENTIS.

5.             TREATMENT OF CONFIDENTIAL INFORMATION;

PUBLICITY.

5.1           CONFIDENTIALITY

5.1.1        CONFIDENTIALITY OBLIGATIONS.  IMMUNOGEN AND SANOFI-AVENTIS EACH
RECOGNIZES THAT THE OTHER PARTY’S CONFIDENTIAL INFORMATION CONSTITUTES HIGHLY
VALUABLE ASSETS OF SUCH OTHER PARTY.  IMMUNOGEN AND SANOFI-AVENTIS EACH AGREES
THAT, SUBJECT TO SECTION 5.1.2, (A) DURING THE TERM AND FOR AN ADDITIONAL [***]
([***]) YEARS THEREAFTER IT WILL NOT DISCLOSE, AND WILL CAUSE ITS AFFILIATES AND
SUBLICENSEES NOT TO DISCLOSE, ANY CONFIDENTIAL INFORMATION OF THE OTHER PARTY
AND (B) DURING AND AFTER THE TERM, IT WILL NOT USE, AND WILL CAUSE ITS
AFFILIATES NOT TO USE, ANY CONFIDENTIAL INFORMATION OF THE OTHER PARTY, IN
EITHER CASE, EXCEPT AS EXPRESSLY PERMITTED HEREUNDER.  WITHOUT LIMITING THE
GENERALITY OF THE FOREGOING, EACH PARTY SHALL TAKE SUCH ACTION, AND SHALL CAUSE
ITS AFFILIATES AND SUBLICENSEES TO TAKE SUCH ACTION, TO PRESERVE THE
CONFIDENTIALITY OF THE OTHER PARTY’S CONFIDENTIAL INFORMATION AS SUCH PARTY
WOULD CUSTOMARILY TAKE TO PRESERVE THE CONFIDENTIALITY OF ITS OWN CONFIDENTIAL
INFORMATION AND SHALL, IN ANY EVENT, USE AT LEAST REASONABLE CARE TO PRESERVE
THE CONFIDENTIALITY OF THE OTHER PARTY’S CONFIDENTIAL INFORMATION.

5.1.2        LIMITED DISCLOSURE.  IMMUNOGEN AND SANOFI-AVENTIS EACH AGREES THAT
DISCLOSURE OF ITS CONFIDENTIAL INFORMATION MAY BE MADE BY THE OTHER PARTY TO ANY
EMPLOYEE, CONSULTANT OR AFFILIATE OF SUCH OTHER PARTY TO ENABLE SUCH OTHER PARTY
TO EXERCISE ITS RIGHTS OR TO CARRY OUT ITS RESPONSIBILITIES UNDER THIS
AGREEMENT, PROVIDED THAT ANY SUCH DISCLOSURE OR TRANSFER SHALL ONLY BE MADE TO
PERSONS WHO ARE BOUND BY WRITTEN OBLIGATIONS AS DESCRIBED IN SECTION 5.1.3.  IN
ADDITION, IMMUNOGEN AND SANOFI-AVENTIS EACH AGREES THAT THE OTHER PARTY MAY
DISCLOSE ITS CONFIDENTIAL INFORMATION (A) ON A NEED-TO-KNOW BASIS TO SUCH OTHER
PARTY’S LEGAL AND FINANCIAL ADVISORS AND (B) AS REASONABLY NECESSARY IN
CONNECTION WITH AN ACTUAL OR POTENTIAL (I) PERMITTED SUBLICENSE OF SUCH OTHER
PARTY’S RIGHTS HEREUNDER, (II) DEBT OR EQUITY FINANCING OF SUCH OTHER PARTY OR
(III) PURCHASE BY ANY THIRD PARTY OF ALL OF THE CAPITAL STOCK OR ALL OR
SUBSTANTIALLY ALL OF THE ASSETS OF SUCH OTHER PARTY OR ANY MERGER OR
CONSOLIDATION INVOLVING SUCH OTHER PARTY; IF, IN EACH CASE, THE PERSON RECEIVING
SUCH CONFIDENTIAL INFORMATION OF THE OTHER PARTY AGREES IN WRITING TO MAINTAIN
THE CONFIDENTIALITY OF SUCH CONFIDENTIAL INFORMATION OF THE OTHER PARTY WITH
TERMS AT LEAST AS RESTRICTIVE AS THOSE CONTAINED IN SECTION 5.1.1.  IN ADDITION,
EACH PARTY AGREES THAT THE OTHER PARTY MAY DISCLOSE SUCH PARTY’S CONFIDENTIAL
INFORMATION (A) AS REASONABLY NECESSARY TO FILE, PROSECUTE OR MAINTAIN PATENTS
OR PATENT APPLICATIONS, OR TO FILE, PROSECUTE OR DEFEND LITIGATION

A-19

--------------------------------------------------------------------------------

RELATED TO PATENTS OR PATENT APPLICATIONS, IN ACCORDANCE WITH THIS AGREEMENT; OR
(B) AS REQUIRED BY APPLICABLE LAWS, PROVIDED THAT, IN THE CASE OF ANY DISCLOSURE
UNDER THIS CLAUSE (B), THE DISCLOSING PARTY SHALL (1) IF PRACTICABLE, PROVIDE
THE OTHER PARTY WITH REASONABLE ADVANCE NOTICE OF AND AN OPPORTUNITY TO COMMENT
ON ANY SUCH REQUIRED DISCLOSURE, (2) IF REQUESTED BY THE OTHER PARTY, COOPERATE
IN ALL REASONABLE RESPECTS WITH THE OTHER PARTY’S EFFORTS TO OBTAIN CONFIDENTIAL
TREATMENT OR A PROTECTIVE ORDER WITH RESPECT TO ANY SUCH DISCLOSURE, AT THE
OTHER PARTY’S EXPENSE AND (3) USE GOOD FAITH EFFORTS TO INCORPORATE THE COMMENTS
OF SUCH OTHER PARTY IN ANY SUCH DISCLOSURE OR REQUEST FOR CONFIDENTIAL TREATMENT
OR A PROTECTIVE ORDER.

5.1.3        EMPLOYEES AND CONSULTANTS.  IMMUNOGEN AND SANOFI-AVENTIS EACH
HEREBY REPRESENTS THAT ALL OF ITS EMPLOYEES AND CONSULTANTS, AND ALL OF THE
EMPLOYEES AND CONSULTANTS OF ITS AFFILIATES, WHO PARTICIPATE IN THE ACTIVITIES
CONTEMPLATED BY THIS AGREEMENT OR HAVE ACCESS TO CONFIDENTIAL INFORMATION OF THE
OTHER PARTY ARE OR WILL, PRIOR TO THEIR PARTICIPATION OR ACCESS, BE BOUND BY
WRITTEN OBLIGATIONS TO MAINTAIN SUCH CONFIDENTIAL INFORMATION IN CONFIDENCE AND
NOT TO USE SUCH INFORMATION EXCEPT AS EXPRESSLY PERMITTED HEREUNDER.  EACH PARTY
AGREES TO USE, AND TO CAUSE ITS AFFILIATES TO USE, REASONABLE EFFORTS TO ENFORCE
SUCH OBLIGATIONS.

5.2           PUBLICITY.  THE PARTIES ACKNOWLEDGE THAT THE TERMS OF THIS
AGREEMENT CONSTITUTE CONFIDENTIAL INFORMATION OF EACH PARTY AND MAY NOT BE
DISCLOSED EXCEPT AS PERMITTED BY SECTION 5.1.2.  NOTWITHSTANDING ANYTHING TO THE
CONTRARY IN SECTION 5.1, THE PARTIES, UPON THE EXECUTION OF THIS AGREEMENT, MAY
MUTUALLY AGREE TO A PRESS RELEASE WITH RESPECT TO THIS AGREEMENT AND EITHER
PARTY MAY MAKE SUBSEQUENT PUBLIC DISCLOSURE OF THE CONTENTS OF SUCH PRESS
RELEASE WITHOUT FURTHER APPROVAL OF THE OTHER PARTY.  AFTER ISSUANCE OF SUCH
PRESS RELEASE, EXCEPT AS REQUIRED BY APPLICABLE LAWS, NEITHER PARTY SHALL ISSUE
A PRESS OR NEWS RELEASE OR MAKE ANY SIMILAR PUBLIC ANNOUNCEMENT (OTHER THAN
PUBLICATION IN SCIENTIFIC JOURNALS, IN ADVERTISING MATERIALS AND BROCHURES, OR
PRESENTATION AT SCIENTIFIC CONFERENCES AND MEETINGS AND THE LIKE THAT ARE
INTENDED TO BE COVERED BY, AND ARE ISSUED IN COMPLIANCE WITH, SECTION 5.3)
RELATED TO THE DEVELOPMENT OR COMMERCIALIZATION OF A LICENSED PRODUCT WITHOUT
THE PRIOR WRITTEN CONSENT OF THE OTHER PARTY, PROVIDED THAT NOTWITHSTANDING THE
FOREGOING, IMMUNOGEN SHALL BE EXPRESSLY PERMITTED TO PUBLICLY ANNOUNCE THE
OCCURRENCE OF ANY MILESTONE EVENT UNDER SECTION 4.2.1, PROVIDED, HOWEVER, THAT
THE TEXT OF SUCH ANNOUNCEMENT SHALL BE MUTUALLY AGREED TO BY THE PARTIES.

5.3           PUBLICATIONS AND PRESENTATIONS.  THE PARTIES ACKNOWLEDGE THAT
SCIENTIFIC PUBLICATIONS AND PRESENTATIONS MUST BE STRICTLY MONITORED TO PREVENT
ANY ADVERSE EFFECT FROM PREMATURE PUBLICATION OR DISSEMINATION OF RESULTS OF THE
ACTIVITIES HEREUNDER.  EACH PARTY AGREES THAT, EXCEPT AS REQUIRED BY APPLICABLE
LAWS, IT SHALL NOT PUBLISH OR PRESENT, OR PERMIT TO BE PUBLISHED OR PRESENTED,
THE RESULTS OF THE DEVELOPMENT OR COMMERCIALIZATION OF A LICENSED PRODUCT TO THE
EXTENT SUCH RESULTS REFER TO OR OTHERWISE RELATE TO THE LICENSED TECHNOLOGY OR
LICENSED PATENT RIGHTS (THE “COVERED RESULTS”) WITHOUT THE PRIOR REVIEW BY AND
APPROVAL OF THE OTHER PARTY.  EACH PARTY SHALL PROVIDE TO THE OTHER PARTY THE
OPPORTUNITY TO REVIEW EACH OF THE SUBMITTING PARTY’S PROPOSED ABSTRACTS,
MANUSCRIPTS OR PRESENTATIONS (INCLUDING, WITHOUT LIMITATION, INFORMATION TO BE
PRESENTED VERBALLY) THAT RELATE TO THE COVERED RESULTS AT LEAST [***] ([***])
DAYS PRIOR TO ITS INTENDED PRESENTATION OR SUBMISSION FOR PUBLICATION, AND SUCH
SUBMITTING PARTY AGREES, UPON WRITTEN REQUEST FROM THE OTHER PARTY GIVEN WITHIN
SUCH [***] PERIOD, NOT TO SUBMIT SUCH ABSTRACT OR MANUSCRIPT FOR PUBLICATION OR
TO MAKE SUCH PRESENTATION UNTIL THE OTHER PARTY IS GIVEN UP TO [***] ([***])
DAYS FROM THE DATE OF SUCH WRITTEN REQUEST TO SEEK APPROPRIATE PATENT PROTECTION
FOR ANY COVERED RIGHTS IN SUCH PUBLICATION OR PRESENTATION THAT IT REASONABLY

A-20

--------------------------------------------------------------------------------

BELIEVES MAY BE PATENTABLE.  ONCE SUCH ABSTRACTS, MANUSCRIPTS OR PRESENTATIONS
HAVE BEEN REVIEWED AND APPROVED BY EACH PARTY, THE SAME ABSTRACTS, MANUSCRIPTS
OR PRESENTATIONS DO NOT HAVE TO BE PROVIDED AGAIN TO THE OTHER PARTY FOR REVIEW
FOR A LATER SUBMISSION FOR PUBLICATION.  EACH PARTY ALSO SHALL HAVE THE RIGHT TO
REQUIRE THAT ANY OF ITS CONFIDENTIAL INFORMATION THAT IS DISCLOSED IN ANY SUCH
PROPOSED PUBLICATION OR PRESENTATION BE DELETED PRIOR TO SUCH PUBLICATION OR
PRESENTATION.  IN ANY PERMITTED PUBLICATION OR PRESENTATION BY A PARTY, THE
OTHER PARTY’S CONTRIBUTION SHALL BE DULY RECOGNIZED, AND CO-AUTHORSHIP SHALL BE
DETERMINED IN ACCORDANCE WITH CUSTOMARY INDUSTRY STANDARDS.

6.             FILING, PROSECUTION AND MAINTENANCE OF PATENT RIGHTS

6.1           PATENT FILING, PROSECUTION AND MAINTENANCE.

6.1.1        LICENSED PATENT RIGHTS.  IMMUNOGEN, ACTING THROUGH PATENT COUNSEL
OR AGENTS OF ITS CHOICE, SHALL BE RESPONSIBLE, AT ITS SOLE COST AND EXPENSE, FOR
THE PREPARATION, FILING, PROSECUTION AND MAINTENANCE OF ALL LICENSED PATENT
RIGHTS.  ALL COSTS AND EXPENSES INCURRED BY IMMUNOGEN IN CONNECTION WITH THE
PREPARATION, FILING, PROSECUTION AND MAINTENANCE OF LICENSED PATENT RIGHTS SHALL
BE THE SOLE RESPONSIBILITY OF IMMUNOGEN.  AT IMMUNOGEN’S REQUEST, SANOFI-AVENTIS
SHALL COOPERATE WITH IMMUNOGEN IN ALL REASONABLE RESPECTS IN CONNECTION WITH
SUCH PREPARATION, FILING, PROSECUTION AND MAINTENANCE OF LICENSED PATENT RIGHTS.

6.1.2        SANOFI-AVENTIS IMPROVEMENTS.  SANOFI-AVENTIS, ACTING THROUGH PATENT
COUNSEL OR AGENTS OF ITS CHOICE, SHALL BE RESPONSIBLE, AT ITS SOLE COST AND
EXPENSE, FOR THE PREPARATION, FILING, PROSECUTION AND MAINTENANCE OF PATENT
RIGHTS CLAIMING SANOFI-AVENTIS IMPROVEMENTS.  SANOFI-AVENTIS (I) WILL PROVIDE
IMMUNOGEN WITH A COPY OF ANY SUCH PROPOSED PATENT APPLICATION FOR REVIEW AND
COMMENT REASONABLY IN ADVANCE OF FILING, AND (II) WILL KEEP IMMUNOGEN REASONABLY
INFORMED OF THE STATUS OF SUCH FILING, PROSECUTION AND MAINTENANCE, INCLUDING,
WITHOUT LIMITATION, (A) BY PROVIDING IMMUNOGEN WITH COPIES OF ALL COMMUNICATIONS
RECEIVED FROM OR FILED IN PATENT OFFICE(S) WITH RESPECT TO SUCH FILING, AND
(B) BY PROVIDING IMMUNOGEN A REASONABLE TIME PRIOR TO TAKING OR FAILING TO TAKE
ANY ACTION THAT WOULD AFFECT THE SCOPE OR VALIDITY OF ANY SUCH FILING (INCLUDING
THE SUBSTANTIALLY NARROWING, CANCELLATION OR ABANDONMENT OF ANY CLAIM(S) WITHOUT
RETAINING THE RIGHT TO PURSUE SUCH SUBJECT MATTER IN A SEPARATE APPLICATION, OR
THE FAILURE TO FILE OR PERFECT THE FILING OF ANY CLAIM(S) IN ANY COUNTRY), WITH
PRIOR WRITTEN NOTICE OF SUCH PROPOSED ACTION OR INACTION SO THAT IMMUNOGEN HAS A
REASONABLE OPPORTUNITY TO REVIEW AND COMMENT.  IF SANOFI-AVENTIS FAILS TO
UNDERTAKE THE FILING(S) OF ANY SUCH PATENT APPLICATION WITH RESPECT TO ANY SUCH
INVENTION WITHIN [***] ([***]) DAYS AFTER RECEIPT OF WRITTEN NOTICE FROM
IMMUNOGEN THAT IMMUNOGEN BELIEVES FILING(S) OF SUCH AN APPLICATION BY
SANOFI-AVENTIS IS APPROPRIATE, IMMUNOGEN MAY UNDERTAKE SUCH FILING(S) AT ITS OWN
EXPENSE, IN WHICH CASE SANOFI-AVENTIS WILL ASSIGN ALL OF ITS RIGHTS TO SUCH
SANOFI-AVENTIS IMPROVEMENTS TO IMMUNOGEN AND ANY SUBSEQUENTLY ISSUED PATENT
THEREON WILL BE OWNED SOLELY BY IMMUNOGEN.

6.1.3        COOPERATION.  EACH PARTY AGREES TO COOPERATE REASONABLY WITH THE
OTHER PARTY IN THE PREPARATION, FILING, AND PROSECUTION OF ANY PATENT
APPLICATIONS PURSUANT TO THIS SECTION 6.1.  SUCH COOPERATION INCLUDES, BUT IS
NOT LIMITED TO, EXECUTING ALL PAPERS AND INSTRUMENTS, OR REQUIRING ITS EMPLOYEES
OR AGENTS TO EXECUTE SUCH PAPERS AND INSTRUMENTS, SO AS

A-21

--------------------------------------------------------------------------------

TO EFFECTUATE THE OWNERSHIP OF SUCH PATENT APPLICATIONS AND ANY PATENTS THEREON
AND TO ENABLE THE FILING AND PROSECUTION OF APPLICATIONS IN ANY COUNTRY.

6.2           ABANDONMENT.

6.2.1     LICENSED PATENT RIGHTS.  IF IMMUNOGEN DECIDES TO ABANDON OR TO ALLOW
TO LAPSE ANY OF THE LICENSED PATENT RIGHTS THAT COVER ANY LICENSED PRODUCT IN
ANY COUNTRY OR REGION IN THE TERRITORY, IMMUNOGEN SHALL INFORM SANOFI-AVENTIS OF
SUCH DECISION PROMPTLY AND, IN ANY EVENT, SO AS TO PROVIDE SANOFI-AVENTIS A
REASONABLE AMOUNT OF TIME TO MEET ANY APPLICABLE DEADLINE TO ESTABLISH OR
PRESERVE SUCH LICENSED PATENT RIGHTS IN SUCH COUNTRY OR REGION.  SANOFI-AVENTIS
SHALL HAVE THE RIGHT TO ASSUME RESPONSIBILITY FOR CONTINUING THE PROSECUTION OF
SUCH LICENSED PATENT RIGHTS IN SUCH COUNTRY OR REGION AND PAYING ANY REQUIRED
FEES TO MAINTAIN SUCH LICENSED PATENT RIGHTS IN SUCH COUNTRY OR REGION OR
DEFENDING SUCH LICENSED PATENT RIGHTS, IN EACH CASE AT SANOFI-AVENTIS’ SOLE
EXPENSE AND THROUGH PATENT COUNSEL OR AGENTS OF ITS CHOICE.  SANOFI-AVENTIS
SHALL NOT BECOME AN ASSIGNEE OF SUCH LICENSED PATENT RIGHTS AS A RESULT OF ITS
ASSUMPTION OF ANY SUCH RESPONSIBILITY.  UPON TRANSFER OF IMMUNOGEN’S
RESPONSIBILITY FOR PROSECUTING, MAINTAINING AND DEFENDING ANY OF THE LICENSED
PATENT RIGHTS TO SANOFI-AVENTIS UNDER THIS SECTION 6.2.1, IMMUNOGEN SHALL
PROMPTLY DELIVER TO SANOFI-AVENTIS COPIES OF ALL NECESSARY FILES RELATED TO THE
LICENSED PATENT RIGHTS WITH RESPECT TO WHICH RESPONSIBILITY HAS BEEN TRANSFERRED
AND SHALL TAKE ALL ACTIONS AND EXECUTE ALL DOCUMENTS REASONABLY NECESSARY FOR
SANOFI-AVENTIS TO ASSUME SUCH PROSECUTION, MAINTENANCE AND DEFENSE.

6.2.2     SANOFI-AVENTIS IMPROVEMENTS.  IF SANOFI-AVENTIS DECIDES TO ABANDON OR
TO ALLOW TO LAPSE ANY OF THE PATENT RIGHTS THAT COVER SANOFI-AVENTIS
IMPROVEMENTS IN ANY COUNTRY OR REGION IN THE TERRITORY, SANOFI-AVENTIS SHALL
INFORM IMMUNOGEN OF SUCH DECISION PROMPTLY AND, IN ANY EVENT, SO AS TO PROVIDE
IMMUNOGEN A REASONABLE AMOUNT OF TIME TO MEET ANY APPLICABLE DEADLINE TO
ESTABLISH OR PRESERVE SUCH PATENT RIGHTS IN SUCH COUNTRY OR REGION.  IMMUNOGEN
SHALL HAVE THE RIGHT TO ASSUME RESPONSIBILITY FOR CONTINUING THE PROSECUTION OF
SUCH PATENT RIGHTS IN SUCH COUNTRY OR REGION AND PAYING ANY REQUIRED FEES TO
MAINTAIN SUCH PATENT RIGHTS IN SUCH COUNTRY OR REGION OR DEFENDING SUCH PATENT
RIGHTS, IN EACH CASE AT IMMUNOGEN’S SOLE EXPENSE AND THROUGH PATENT COUNSEL OR
AGENTS OF ITS CHOICE.  IMMUNOGEN SHALL NOT BECOME AN ASSIGNEE OF SUCH PATENT
RIGHTS AS A RESULT OF ITS ASSUMPTION OF ANY SUCH RESPONSIBILITY.  UPON TRANSFER
OF SANOFI-AVENTIS’ RESPONSIBILITY FOR PROSECUTING, MAINTAINING AND DEFENDING ANY
SUCH PATENT RIGHTS TO IMMUNOGEN UNDER THIS SECTION 6.2.2, SANOFI-AVENTIS SHALL
PROMPTLY DELIVER TO IMMUNOGEN COPIES OF ALL NECESSARY FILES RELATED TO SUCH
PATENT RIGHTS WITH RESPECT TO WHICH RESPONSIBILITY HAS BEEN TRANSFERRED AND
SHALL TAKE ALL ACTIONS AND EXECUTE ALL DOCUMENTS REASONABLY NECESSARY FOR
IMMUNOGEN TO ASSUME SUCH PROSECUTION, MAINTENANCE AND DEFENSE.

6.3           LEGAL ACTIONS.

6.3.1        THIRD PARTY INFRINGEMENT.

(A)           IN THE EVENT EITHER PARTY BECOMES AWARE OF ANY POSSIBLE
INFRINGEMENT OF, OR THE SUBMISSION BY ANY THIRD PARTY OF AN ABBREVIATED NEW DRUG
APPLICATION UNDER THE HATCH-WAXMAN ACT THAT IS COVERED BY, ANY LICENSED PATENT
RIGHTS THAT COVER A LICENSED PRODUCT OR ANY SANOFI-AVENTIS IMPROVEMENT (AN
“INFRINGEMENT”), THAT PARTY SHALL PROMPTLY NOTIFY THE OTHER PARTY AND PROVIDE IT
WITH ALL DETAILS OF SUCH INFRINGEMENT OF WHICH IT IS AWARE (EACH, AN
“INFRINGEMENT NOTICE”).

A-22

--------------------------------------------------------------------------------

(B)           IMMUNOGENSHALL HAVE THE FIRST RIGHT AND OPTION TO ELIMINATE SUCH
INFRINGEMENT WITH RESPECT TO LICENSED PATENT RIGHTS THAT COVER LICENSED PRODUCTS
BY REASONABLE STEPS, WHICH MAY INCLUDE THE INSTITUTION OF LEGAL PROCEEDINGS OR
OTHER ACTION.  ALL COSTS, INCLUDING WITHOUT LIMITATION ATTORNEYS’ FEES, RELATING
TO SUCH LEGAL PROCEEDINGS OR OTHER ACTION SHALL BE BORNE BY IMMUNOGEN.  IF
IMMUNOGEN DOES NOT TAKE COMMERCIALLY REASONABLE STEPS TO ELIMINATE THE
INFRINGEMENT WITHIN [***] [***] [***] ([***]) DAYS FROM ANY INFRINGEMENT NOTICE
(OR [***] ([***]) DAYS IN THE CASE OF AN INFRINGEMENT UNDER THE HATCH-WAXMAN
ACT), THEN SANOFI-AVENTIS SHALL HAVE THE RIGHT AND OPTION TO DO SO AT ITS
EXPENSE, PROVIDED THAT IF IMMUNOGEN HAS COMMENCED NEGOTIATIONS WITH AN ALLEGED
INFRINGER FOR ELIMINATION OF SUCH INFRINGEMENT WITHIN SUCH [***]-DAY (OR, IF
APPLICABLE [***]-DAY) PERIOD, IMMUNOGEN SHALL HAVE AN ADDITIONAL [***] ([***])
DAYS (OR IN THE CASE OF AN INFRINGEMENT UNDER THE HATCH-WAXMAN ACT, [***]
([***]) DAYS) TO CONCLUDE ITS NEGOTIATIONS BEFORE SANOFI-AVENTIS MAY TAKE STEPS
TO ELIMINATE SUCH INFRINGEMENT.

(C)           SANOFI-AVENTIS SHALL HAVE THE FIRST RIGHT AND OPTION TO ELIMINATE
SUCH INFRINGEMENT WITH RESPECT TO SANOFI-AVENTIS IMPROVEMENTS BY REASONABLE
STEPS, WHICH MAY INCLUDE THE INSTITUTION OF LEGAL PROCEEDINGS OR OTHER ACTION. 
ALL COSTS, INCLUDING WITHOUT LIMITATION ATTORNEYS’ FEES, RELATING TO SUCH LEGAL
PROCEEDINGS OR OTHER ACTION SHALL BE BORNE BY SANOFI-AVENTIS.  IF SANOFI-AVENTIS
DOES NOT TAKE COMMERCIALLY REASONABLE STEPS TO ELIMINATE THE INFRINGEMENT WITHIN
[***] [***] [***] ([***]) DAYS FROM ANY INFRINGEMENT NOTICE (OR [***] ([***])
DAYS IN THE CASE OF AN INFRINGEMENT UNDER THE HATCH-WAXMAN ACT), THEN IMMUNOGEN
SHALL HAVE THE RIGHT AND OPTION TO DO SO AT ITS EXPENSE, PROVIDED THAT IF
SANOFI-AVENTIS HAS COMMENCED NEGOTIATIONS WITH AN ALLEGED INFRINGER FOR
ELIMINATION OF SUCH INFRINGEMENT WITHIN SUCH [***]-DAY (OR, IF APPLICABLE
[***]-DAY) PERIOD, SANOFI-AVENTIS SHALL HAVE AN ADDITIONAL [***] ([***]) DAYS
(OR IN THE CASE OF AN INFRINGEMENT UNDER THE HATCH-WAXMAN ACT, [***] ([***])
DAYS) TO CONCLUDE ITS NEGOTIATIONS BEFORE IMMUNOGEN MAY TAKE STEPS TO ELIMINATE
SUCH INFRINGEMENT.

(D)           NEITHER PARTY SHALL SETTLE ANY INFRINGEMENT CLAIM OR PROCEEDING
UNDER THIS SECTION 6.3.1 WITHOUT THE PRIOR WRITTEN CONSENT OF THE OTHER PARTY,
WHICH CONSENT SHALL NOT BE UNREASONABLY WITHHELD, CONDITIONED OR DELAYED.

(E)           EACH PARTY SHALL HAVE THE RIGHT TO PARTICIPATE, AND BE REPRESENTED
BY COUNSEL THAT IT SELECTS, IN ANY LEGAL PROCEEDINGS OR OTHER ACTION INSTITUTED
UNDER THIS SECTION 6.3.1 BY THE OTHER PARTY.  IF A PARTY WITH THE RIGHT TO
INITIATE LEGAL PROCEEDINGS UNDER SECTION 6.3.1 TO ELIMINATE AN INFRINGEMENT
LACKS STANDING TO DO SO AND THE OTHER PARTY HAS STANDING TO INITIATE SUCH LEGAL
PROCEEDINGS, THEN THE PARTY WITH STANDING SHALL INITIATE SUCH LEGAL PROCEEDINGS
AT THE REQUEST AND EXPENSE OF THE OTHER PARTY.

(F)            IN ANY ACTION, SUIT OR PROCEEDING INSTITUTED UNDER THIS SECTION
6.3.1, THE PARTIES SHALL COOPERATE WITH AND ASSIST EACH OTHER IN ALL REASONABLE
RESPECTS.  UPON THE REASONABLE REQUEST OF THE PARTY INSTITUTING SUCH ACTION,
SUIT OR LEGAL PROCEEDING, THE OTHER PARTY SHALL JOIN SUCH ACTION, SUIT OR LEGAL
PROCEEDING AND SHALL BE REPRESENTED USING COUNSEL OF ITS OWN CHOICE, AT THE
REQUESTING PARTY’S EXPENSE.

(G)           ANY AMOUNTS RECOVERED BY EITHER PARTY PURSUANT TO SECTION
6.3.1(B), WHETHER BY SETTLEMENT OR JUDGMENT, SHALL BE ALLOCATED IN THE FOLLOWING
ORDER: (I) FIRST, TO REIMBURSE IMMUNOGEN AND SANOFI-AVENTIS FOR THEIR REASONABLE
OUT-OF-POCKET EXPENSES IN MAKING SUCH RECOVERY (WHICH AMOUNTS SHALL BE ALLOCATED
PRO RATA ACCORDING TO SUCH EXPENSES IF INSUFFICIENT TO COVER THE TOTALITY OF
SUCH EXPENSES); (II) TO SANOFI-AVENTIS IN REIMBURSEMENT FOR LOST SALES (NET OF
ROYALTIES) ASSOCIATED WITH LICENSED PRODUCTS AND TO IMMUNOGEN IN REIMBURSEMENT

A-23

--------------------------------------------------------------------------------

FOR LOST ROYALTIES OWING HEREUNDER BASED ON SUCH LOST SALES; AND (III) ANY
AMOUNTS REMAINING SHALL BE ALLOCATED AS FOLLOWS: (A) IF IMMUNOGEN IS THE PARTY
BRINGING SUCH SUIT OR PROCEEDING OR TAKING SUCH OTHER LEGAL ACTION, ONE HUNDRED
PERCENT (100%) TO IMMUNOGEN, (B) IF SANOFI-AVENTIS IS THE PARTY BRINGING SUCH
SUIT OR PROCEEDING OR TAKING SUCH OTHER LEGAL ACTION, SEVENTY-FIVE PERCENT (75%)
TO SANOFI-AVENTIS AND TWENTY-FIVE PERCENT (25%) TO IMMUNOGEN, AND (C) IF THE
SUIT IS BROUGHT JOINTLY, FIFTY PERCENT (50%) TO EACH PARTY.  ANY AMOUNTS
RECOVERED BY EITHER PARTY PURSUANT TO SECTION 6.3.1(C) WHETHER BY SETTLEMENT OR
JUDGMENT, SHALL BE ALLOCATED IN THE FOLLOWING ORDER: (A) IF IMMUNOGEN IS THE
PARTY BRINGING SUCH SUIT OR PROCEEDING OR TAKING SUCH OTHER LEGAL ACTION, ONE
HUNDRED PERCENT (100%) TO IMMUNOGEN, AND (B) IF SANOFI-AVENTIS IS THE PARTY
BRINGING SUCH SUIT OR PROCEEDING OR TAKING SUCH OTHER LEGAL ACTION, ONE HUNDRED
PERCENT (100%) TO SANOFI-AVENTIS.

6.3.2        DEFENSE OF CLAIMS.  IN THE EVENT THAT ANY ACTION, SUIT OR
PROCEEDING IS BROUGHT AGAINST EITHER PARTY OR ANY AFFILIATE OR SUBLICENSEE OF
EITHER PARTY ALLEGING THE INFRINGEMENT OF THE TECHNOLOGY OR PATENT RIGHTS OF A
THIRD PARTY BY REASON OF THE USE BY SANOFI-AVENTIS OF THE LICENSED TECHNOLOGY OR
LICENSED PATENT RIGHTS TO DEVELOP OR COMMERCIALIZE ANY LICENSED PRODUCT:
(A)IMMUNOGEN SHALL HAVE THE OBLIGATION TO DEFEND SUCH ACTION, SUIT OR PROCEEDING
AT ITS SOLE EXPENSE; (B) SANOFI-AVENTIS SHALL HAVE THE RIGHT TO SEPARATE COUNSEL
AT ITS OWN EXPENSE IN ANY SUCH ACTION, SUIT OR PROCEEDING; AND (C) THE PARTIES
SHALL COOPERATE WITH EACH OTHER IN ALL REASONABLE RESPECTS IN ANY SUCH ACTION,
SUIT OR PROCEEDING.  IN THE EVENT THAT ANY ACTION, SUIT OR PROCEEDING IS BROUGHT
AGAINST EITHER PARTY OR ANY AFFILIATE OR SUBLICENSEE OF EITHER PARTY ALLEGING
THE INFRINGEMENT OF THE TECHNOLOGY OR PATENT RIGHTS OF A THIRD PARTY BY REASON
OF THE USE BY IMMUNOGEN OF THE SANOFI-AVENTIS IMPROVEMENTS
(A)SANOFI-AVENTISSHALL HAVE THE OBLIGATION TO DEFEND SUCH ACTION, SUIT OR
PROCEEDING AT ITS SOLE EXPENSE; (B) IMMUNOGEN SHALL HAVE THE RIGHT TO SEPARATE
COUNSEL AT ITS OWN EXPENSE IN ANY SUCH ACTION, SUIT OR PROCEEDING; AND (C) THE
PARTIES SHALL COOPERATE WITH EACH OTHER IN ALL REASONABLE RESPECTS IN ANY SUCH
ACTION, SUIT OR PROCEEDING.  EACH PARTY SHALL PROVIDE THE OTHER PARTY WITH
PROMPT WRITTEN NOTICE OF THE COMMENCEMENT OF ANY SUCH SUIT, ACTION OR
PROCEEDING, OR OF ANY ALLEGATION OF INFRINGEMENT OF WHICH SUCH PARTY BECOMES
AWARE, AND SHALL PROMPTLY FURNISH THE OTHER PARTY WITH A COPY OF EACH
COMMUNICATION RELATING TO THE ALLEGED INFRINGEMENT THAT IS RECEIVED BY SUCH
PARTY.  FOR PURPOSES OF CLARITY, NOTHING IN THIS SECTION 6.3.2 SHALL AFFECT THE
RIGHT OF EITHER PARTY TO DEFEND ITSELF IN ANY ACTION SUIT OR PROCEEDING.

7.             TERM AND TERMINATION

7.1           TERM.  THIS AGREEMENT SHALL COMMENCE ON THE EFFECTIVE DATE AND
SHALL CONTINUE IN FULL FORCE AND EFFECT UNTIL SUCH TIME AS ALL ROYALTY TERMS FOR
THE LICENSED PRODUCT HAVE ENDED, UNLESS EARLIER TERMINATED IN ACCORDANCE WITH
THE PROVISIONS OF THIS ARTICLE 7(THE “TERM”).

7.2           TERMINATION.  THIS AGREEMENT MAY BE TERMINATED AT ANY TIME BY
EITHER PARTY AS FOLLOWS:

7.2.1        TERMINATION FOR BREACH.  EXCEPT AS SET FORTH HEREIN, EITHER PARTY
MAY TERMINATE THIS AGREEMENT, EFFECTIVE IMMEDIATELY UPON WRITTEN NOTICE TO THE
OTHER PARTY, FOR A BREACH BY THE OTHER PARTY OF ANY MATERIAL TERM OF THIS
AGREEMENT THAT REMAINS UNCURED [***] ([***]) DAYS ([***] ([***]) DAYS IN THE
EVENT THAT THE BREACH IS A FAILURE OF SANOFI-AVENTIS TO MAKE ANY PAYMENT
REQUIRED HEREUNDER) AFTER THE NON-BREACHING PARTY FIRST GIVES WRITTEN NOTICE OF
SUCH

A-24

--------------------------------------------------------------------------------

BREACH TO THE OTHER PARTY.  NOTWITHSTANDING ANYTHING TO THE CONTRARY SET FORTH
HEREIN, (A) IF THE ASSERTED BREACH IS CURED OR SHOWN TO BE NON-EXISTENT WITHIN
THE APPLICABLE CURE PERIOD, THE NOTICE OF BREACH HEREUNDER SHALL BE DEEMED
AUTOMATICALLY WITHDRAWN; AND (B) A MATERIAL BREACH BY A PARTY SHALL NOT GIVE
RISE TO THE TERMINATION RIGHT UNDER THIS SECTION 7.2.1 TO THE EXTENT SUCH
MATERIAL BREACH ARISES FROM A FORCE MAJEURE EVENT AS DESCRIBED IN SECTION 10.11,
PROVIDED, THAT THE PARTY BREACHING THIS AGREEMENT SHALL HAVE THE BURDEN OF
DEMONSTRATING THE OCCURRENCE OF A FORCE MAJEURE.  NOTWITHSTANDING THE FOREGOING,
A PARTY MAY NOT TERMINATE THIS AGREEMENT PURSUANT TO THIS SECTION 7.2.1 AT A
TIME WHEN SUCH PARTY HAS COMMITTED A BREACH OF A MATERIAL TERM OF THIS AGREEMENT
WHICH REMAINS UNCURED.

7.2.2        TERMINATION FOR INSOLVENCY.  IN THE EVENT THAT EITHER PARTY FILES
FOR PROTECTION UNDER BANKRUPTCY LAWS, MAKES AN ASSIGNMENT FOR THE BENEFIT OF
CREDITORS, APPOINTS OR SUFFERS APPOINTMENT OF A RECEIVER OR TRUSTEE OVER ITS
PROPERTY, FILES A PETITION UNDER ANY BANKRUPTCY OR INSOLVENCY ACT OR HAS ANY
SUCH PETITION FILED AGAINST IT WHICH IS NOT DISCHARGED WITHIN [***] ([***]) DAYS
OF THE FILING THEREOF, THEN THE OTHER PARTY MAY TERMINATE THIS AGREEMENT
EFFECTIVE IMMEDIATELY UPON WRITTEN NOTICE TO SUCH PARTY.  IN CONNECTION
THEREWITH, ALL RIGHTS AND LICENSES GRANTED UNDER THIS AGREEMENT ARE, AND SHALL
BE DEEMED TO BE, FOR PURPOSES OF SECTION 365(N) OF THE UNITED STATES BANKRUPTCY
CODE, LICENSES OF RIGHTS TO “INTELLECTUAL PROPERTY” AS DEFINED UNDER
SECTION 101(56) OF THE UNITED STATES BANKRUPTCY CODE.  IN THE EVENT THAT EITHER
PARTY UNDERGOES A VOLUNTARY DISSOLUTION OR WINDING-UP OF ITS AFFAIRS, THEN THE
OTHER PARTY MAY TERMINATE THIS AGREEMENT EFFECTIVE IMMEDIATELY UPON WRITTEN
NOTICE TO SUCH PARTY.

7.2.3        Sanofi-aventis Termination Without Cause.  Sanofi-aventis shall
have the right, in its sole discretion, to terminate this Agreement upon [***]
([***]) month’s written notice to ImmunoGen.

7.3           CONSEQUENCES OF TERMINATION OF AGREEMENT.  IN THE EVENT OF THE
TERMINATION OF THIS AGREEMENT PURSUANT TO SECTION 7.2, THE FOLLOWING PROVISIONS
SHALL APPLY, AS APPLICABLE.

7.3.1        TERMINATION BY IMMUNOGEN UNDER SECTION 7.2.1 OR BY SANOFI-AVENTIS
UNDER SECTION 7.2.3.  IF THIS AGREEMENT IS TERMINATED BY IMMUNOGEN PURSUANT TO
SECTION 7.2.1 OR BY SANOFI-AVENTIS UNDER SECTION 7.2.3:

(A)           ALL OF THE LICENSES GRANTED BY IMMUNOGEN TO SANOFI-AVENTIS
PURSUANT TO SECTION 2.1.1 SHALL IMMEDIATELY TERMINATE; AND

(B)           EACH PARTY SHALL PROMPTLY RETURN OR DESTROY ALL CONFIDENTIAL
INFORMATION OF THE OTHER PARTY THAT ARE NOT SUBJECT TO A CONTINUING LICENSE
HEREUNDER, PROVIDED THAT EACH PARTY MAY RETAIN ONE COPY OF THE CONFIDENTIAL
INFORMATION OF THE OTHER PARTY IN ITS ARCHIVES SOLELY FOR THE PURPOSE OF
ESTABLISHING THE CONTENTS THEREOF AND ENSURING COMPLIANCE WITH ITS OBLIGATIONS
HEREUNDER.

7.3.2        TERMINATION BY SANOFI-AVENTIS PURSUANT TO SECTION 7.2.1.  IF THIS
AGREEMENT IS TERMINATED BY SANOFI-AVENTIS PURSUANT TO SECTION 7.2.1:

(A)           THE LICENSE GRANTED BY IMMUNOGEN TO SANOFI-AVENTIS PURSUANT TO
SECTION 2.1.1 SHALL SURVIVE SOLELY AS APPLIED TO THE LICENSED PRODUCT BEING
DEVELOPED OR

A-25

--------------------------------------------------------------------------------

COMMERCIALIZED BY SANOFI-AVENTIS AS OF THE EFFECTIVE DATE OF TERMINATION,
SUBJECT TO SANOFI-AVENTIS’ CONTINUED PAYMENT OF ALL MILESTONE, ROYALTY AND OTHER
PAYMENTS UNDER AND IN ACCORDANCE WITH THIS AGREEMENT WITH RESPECT THERETO;

(B)           ALL OTHER LICENSES GRANTED BY IMMUNOGEN TO SANOFI-AVENTIS PURSUANT
TO SECTION 2.1.1 SHALL IMMEDIATELY TERMINATE; AND

(C)           EACH PARTY SHALL PROMPTLY RETURN OR DESTROY ALL CONFIDENTIAL
INFORMATION OF THE OTHER PARTY THAT ARE NOT SUBJECT TO A CONTINUING LICENSE
HEREUNDER, PROVIDED THAT EACH PARTY MAY RETAIN ONE COPY OF THE CONFIDENTIAL
INFORMATION OF THE OTHER PARTY IN ITS ARCHIVES SOLELY FOR THE PURPOSE OF
ESTABLISHING THE CONTENTS THEREOF AND ENSURING COMPLIANCE WITH ITS OBLIGATIONS
HEREUNDER.

7.3.3        TERMINATION PURSUANT TO SECTION 7.2.2.  IF THIS AGREEMENT IS
TERMINATED BY SANOFI-AVENTIS OR IMMUNOGEN PURSUANT TO SECTION 7.2.2, UNLESS
PROHIBITED BY APPLICABLE LAWS:

(A)           THE LICENSE SET FORTH IN SECTION 2.1.1 SHALL SURVIVE SOLELY AS
APPLIED TO LICENSED PRODUCT BEING DEVELOPED OR COMMERCIALIZED BY SANOFI-AVENTIS
AS OF THE EFFECTIVE DATE OF TERMINATION, SUBJECT TO SANOFI-AVENTIS’ CONTINUED
PAYMENT OF ALL MILESTONE, ROYALTY AND OTHER PAYMENTS UNDER AND IN ACCORDANCE
WITH THIS AGREEMENT WITH RESPECT THERETO;

(B)           ALL OTHER LICENSES GRANTED BY IMMUNOGEN TO SANOFI-AVENTIS PURSUANT
TO SECTION 2.1.1 SHALL IMMEDIATELY TERMINATE; AND

(C)           EACH PARTY SHALL PROMPTLY RETURN ALL CONFIDENTIAL INFORMATION OF
THE OTHER PARTY THAT ARE NOT SUBJECT TO A CONTINUING LICENSE HEREUNDER, PROVIDED
THAT EACH PARTY MAY RETAIN ONE COPY OF THE CONFIDENTIAL INFORMATION OF THE OTHER
PARTY IN ITS ARCHIVES SOLELY FOR THE PURPOSE OF ESTABLISHING THE CONTENTS
THEREOF AND ENSURING COMPLIANCE WITH ITS OBLIGATIONS HEREUNDER.

7.4           SURVIVING PROVISIONS.  TERMINATION OR EXPIRATION OF THIS AGREEMENT
FOR ANY REASON SHALL BE WITHOUT PREJUDICE TO:

(A)           THE RIGHTS AND OBLIGATIONS OF THE PARTIES PROVIDED IN SECTIONS
7.4, 9.2, 9.3, 9.4 AND 9.5 AND ARTICLES 5 AND 10 (INCLUDING ALL OTHER SECTIONS
OR ARTICLES REFERENCED IN ANY SUCH SECTION OR ARTICLE AND INCLUDING ARTICLE 1),
ALL OF WHICH SHALL SURVIVE SUCH TERMINATION;

(B)           IMMUNOGEN’S RIGHTS TO RECEIVE ROYALTIES AND MILESTONE PAYMENTS FOR
THE DURATION OF ANY APPLICABLE ROYALTY TERM, IF ANY; AND

(C)           ANY OTHER RIGHTS OR REMEDIES PROVIDED AT LAW OR EQUITY WHICH
EITHER PARTY MAY OTHERWISE HAVE.

8.             REPRESENTATIONS, WARRANTIES AND COVENANTS

8.1           MUTUAL REPRESENTATIONS AND WARRANTIES.  IMMUNOGEN AND
SANOFI-AVENTIS EACH REPRESENTS AND WARRANTS TO THE OTHER, AS OF THE EFFECTIVE
DATE, AS FOLLOWS:

8.1.1        ORGANIZATION.  IT IS A CORPORATION DULY ORGANIZED, VALIDLY EXISTING
AND IN

A-26

--------------------------------------------------------------------------------

GOOD STANDING UNDER THE LAWS OF THE JURISDICTION OF ITS ORGANIZATION, AND HAS
ALL REQUISITE POWER AND AUTHORITY, CORPORATE OR OTHERWISE, TO EXECUTE, DELIVER
AND PERFORM THIS AGREEMENT.

8.1.2        AUTHORIZATION.  THE EXECUTION AND DELIVERY OF THIS AGREEMENT AND
THE PERFORMANCE BY IT OF THE TRANSACTIONS CONTEMPLATED HEREBY HAVE BEEN DULY
AUTHORIZED BY ALL NECESSARY CORPORATE ACTION AND WILL NOT VIOLATE (A) SUCH
PARTY’S CERTIFICATE OF INCORPORATION OR BYLAWS, (B) ANY AGREEMENT, INSTRUMENT OR
CONTRACTUAL OBLIGATION TO WHICH SUCH PARTY IS BOUND IN ANY MATERIAL RESPECT, (C)
ANY REQUIREMENT OF ANY APPLICABLE LAW, OR (D) ANY ORDER, WRIT, JUDGMENT,
INJUNCTION, DECREE, DETERMINATION OR AWARD OF ANY COURT OR GOVERNMENTAL AGENCY
PRESENTLY IN EFFECT APPLICABLE TO SUCH PARTY.

8.1.3        BINDING AGREEMENT.  THIS AGREEMENT IS A LEGAL, VALID AND BINDING
OBLIGATION OF SUCH PARTY ENFORCEABLE AGAINST IT IN ACCORDANCE WITH ITS TERMS AND
CONDITIONS.

8.1.4        NO INCONSISTENT OBLIGATION.  IT IS NOT UNDER ANY OBLIGATION,
CONTRACTUAL OR OTHERWISE, TO ANY PERSON THAT CONFLICTS WITH OR IS INCONSISTENT
IN ANY RESPECT WITH THE TERMS OF THIS AGREEMENT OR THAT WOULD IMPEDE THE
DILIGENT AND COMPLETE FULFILLMENT OF ITS OBLIGATIONS HEREUNDER.

8.2           ADDITIONAL REPRESENTATIONS OF IMMUNOGEN.  IMMUNOGEN FURTHER
REPRESENTS AND WARRANTS TO SANOFI-AVENTIS, AS OF THE EFFECTIVE DATE, AS FOLLOWS:

8.2.1        LICENSED PATENT RIGHTS.  ALL LICENSED PATENT RIGHTS EXISTING AS OF
THE EFFECTIVE DATE ARE EXISTING AND, TO IMMUNOGEN’S KNOWLEDGE, NO SUCH LICENSED
PATENT RIGHTS ARE INVALID OR UNENFORCEABLE.

8.2.2        CLAIMS OR JUDGMENTS.  THERE ARE NO CLAIMS, JUDGMENT OR SETTLEMENTS
AGAINST IMMUNOGEN PENDING, OR TO IMMUNOGEN’S KNOWLEDGE, THREATENED, THAT
INVALIDATE OR SEEK TO INVALIDATE THE LICENSED PATENT RIGHTS EXISTING AS OF THE
EFFECTIVE DATE.

8.2.3        RIGHT TO TECHNOLOGY.  IMMUNOGEN HAS THE RIGHT TO (A) USE THE
LICENSED TECHNOLOGY AND LICENSED PATENT RIGHTS EXISTING AS OF THE EFFECTIVE DATE
AS IS NECESSARY TO FULFILL ITS OBLIGATIONS UNDER THIS AGREEMENT; AND (B) GRANT
THE LICENSES UNDER THE LICENSED PATENT RIGHTS GRANTED PURSUANT TO THIS
AGREEMENT.

8.2.4        NO INFRINGEMENT.  TO IMMUNOGEN’S KNOWLEDGE, NO THIRD PARTY IS
INFRINGING, OR THREATENING TO INFRINGE, THE LICENSED PATENT RIGHTS.  TO
IMMUNOGEN’S KNOWLEDGE, THE USE OF LICENSED PATENT RIGHTS UNDER THIS AGREEMENT
FOR THE DEVELOPMENT, MANUFACTURE, USE OR COMMERCIALIZATION OF LICENSED PRODUCTS
DOES NOT INFRINGE THE PATENT RIGHTS OF ANY THIRD PARTY, NOR HAS IMMUNOGEN
RECEIVED ANY WRITTEN NOTICE ALLEGING SUCH INFRINGEMENT.

8.2.5        NO LITIGATION.  TO IMMUNOGEN’S KNOWLEDGE, THERE IS NO PENDING OR
THREATENED LITIGATION THAT ALLEGES THAT IMMUNOGEN’S PROPOSED ACTIVITIES UNDER
THIS AGREEMENT WOULD INFRINGE OR MISAPPROPRIATE ANY INTELLECTUAL PROPERTY RIGHTS
OF ANY THIRD PARTY.

8.3           COVENANT OF IMMUNOGEN.  IMMUNOGEN AGREES TO USE COMMERCIALLY
REASONABLE EFFORTS TO MAINTAIN THE RIGHT, TO (A) USE THE LICENSED TECHNOLOGY AND
LICENSED PATENT RIGHTS EXISTING AS OF THE EFFECTIVE DATE AS IS NECESSARY TO
FULFILL ITS OBLIGATIONS UNDER THIS AGREEMENT; AND (B) GRANT THE LICENSES UNDER
THE LICENSED PATENT RIGHTS GRANTED PURSUANT TO THIS AGREEMENT.

A-27

--------------------------------------------------------------------------------

9.             INDEMNIFICATION

9.1           INDEMNIFICATION OF SANOFI-AVENTIS BY IMMUNOGEN.  IMMUNOGEN SHALL
INDEMNIFY, DEFEND AND HOLD HARMLESS SANOFI-AVENTIS, ITS AFFILIATES, THEIR
RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS, AND THEIR RESPECTIVE
SUCCESSORS, HEIRS AND ASSIGNS (COLLECTIVELY, THE “SANOFI-AVENTIS INDEMNITEES”),
AGAINST ALL LIABILITIES, DAMAGES, LOSSES AND EXPENSES (INCLUDING, WITHOUT
LIMITATION, REASONABLE ATTORNEYS’ FEES AND EXPENSES OF LITIGATION)
(COLLECTIVELY, “LOSSES”) INCURRED BY OR IMPOSED UPON THE SANOFI-AVENTIS
INDEMNITEES, OR ANY ONE OF THEM, AS A DIRECT RESULT OF CLAIMS, SUITS, ACTIONS,
DEMANDS OR JUDGMENTS OF THIRD PARTIES, INCLUDING WITHOUT LIMITATION PERSONAL
INJURY AND PRODUCT LIABILITY CLAIMS AND CLAIMS OF SUPPLIERS AND IMMUNOGEN
EMPLOYEES (COLLECTIVELY, “CLAIMS”), ARISING OUT OF THE MATERIAL BREACH BY
IMMUNOGEN OF THIS AGREEMENT, EXCEPT WITH RESPECT TO ANY CLAIM OR LOSSES THAT
RESULT FROM A MATERIAL BREACH OF THIS AGREEMENT BY, OR THE GROSS NEGLIGENCE OR
WILLFUL MISCONDUCT OF, SANOFI-AVENTIS, PROVIDED THAT, WITH RESPECT TO ANY CLAIM
FOR WHICH IMMUNOGEN HAS AN OBLIGATION TO ANY SANOFI-AVENTIS INDEMNITEE PURSUANT
TO THIS SECTION 9.1 AND SANOFI-AVENTIS HAS AN OBLIGATION TO ANY IMMUNOGEN
INDEMNITEE PURSUANT TO SECTION 9.2, EACH PARTY SHALL INDEMNIFY EACH OF THE OTHER
PARTY’S INDEMNITEES FOR ITS LOSSES TO THE EXTENT OF ITS RESPONSIBILITY, RELATIVE
TO THE OTHER PARTY, FOR THE FACTS UNDERLYING THE CLAIM.

9.2           INDEMNIFICATION OF IMMUNOGEN BY SANOFI-AVENTIS.  SANOFI-AVENTIS
SHALL INDEMNIFY, DEFEND AND HOLD HARMLESS IMMUNOGEN, ITS AFFILIATES, THEIR
RESPECTIVE DIRECTORS, OFFICERS, EMPLOYEES AND AGENTS, AND THEIR RESPECTIVE
SUCCESSORS, HEIRS AND ASSIGNS (THE “IMMUNOGEN INDEMNITEES”), AGAINST ANY LOSSES
INCURRED BY OR IMPOSED UPON THE IMMUNOGEN INDEMNITEES, OR ANY ONE OF THEM, AS A
DIRECT RESULT OF CLAIMS ARISING OUT OF (A) THE MATERIAL BREACH BY SANOFI-AVENTIS
OF THIS AGREEMENT; (B) THE DEVELOPMENT OR COMMERCIALIZATION (INCLUDING, WITHOUT
LIMITATION, THE PRODUCTION, MANUFACTURE, PROMOTION, IMPORT, SALE OR USE BY ANY
PERSON) OF ANY LICENSED PRODUCT BY SANOFI-AVENTIS OR ANY OF ITS AFFILIATES,
SUBLICENSEES, DISTRIBUTORS OR AGENTS, EXCEPT WITH RESPECT TO ANY CLAIM OR LOSSES
THAT RESULT FROM A BREACH OF THIS AGREEMENT BY, OR THE GROSS NEGLIGENCE OR
WILLFUL MISCONDUCT OF, IMMUNOGEN, PROVIDED THAT WITH RESPECT TO ANY CLAIM FOR
WHICH IMMUNOGEN HAS AN OBLIGATION TO ANY SANOFI-AVENTIS INDEMNITEE PURSUANT TO
SECTION 9.1 AND SANOFI-AVENTIS HAS AN OBLIGATION TO ANY IMMUNOGEN INDEMNITEE
PURSUANT TO THIS SECTION 9.2, EACH PARTY SHALL INDEMNIFY EACH OF THE OTHER
PARTY’S INDEMNITEES FOR ITS LOSSES TO THE EXTENT OF ITS RESPONSIBILITY, RELATIVE
TO THE OTHER PARTY, FOR THE FACTS UNDERLYING THE CLAIM.

9.3           CONDITIONS TO INDEMNIFICATION.  A PERSON SEEKING RECOVERY UNDER
THIS ARTICLE 9(THE “INDEMNIFIED PARTY”) IN RESPECT OF A CLAIM SHALL GIVE PROMPT
NOTICE OF SUCH CLAIM TO THE PARTY FROM WHICH RECOVERY IS SOUGHT (THE
“INDEMNIFYING PARTY”) AND, PROVIDED THAT THE INDEMNIFYING PARTY IS NOT
CONTESTING ITS OBLIGATION UNDER THIS ARTICLE 9, SHALL PERMIT THE INDEMNIFYING
PARTY TO CONTROL ANY LITIGATION RELATING TO SUCH CLAIM AND THE DISPOSITION OF
SUCH CLAIM, PROVIDED THAT THE INDEMNIFYING PARTY SHALL (A) ACT REASONABLY AND IN
GOOD FAITH WITH RESPECT TO ALL MATTERS RELATING TO THE SETTLEMENT OR DISPOSITION
OF SUCH CLAIM AS THE SETTLEMENT OR DISPOSITION RELATES TO SUCH INDEMNIFIED PARTY
AND (B) NOT SETTLE OR OTHERWISE RESOLVE SUCH CLAIM WITHOUT THE PRIOR WRITTEN
CONSENT OF SUCH INDEMNIFIED PARTY (WHICH CONSENT SHALL NOT BE UNREASONABLY
WITHHELD, CONDITIONED OR DELAYED).  EACH INDEMNIFIED PARTY SHALL COOPERATE WITH
THE INDEMNIFYING PARTY IN ITS DEFENSE OF ANY SUCH CLAIM IN ALL REASONABLE
RESPECTSAND SHALL HAVE THE RIGHT TO BE PRESENT IN PERSON OR THROUGH COUNSEL AT
ALL LEGAL PROCEEDINGS WITH RESPECT TO SUCH CLAIM.

A-28

--------------------------------------------------------------------------------

9.4           WARRANTY DISCLAIMER.  EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN
THIS AGREEMENT, NEITHER PARTY MAKES ANY WARRANTY WITH RESPECT TO ANY TECHNOLOGY,
GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF THIS AGREEMENT AND EACH PARTY
HEREBY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WITHOUT
LIMITATION WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND
NONINFRINGEMENT.

9.5           LIMITED LIABILITY.  NOTWITHSTANDING ANYTHING TO THE CONTRARY IN
THIS AGREEMENT, NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY OR ANY OF ITS
AFFILIATES FOR (I) ANY SPECIAL, PUNITIVE, INDIRECT, INCIDENTAL OR CONSEQUENTIAL
DAMAGES, INCLUDING WITHOUT LIMITATION LOST PROFITS OR LOST REVENUES, OR (II)
COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES, WHETHER UNDER
ANY CONTRACT, WARRANTY, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE
THEORY.

10.          MISCELLANEOUS

10.1         NOTICES.  ALL NOTICES AND COMMUNICATIONS SHALL BE IN WRITING AND
DELIVERED PERSONALLY OR BY COURIER OR MAILED VIA CERTIFIED MAIL, RETURN RECEIPT
REQUESTED, ADDRESSED AS FOLLOWS, OR TO SUCH OTHER ADDRESS AS MAY BE DESIGNATED
FROM TIME TO TIME:

If to sanofi-aventis:

If to ImmunoGen:

 

 

sanofi-aventis U.S. Inc.

ImmunoGen, Inc.

1041 Rt. 202-206

128 Sidney Street

Bridgewater, NJ 08807

Cambridge, Massachusetts 02139

Attn: Head, US Alliances & Partnerships

Attn: Chief Executive Officer

 

 

 

 

With a copy to:

With a copy to:

 

 

Attn: Head, US R&D Legal

Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, PC

 

One Financial Center

 

Boston, Massachusetts 02111

 

Attention: [***] [***], Esq.

 

Tel: (617) 542-6000

 

Fax: (617) 542-2241

 

Except as otherwise expressly provided in this Agreement or mutually agreed in
writing, any notice, communication or document (excluding payment) required to
be given or made shall be deemed given or made and effective upon actual receipt
or, if earlier, (a) three (3) business days after deposit with an
internationally-recognized overnight express courier with changes prepaid, or
(b) five (5) business days after mailed by certified, registered or regular
mail, postage prepaid, in each case addressed to a Parties at its address stated
above or to such other address as such Party may designate by written notice
given in accordance with this Section 10.2.

A-29

--------------------------------------------------------------------------------

10.2         GOVERNING LAW.  THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED
IN ACCORDANCE WITH THE LAWS OF THE STATE OF DELAWARE (USA), WITHOUT REGARD TO
THE APPLICATION OF PRINCIPLES OF CONFLICTS OF LAW.

10.3         BINDING EFFECT.  THIS AGREEMENT SHALL BE BINDING UPON AND INURE TO
THE BENEFIT OF THE PARTIES AND THEIR RESPECTIVE LEGAL REPRESENTATIVES,
SUCCESSORS AND PERMITTED ASSIGNS.

10.4         HEADINGS.  SECTION AND SUBSECTION HEADINGS ARE INSERTED FOR
CONVENIENCE OF REFERENCE ONLY AND DO NOT FORM A PART OF THIS AGREEMENT.

10.5         COUNTERPARTS.  THIS AGREEMENT MAY BE EXECUTED SIMULTANEOUSLY IN TWO
OR MORE COUNTERPARTS, EACH OF WHICH SHALL BE DEEMED AN ORIGINAL AND BOTH OF
WHICH, TOGETHER, SHALL CONSTITUTE A SINGLE AGREEMENT.

10.6         AMENDMENT; WAIVER.  THIS AGREEMENT MAY BE AMENDED, MODIFIED,
SUPERSEDED OR CANCELED, AND ANY OF THE TERMS OF THIS AGREEMENT MAY BE WAIVED,
ONLY BY A WRITTEN INSTRUMENT EXECUTED BY EACH PARTY OR, IN THE CASE OF WAIVER,
BY THE PARTY OR PARTIES WAIVING COMPLIANCE. THE DELAY OR FAILURE OF EITHER PARTY
AT ANY TIME OR TIMES TO REQUIRE PERFORMANCE OF ANY PROVISIONS SHALL IN NO MANNER
AFFECT THE RIGHTS AT A LATER TIME TO ENFORCE THE SAME. NO WAIVER BY EITHER PARTY
OF ANY CONDITION OR OF THE BREACH OF ANY TERM CONTAINED IN THIS AGREEMENT,
WHETHER BY CONDUCT, OR OTHERWISE, IN ANY ONE OR MORE INSTANCES, SHALL BE DEEMED
TO BE, OR CONSIDERED AS, A FURTHER OR CONTINUING WAIVER OF ANY SUCH CONDITION OR
OF THE BREACH OF SUCH TERM OR ANY OTHER TERM OF THIS AGREEMENT.

10.7         NO THIRD PARTY BENEFICIARIES.  EXCEPT AS SET FORTH IN SECTIONS 9.1
AND 9.2, NO THIRD PARTY (INCLUDING, WITHOUT LIMITATION, EMPLOYEES OF EITHER
PARTY) SHALL HAVE OR ACQUIRE ANY RIGHTS BY REASON OF THIS AGREEMENT.

10.8         PURPOSES AND SCOPE.  THE PARTIES HERETO UNDERSTAND AND AGREE THAT
THIS LICENSE AGREEMENT IS LIMITED TO THE ACTIVITIES, RIGHTS AND OBLIGATIONS AS
SET FORTH IN THIS AGREEMENT. NOTHING IN THIS AGREEMENT SHALL BE CONSTRUED (A) TO
CREATE OR IMPLY A GENERAL PARTNERSHIP BETWEEN THE PARTIES, (B) TO MAKE EITHER
PARTY THE AGENT OF THE OTHER FOR ANY PURPOSE, (C) TO ALTER, AMEND, SUPERSEDE OR
VITIATE ANY OTHER ARRANGEMENTS BETWEEN THE PARTIES WITH RESPECT TO ANY SUBJECT
MATTERS NOT COVERED HEREUNDER, (D) TO GIVE EITHER PARTY THE RIGHT TO BIND THE
OTHER, (E) TO CREATE ANY DUTIES OR OBLIGATIONS BETWEEN THE PARTIES EXCEPT AS
EXPRESSLY SET FORTH HEREIN, OR (F) TO GRANT ANY DIRECT OR IMPLIED LICENSES OR
ANY OTHER RIGHT OTHER THAN AS EXPRESSLY SET FORTH HEREIN.

10.9         ASSIGNMENT AND SUCCESSORS.  NEITHER THIS AGREEMENT NOR ANY
OBLIGATION OF A PARTY HEREUNDER MAY BE ASSIGNED BY EITHER PARTY WITHOUT THE
CONSENT OF THE OTHER WHICH SHALL NOT BE UNREASONABLY WITHHELD, EXCEPT THAT EACH
PARTY MAY ASSIGN THIS AGREEMENT AND THE RIGHTS, OBLIGATIONS AND INTERESTS OF
SUCH PARTY, IN WHOLE OR IN PART, TO ANY OF ITS AFFILIATES, AND TO ANY THIRD
PARTY PURCHASER OF ALL OF THE CAPITAL STOCK OF SUCH PARTY OR ALL OR
SUBSTANTIALLY ALL OF ITS ASSETS IN THE LINE OF BUSINESS TO WHICH THIS AGREEMENT
PERTAINS OR TO ANY SUCCESSOR CORPORATION RESULTING FROM ANY MERGER OR
CONSOLIDATION OF SUCH PARTY WITH OR INTO SUCH CORPORATION.

10.10       FORCE MAJEURE EVENT.  NEITHER SANOFI-AVENTIS NOR IMMUNOGEN SHALL BE
LIABLE FOR FAILURE OF OR DELAY IN PERFORMING OBLIGATIONS SET FORTH IN THIS
AGREEMENT, AND NEITHER SHALL BE DEEMED IN BREACH OF ITS OBLIGATIONS, IF SUCH
FAILURE OR DELAY IS DUE TO A FORCE MAJEURE EVENT.  IN

A-30

--------------------------------------------------------------------------------

EVENT OF SUCH FORCE MAJEURE EVENT, THE PARTY AFFECTED SHALL USE REASONABLE
EFFORTS TO CURE OR OVERCOME THE SAME AND RESUME PERFORMANCE OF ITS OBLIGATIONS
HEREUNDER.

10.11       INTERPRETATION.  THE PARTIES HERETO ACKNOWLEDGE AND AGREE THAT EACH
PARTY AND ITS COUNSEL REVIEWED AND NEGOTIATED THE TERMS AND PROVISIONS OF THIS
AGREEMENT AND HAVE CONTRIBUTED TO ITS REVISION.  IN ADDITION, UNLESS A CONTEXT
OTHERWISE REQUIRES, WHEREVER USED, THE SINGULAR SHALL INCLUDE THE PLURAL, THE
PLURAL THE SINGULAR, THE USE OF ANY GENDER SHALL BE APPLICABLE TO ALL GENDERS
AND THE WORD “OR” IS USED IN THE INCLUSIVE SENSE (AND/OR).

10.12       INTEGRATION; SEVERABILITY.  THIS AGREEMENT, THE COLLABORATION
AGREEMENT AND THE OPTION AND LICENSE AGREEMENT ARE THE ENTIRE AGREEMENTS WITH
RESPECT TO THE SUBJECT MATTER HEREOF AND SUPERSEDE ALL OTHER AGREEMENTS AND
UNDERSTANDINGS BETWEEN THE PARTIES WITH RESPECT TO SUCH SUBJECT MATTER.  IF ANY
PROVISION OF THIS AGREEMENT IS OR BECOMES INVALID OR IS RULED INVALID BY ANY
COURT OF COMPETENT JURISDICTION OR IS DEEMED UNENFORCEABLE, IT IS THE INTENTION
OF THE PARTIES THAT THE REMAINDER OF THIS AGREEMENT SHALL NOT BE AFFECTED.

10.13       FURTHER ASSURANCES.  EACH OF IMMUNOGEN AND SANOFI-AVENTIS AGREES TO
DULY EXECUTE AND DELIVER, OR CAUSE TO BE DULY EXECUTED AND DELIVERED, SUCH
FURTHER INSTRUMENTS AND DO AND CAUSE TO BE DONE SUCH FURTHER ACTS AND THINGS,
INCLUDING, WITHOUT LIMITATION, THE FILING OF SUCH ADDITIONAL ASSIGNMENTS,
AGREEMENTS, DOCUMENTS AND INSTRUMENTS, AS THE OTHER PARTY MAY AT ANY TIME AND
FROM TIME TO TIME REASONABLY REQUEST IN CONNECTION WITH THIS AGREEMENT OR TO
CARRY OUT MORE EFFECTIVELY THE PROVISIONS AND PURPOSES OF, OR TO BETTER ASSURE
AND CONFIRM UNTO SUCH OTHER PARTY ITS RIGHTS AND REMEDIES UNDER, THIS AGREEMENT.

[Remainder of page intentionally left blank.]

A-31

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by
their duly authorized representatives.

 

IMMUNOGEN, INC.

 

 

 

 

 

By:

 

 

 

Name:

 

 

 

Title:

 

 

 

 

 

 

 

SANOFI-AVENTIS U.S. LLC

 

 

 

 

 

By:

 

 

 

Name:

 

 

 

Title:

 

 

 

 

 

 

 

SANOFI-AVENTIS U.S. LLC

 

 

 

 

 

By:

 

 

 

Name:

 

 

 

Title:

 

 

 

A-32

--------------------------------------------------------------------------------

Exhibit A

Licensed Target

A-1

--------------------------------------------------------------------------------

Schedule 1

Licensed Patent Rights

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

--------------------------------------------------------------------------------

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

 

[***]

[***]

A-2

--------------------------------------------------------------------------------

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

 

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

A-3

--------------------------------------------------------------------------------

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

A-4

--------------------------------------------------------------------------------

 

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

A-5

--------------------------------------------------------------------------------

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

 

[***]

[***]

 

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

 

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

 

A-6

--------------------------------------------------------------------------------

Schedule 1

Licensed Patent Rights

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

A-7

--------------------------------------------------------------------------------

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

 

A-8

--------------------------------------------------------------------------------

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

 

A-9

--------------------------------------------------------------------------------

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

A-10

--------------------------------------------------------------------------------

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

A-11

--------------------------------------------------------------------------------

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

 

[***]

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

[***]

[***]

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

[***]

 

 

[***]

[***]

[***]

[***]

[***]

[***]

 

 

 

A-12

--------------------------------------------------------------------------------